Unravelling the antidiabetic effects of polyphenols in chamomile: the gastrointestinal tract as a potential site of action by Villa Rodriguez, Jose Alberto
  
 
 
Unravelling the antidiabetic effects of polyphenols in 
chamomile: the gastrointestinal tract as a potential site 
of action. 
 
 
 
 
 
 
 
 
Jose Alberto Villa Rodriguez 
 
 
 
 
 
Submitted in accordance with the requirements for the degree of Doctor of 
Philosophy 
 
 
 
 
 
The University of Leeds  
School of Food Science and Nutrition 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
November, 2017 
- ii - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The best preparation for tomorrow  
is doing your best today 
 
H. Jackson Brown, Jr. 
 
- iii - 
 
The candidate confirms that the work submitted is his own, except where 
work which has formed part of jointly-authored publications has been 
included. The contribution of the candidate and the other authors to this 
work has been explicitly indicated below. The candidate confirms that 
appropriate credit has been given within the thesis where reference has been 
made to the work of others. 
 
Publications 
 
Chapter 2 and 3 and 4 contain work which has also been used in the publications 
 
Villa-Rodriguez, J.A., Kerimi, A., Abranko, L., C., & Williamson, G. (2015) German 
chamomile (Matricaria chamomilla) extract and its major polyphenols inhibit intestinal 
alpha-glycosidases in vitro. FASEB Journal, 21(1), LB323. 
 
Nyambe-Silavwe, H*., Villa-Rodriguez, J.A*., Ifie, I*., Holmes, M., Aydin, E., Jensen, 
J.M. & Williamson, G. (2015). Inhibition of human α-amylase by dietary polyphenols. 
Journal of Functional Foods, 19, 723-732. (*equal contribution). 
 
Villa-Rodriguez, J.A*., Aidyn E*., Gauer, J.S., M., Pyner, A., Williamson, G., & 
Kerimi, A. (2017) Green and chamomile teas, but not acarbose, attenuate glucose and 
fructose transport via inhibition of GLUT2 and GLUT5. Molecular Nutrition & Food 
Research. doi: 10.1002/mnfr.201700566 (*equal contribution). 
 
Villa-Rodriguez, J.A., Kerimi, A., Abranko, L., Ford, L., M., Blackburn, R., Rayner, C., 
& Williamson, G. Acute metabolic actions of the major polyphenols in chamomile: an in 
vitro mechanistic study on their potential to attenuate postprandial hyperglycaemia. 
Manuscript under peer review in Scientific Reports. 
 
 
- iv - 
 
Conference abstracts 
 
 
Villa-Rodriguez, J.A., Kerimi, A., Abranko, L., C., & Williamson, G. German 
chamomile (Matricaria chamomilla) extract and its major polyphenols inhibit intestinal 
alpha-glycosidases in vitro. Experimental Biology Conference, Boston, MA, USA, 2015. 
 
Villa-Rodriguez, J.A., Kerimi, A., Abranko, L., C., & Williamson, G. German 
chamomile extract and its major polyphenols inhibit carbohydrate digestion and 
absorption in vitro. VII International Conference on Polyphenols and Health, Tours, 
France, 2015. 
 
Villa-Rodriguez, J.A., Kerimi, A., Abranko, L., Ford, L., M., Blackburn, R., Rayner, C., 
& Williamson, G. Potential effects of chamomile polyphenols to modulate carbohydrate 
digestion and absorption: targeted analysis on (Z), and (E)-methoxycinnamic acid 
glucoside, apigenin and apigenin 7-O-glucoside. 1st International Conference on Food 
Bioactives and Health, Norwich, UK, 2016. 
 
Konic-Ristic, A., Nyambe-Silavwe, H., Villa-Rodriguez, J.A., Ifie, I., Williamson, G. 
Interactions between polyphenols as inhibitors of human α-amylase. 1st International 
Conference on Food Bioactives and Health, Norwich, UK, 2016. 
 
 
 
 
 
 
© 2017 The University of Leeds and Jose Alberto Villa Rodriguez 
 
- v - 
 
Acknowledgements. 
I would like to take this opportunity to thank the people who have helped and supported 
me over the last four years. 
First of all, I am very grateful to my supervisor, Professor Gary Williamson for giving me 
the opportunity to conduct my doctoral work in his world-renowned group and for all his 
mentorship, guidance and contribution to the research work but most importantly for 
sharing his broad knowledge and enthusiasm for science. I also want to thank him for 
providing the scientific environment to explore the effects of polyphenols on energy 
metabolism, which has proven to be an exciting journey.  
My deepest gratitude goes to all the people that shared with me their intellectual and 
technical knowledge for the successful completion of this research work. I would like to 
particularly recognise the contribution of Dr. Asimina Kerimi for sharing with me the 
technical skills to perform cell culture experiments, for her intellectual input to the work 
and for her endless disposal for discussion. I acknowledge Dr. Laszlo Abranko, Professor 
Christopher Rayner and Ms Lauren Ford for our collaborative work and for their 
analytical expertise in this project. I also extend my gratitude to Dr. Sharka Tumova for 
her approachable attitude and willingness to help at any moment. 
Thanks to all my past and present colleagues, especially to Idolo Ifie, Michael Houghton, 
Julia Gauer, Alison Pyner, Hilda Nyambe Aleksandra Konic Ristic and Samantha 
Gardner. You guys have been my family in Leeds, I have been fortunate to spend such an 
amazing time with you.  
I want to thank to the School of Food Science and Nutrition and its entire staff.   
Special thanks are reserved for Ms. Justine Segui who motivated and encouraged me 
throughout my PhD but most importantly, I want to thank you for your patient and 
understanding. It has not been easy for you travelling to Leeds nearly every weekend and 
I want to dedicate this work to you. Special thanks are also to my family, for their 
consistent love and support. 
Finally, I would like to acknowledge CONACYT Mexico for funding my PhD studies. 
 
 
 
- vi - 
 
Abstract. 
Background and objective: Polyphenol-rich foods and extracts have been proposed of 
being capable of lower imbalance in energy metabolism and type 2 diabetes risk by 
mitigating postprandial glycaemia. However, this physiological action is still 
controversial due to conflicting in vivo evidence which is partially due to their limited 
characterisation in terms of active constituents, their targets and efficacies. This study 
systematically investigated the potential of a polyphenol rich-extract (chamomile) to blunt 
postprandial sugar rise, the compounds involved and biochemical pathways affected.   
Methods: A combination of HPLC and LC/QTOF were used to characterise the 
polyphenol profile of aqueous chamomile extract. The inhibition of carbohydrate-
digesting enzymes was determined using an isolated human salivary α-amylase and 
acetone rat intestinal powder under optimal kinetic conditions. The inhibition of sugar 
transporters and cholesterol uptake was assessed in the well-characterised intestinal cell 
models Caco-2/TC7 and Caco-2 respectively. 
Results: When assessed by inhibition of α-amylase and maltase activities, the active 
components were apigenin-7-O-glucoside, apigenin, and (Z) and (E)-2-hydroxy-4-
methoxycinnamic acid glucosides. The latter two compounds were purified and 
characterised. Molecular docking studies showed that apigenin and cinnamic acids 
present totally different poses in the active site of α-amylase which determined their 
potency. In differentiated Caco-2/TC7 cell monolayers, apigenin-7-O-glucoside and 
apigenin strongly inhibited D-[U-14C]-glucose and D-[U-14C]-sucrose transport, and less 
effectively D-[U-14C]-fructose transport, whereas the cinnamic acids were ineffective on 
all sugar transport. Inhibition of D-[U-14C]-glucose transport by apigenin was stronger 
under Na+-depleted conditions, suggesting interaction with the GLUT2 transporter and 
competitive binding studies with molecular probes indicate interaction primarily at the 
exofacial-binding site. The attenuation of glucose absorption had a knock on effect on [4-
14C]-cholesterol uptake by downregulating Niemann-Pick C1 Like 1 protein.  
Conclusion: Chamomile extract containing apigenin and apigenin 7-O-glucoside or the 
individual components thereof, could potentially reduce glucose absorption and 
availability within the enterocyte attenuating the glucose and cholesterol-rich 
chylomicron particles during the postprandial phase. 
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Chapter 1 Literature review. 
 
1.1 Introduction. 
 
Intake of high-calorie foods and sedentary lifestyles are important contributors in today’s 
society to the prevalence of cardiometabolic disturbances such as obesity, type 2 diabetes 
and cardiovascular disease. It has been predicted that 90 % of obesity-related type 2 
diabetes and 80 % of coronary heart disease conditions are preventable by decreasing 
caloric intake and increasing expenditure (Willett, 2002).  
 
Epidemiological evidence supports that dietary habits rich in fruits and vegetables and 
plant-derived food products could be inversely associated with the risk of developing type 
2 diabetes and cardiovascular disease (Ley et al., 2014; Amiot et al., 2016; Bertoia et al., 
2016). A common attribute of a plant-derived diet is its polyphenol content and thus 
polyphenols have been postulated as key mediators of the underlined health effects. 
Polyphenols present variable bioavailability, are highly metabolised and their 
biotransformation in the gastrointestinal (GI) tract is heterogeneous across individuals 
(Manach et al., 2016; Williamson and Clifford, 2017). This has been a major shortcoming 
to establish functional connections between plasma metabolites and the vast range of 
claimed metabolic changes, limiting our understanding of their biological actions in the 
human body, including their cardiometabolic protection. The GI tract has postprandially 
the highest concentration of polyphenols compared to any other site in the body by one or 
more orders of magnitude (Williamson, 2013) and therefore it could be a major site where 
polyphenols can mediate cardiometabolic protection by for example, reducing 
postprandial sugar excursions.  
 
This literature review will present and integrate the current understanding of diet-related 
factors contributing to metabolic disorders and describe the recent advancements and 
limitations in the study of polyphenols, which are exemplified by studies conducted in 
chamomile, a significance source of these molecules. Moreover, a prospective view is 
provided for the translational application to protect and/or manage the metabolic 
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phenotype observed in type 2 diabetes, emphasising the GI tract as a short-term realistic 
target.  
 
1.2 Carbohydrate and lipid metabolism: an interplay in the 
development of type 2 diabetes and cardiovascular disease. 
 
The current concept of metabolic disorders is that ‘high caloric diets’ cause a disruption 
in normal cell energy metabolism resulting in the development of cardiometabolic 
diseases such as type 2 diabetes. Sugars and fats are energy-dense nutrients that 
contribute ~75 % of the total calorie intake in a diet; therefore it is not surprising that the 
interaction between carbohydrate and lipid metabolism which are intimately interlinked 
through the intersection of metabolic pathways is fundamental for energy balance. 
 
After a meal, upon digestion and absorption by α-glycosidases and membrane 
transporters respectively (for a detailed description of carbohydrate digestion and 
absorption see chapter 3 and 4, respectively), simple carbohydrates are delivered to the 
liver via the lymphatic system. The liver processes a substantial part of these sugars 
through the glycolysis, glycogenesis and de novo lipogenesis (DNL) pathways producing 
energy, glycogen and lipids respectively (Vacca et al., 2015). In the case of lipids, a 
proportion is stored in the adipose tissue and the remaining part exported into circulation 
as very low-density lipoproteins (VLDL) particles to cardiac and skeletal muscle for 
energy consumption (Harwood, 2012).  
 
In a similar way, dietary lipids travel to the liver forming part of chylomicron particles 
after a series of reactions that take place in the small intestine (see chapter 5 for a 
comprehensive description). These include hydrolysis by pancreatic and intestinal lipases, 
uptake by the enterocytes, re-esterification and conjugation with apolipoprotein B48 in 
the enterocyte to form the chylomicrons (Dash et al., 2015). Once in circulation, the 
chylomicron-triglyceride component is hydrolysed by lipoprotein lipase (LPL) expressed 
on the surface of peripheral tissues such as adipocyte, myocytes, and macrophages, 
producing the low-density lipoproteins (LDL). The triglyceride component is used for 
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energy production, stored in the liver or adipocytes via lipogenesis or exported back into 
circulation as a VLDL component (Vacca et al., 2015; Bays et al., 2016).  
 
Therefore, systemic glucose and lipid levels are in a constant state of flux, with overall 
levels ultimately dependent on the balance between glucose and lipid acquisition and 
removal (regulated by a complex system of network of transcription factors, signal 
transducer proteins and metabolic enzymes) governed by highly active metabolic tissues 
such as the liver (Cheng et al., 2015; Vacca et al., 2015), adipocytes (Harwood, 2012), 
myocytes and pancreas (Muoio and Newgard, 2008; Taylor, 2013). However, in 
situations of chronic energy excess (high calorie diets), a dysregulation of glucose and 
lipids flux occurs contributing to a coordinated breakdown in cellular functions. 
 
The biochemical pathways linked to type 2 diabetes have been deciphered and it is 
consensual that the major pathogenesis factor is the accumulation of lipids in the liver and 
adipose tissue. Chronic excess of calorie intake in the form of carbohydrates (which are 
ultimately metabolised to glucose) overactivates the DNL pathway through the action of 
insulin facilitating the synthesis of fatty acids. The excess of fatty acids are primarily 
stored and exported into circulation (to counterbalance the accumulation of lipids) due to 
the inhibition of β-oxidation by the malonyl-CoA produced during DNL (Taylor, 2013).  
 
Fatty acids are therefore esterified with glycerol to produce mono-, di-, and triglycerides 
where raised levels of dyacylglycerol have been implicated in an impaired insulin action 
(Taylor, 2013). Moreover, when the storage capability of the adipose tissue is reached 
(normally occurring in the obesity condition), there is a dysregulated secretion of 
adipokines (i.e. adiponectin, leptin, resistin, retinol binding protein 4) along with the gain 
of a proinflammatory state (promotion of adipocytokines), resulting in an increased fatty 
acid release from adipocytes (Harwood, 2012). These adipocyte-derived fatty acids and 
the circulating fraction originating from the DNL are taken up and stored in the liver. 
Thus irregularities in the DNL and adipose tissue dysfunction during metabolic stress 
promotes the inundation of lipids in the liver and an inflammatory response, which 
ultimately impairs insulin signalling resulting in systemic insulin resistance; a 
pathophysiological state where cells fail to respond to the normal actions of insulin. 
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Although whether insulin resistance arises first in the peripheral tissues or in the liver is 
still a matter of debate. 
 
Insulin exerts a variety of physiological effects to integrate nutrient processing and energy 
assimilation. Insulin promotes hepatic glucose uptake, glycolysis, glycogenesis and 
inhibits gluconeogenesis, promotes DNL, free fatty acid influx and efflux of VLDL 
(Vacca et al., 2015). Thus the insulin resistant state leads to uncontrolled gluconeogenesis 
and reduced catabolism of circulating VLDL and chylomicron remnants, which seems to 
be mediated by an aberrant adipose tissue hormonal function (Harwood, 2012) driving to 
hyperglycaemia and dyslipidaemia. Hyperglycaemia and dyslipidaemia lead to systemic 
increases in oxidative stress, produces a pro-inflammatory state predominantly resulting 
in increased levels of TNF-α, IL-6 and C-reactive protein which increase lipid deposition 
and the development of endothelial dysfunction and atherosclerotic plaque (Lumeng and 
Saltiel, 2011). Thus, type 2 diabetes results from a vicious cycle of conditions such as 
hyperglycaemia, hyperinsulinemia, systemic inflammation, dyslipidaemia and insulin 
resistance, ultimately ensuing the loss of β-cell function (figure 1.1). 
  
 
 
 
 
 
 
 
 
Figure 1.1 The role of obesity on tissue-specific metabolic dysregulations leading to type 2 
diabetes and cardiovascular disease. The interplay between sugar and lipid metabolism 
responsible for the metabolic dysregulations described in the text. Increase     ;decrease    ; altered        
. TG: triglycerides. 
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Type 2 diabetes is a condition that affects over ~420 million people worldwide (WHO, 
2016) and is rapidly becoming a global epidemic with a projected increase of ~55 % by 
2035 (Guariguata et al., 2014). Overweight and obesity are the two main risk factors 
associated with this disease (Forouzanfar et al., 2015). Findings from meta-analyses 
indicate that consumption of readily absorbable sugars such as sucrose, fructose and 
glucose increases the prospect of body fat gain via changes in energy intake (Te Morenga 
et al., 2013) and independently of adiposity, they contribute to type 2 diabetes onset 
(Imamura et al., 2015). 
 
In support of this, two independent meta-analyses suggest that carbohydrate quality, 
rather than quantity, as evidenced by the glycaemic index (GI) and the glycaemic load, 
has a greater impact on type 2 diabetes risk (Livesey et al., 2008; Bhupathiraju et al., 
2014) and management (Brand-Miller et al., 2003; Livesey et al., 2008). Reduced sugar 
intake, consumption of low glycaemic index diets and regular exercise have been 
suggested as effective modifiable factors to avoid type 2 diabetes (Ley et al., 2014). 
However, the rising numbers of cases indicates compliance is poor and other actions are 
needed. 
 
Dietary patterns that include the consumption of plant-based food items such as coffee, 
tea, fruits and vegetables and plant extracts have been associated with a reduced risk of 
developing type 2 diabetes (Liu et al., 2013; Ding et al., 2014; Salas-Salvadó et al., 2014; 
Bertoia et al., 2016; Martel et al., 2016). For instance, consumption of a Mediterranean 
diet with extra virgin olive oil without calorie restriction has shown to reduce the 
incidence of type 2 diabetes by 40 % (Salas-Salvadó et al., 2014). Common dietary 
constituents of these diets are polyphenols, a group of molecules which are not included 
in the classical definition of a nutrient, but which are plausible mediators of the 
underlined health effects. This has placed polyphenols in the spotlight for the prevention 
and treatment of type 2 diabetes, and worldwide efforts are being conducted to establish 
functional connections between in vitro and in vivo studies in order to prove causation. 
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1.3 Polyphenols: from antioxidants to modulators of human 
metabolism. 
 
Since the establishment of the free radical theory, which stated the role of free radicals 
and other ‘reactive oxygen species (ROS)’ in the development of many human diseases 
(Harman, 1956), the belief that molecules with antioxidant properties would delay or 
prevent disease risk started emerging in the minds of the scientific community. 
Polyphenols, naturally-occurring compounds in planta belonging to the group of the so 
called phytochemicals (for a comprehensive review on their biosynthesis and content in 
certain plant-base foods and beverages see Crozier et al. (2009)) were among these 
molecules. Recognition that polyphenols, due to their inherent chemical antioxidant 
activity (conferred by the availability OH groups), were responsible for protecting 
biomolecules for oxidation helping to maintain key cellular process, provided the 
scientific basis to explain the epidemiological evidence stating an association between the 
consumption polyphenol-rich foods (fruits, vegetables, cocoa and cereals) and the 
prevention/reduction of some chronic and degenerative diseases. However, as soon as 
bioavailability studies started to be conducted, an increasing awareness about the 
biological relevance of such findings emerged, and the paradigm of their mode of action 
started to change.  
 
The process of absorption, metabolism and excretion of the most abundant polyphenols 
after dietary intake is well understood (figure 1.2). Bioavailability studies on polyphenols 
revealed that they are extensively metabolised during absorption from the small intestine, 
resulting in the formation of glucuronides, sulphates (Wong et al., 2010) and methyl 
metabolites (Lotito et al., 2011), while in the colon breakdown to phenolic acids and non-
phenolic catabolites occurs (Roowi et al., 2010). As such, the compounds that are found 
in the circulatory system and reach the peripheral tissues are chemically different from 
the dietary form, and therefore, they do not retain the same in vitro antioxidant capacity 
(Lotito et al., 2011). 
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Figure 1.2 Absorption, metabolism and excretion of polyphenols in the human body.  The 
absorption of polyphenols is associated with cleavage and release of the aglycone by the action of 
lactase phloridzin hydrolase (LPH) in the small intestine and by an alternative step mediated by β-
glucosidase (BGC) within the epithelial cells (Day et al., 1998; Day et al., 2000; Crozier et al., 
2009), thus allowing passage through enterocytes and then to the blood stream via efflux 
transporters. Before this last, the aglycones undergo phase II metabolism forming sulfate, 
glucoronide, and/or methylated metabolites via the action of phenol sulfotransferases, UDP 
glucurosyl transferase and catechol-O-methyltransferase, respectively (Wong et al., 2010). The 
conjugates formed can be excreted back into the intestinal lumen by efflux transporters. Once in 
the bloodstream, metabolites rapidly reach the liver, where they can be subjected to further phase 
II metabolism and then secreted into circulation where they can reach and be absorbed in other 
peripheral tissues or excreted in the urine or bile. Conjugated polyphenols (i.e sugars and organic 
acids) that are resistant to the action of LPH/BGC are not absorbed in the small intestine and pass 
to the colon (Day et al., 1998; Day et al., 2000; Crozier et al., 2009). Once in the colon, the 
colonic microbiota transform these polyphenols into absorbable products yielding different 
catabolites although predominant groups (i.e phenolic acids with zero to three aromatic hydroxyls, 
or their mono- or di-methoxy analogues) originated from varying substrates (i.e chlorogenic acids, 
flavanols, proanthocyanidins, theaflavins) can be found (Williamson and Clifford, 2017).  
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Moreover, polyphenols are absorbed with an estimated maximum concentration of 10 µM 
in plasma for metabolites and 1 µM for total aglycones (Clifford, 2004), suggesting that 
their biological activity once absorbed goes beyond the modulation of oxidative stress and 
therefore, their mechanism of action might be far more complex. Because of the relatively 
concentration of absorbed aglycones, it is widely acknowledged that metabolites are the 
active forms, although it has also been proposed that aglycones can mediate biological 
functions after intracellular deconjugation as evidenced for quercetin (Menendez et al., 
2011; Dueñas et al., 2013). 
 
The current view of the cellular effects of dietary polyphenols and their metabolites is that 
they interact with specific proteins central to intracellular signalling cascades. These 
interactions, through the activation of specific genes, either directly or indirectly, are 
associated with the modulation of cellular functions related to oxidative processes, 
inflammation, insulin resistance, energy metabolism and mitochondrial function (Kerimi 
and Williamson, 2016). As such, there are multiple and complex metabolic pathways 
affected making almost an impossible task to establish a clear association between 
aglycones, plasma metabolites (rarely available for mechanistic studies) and the 
overwhelming range of induced metabolic changes in peripheral tissues such as the 
pancreas, liver, skeletal muscle and adipose tissue. This is further complicated by our 
very limited understanding of the distribution and concentrations reached in these organs. 
Although this issue is currently being addressed with the use of metabolomics, one of the 
main challenges is to obtain robust predictive biomarkers of exposure since large 
interpersonal variation exist (Manach et al., 2016). Furthermore, the development of these 
biomarkers has been further complicated by the incomplete qualitative and quantitative 
characterisation of polyphenol-rich foods and extracts. The metabolites present in 
circulation are determined in the first instance by the precursor polyphenol in planta and 
so, in order to strengthen the evidence for a specific food containing polyphenols, and 
indeed, a specific polyphenol and human health, a reliable and full characterisation is 
required.  
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1.4 Importance of polyphenol characterisation to establish their health 
effects. 
 
As products of plant secondary metabolism, polyphenols are present in virtually all foods 
of plant origin and many phenolic structures have been reported so far (Crozier et al., 
2009). This huge diversity of chemical structures of polyphenols is one of the main 
limitations to estimate their content in foodstuff, estimate their daily average intake and 
establish a clear relationship between their intake and health and disease state. 
 
There are many factors than can affect the polyphenol profile and content in planta and in 
food items. These include the species, geographic distribution, seasonal variation and 
processing and storage conditions. Certain polyphenols are widely distributed, whereas 
others are specific to a particular plant or food. All these factors make the qualitative and 
quantitative estimation of polyphenols a challenging task and it has been regarded as the 
main limitation to correlate the insights obtained from epidemiological studies to those 
observed in in vitro studies using a particular polyphenol, polyphenol-rich food or extract 
(Crozier et al., 2009).  
 
In planta, polyphenols are generally found conjugated to sugars and organic acids. They 
are hydroxylated, methoxylated, and/or glycosylated derivatives and the linked sugar is 
often glucose or rhamnose (Crozier et al., 2009). The number of sugar moieties ranges 
from one to two or three, and there are several positions of substitution on the polyphenol 
(Singh et al., 2008). Therefore, a complex mixture of chemical structures can be found in 
planta and so highly specialised and costly analytical instrumentation are required to 
characterise the polyphenol constituents in a plant matrix. Instrumentation requirements 
have been addressed with the development of powerful techniques such as LC-ESI-MS 
and tandem MS which have provided the necessary measurements to selectively 
characterise compounds in a complex matrix (Gosslau et al., 2011; Joven et al., 2013). 
However, the development of suitable standards required for a confident and rigorous 
identification and quantification has not been fully overcome. Arguably, surrogate 
standards supported by LC-MS data providing retention time, UV−Vis spectrum, 
molecular mass, and mass fragmentation data can be employed to fingerprint and 
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unequivocally identify polyphenols in plant matrices (Clifford and Madala, 2017). This 
information is open to interpretation and therefore, very often can result in the 
identification of erroneous polyphenol structures without a careful interpretation of the 
analytical data. This is clearly demonstrated by the polyphenol characterisation of 
chamomile where two abundant compounds were mistakenly identified by Mulinacci et 
al. (2000) and this work has served as a reference for the identification of these 
compounds in further studies (discussed in chapter 2). 
  
Polyphenols are natural compounds and consequently, their content and distribution will 
vary in planta and will do so in plant-based foods and extracts that are used in vivo and in 
vitro studies for exploring their effects on health. This could explain the heterogeneity of 
results reported in the literature for polyphenol-rich foods and extracts on putative health 
benefits. An example could be cocoa polyphenols, particularly flavan-3-ols, where a 
health claim on their vasodilatory effects has been accepted by the European Commission 
(Tallon, 2015). The claim indicates that intake of 200 mg of cocoa flavanols with a 
degree of polymerisation of 1-10 can help to maintain the elasticity of blood vessels 
contributing to normal blood flow. More than 20 oligomers with a degree of 
polymerisation from 2-20 have been reported in cocoa (Porter et al., 1991) and their 
composition, content and bioavailability are greatly influence by processing techniques 
(Payne et al., 2010). This implies that the vasodilatory effects of cocoa may be present or 
totally absent since it is elusive which of the polymers is likely responsible for the activity 
and so, the proposed physiological effect may not be sustained from batch to batch. 
Therefore a full and reliable characterisation of the polyphenol source under investigation 
seems to be a first and necessary step in order to establish functional links between active 
constituents, their molecular targets and mode(s) of action. Only with this data, will we be 
able to formulate polyphenol-nutritional approaches for lowering the risk and managing 
cardiometabolic diseases such as type 2 diabetes. 
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1.5 Botanical extracts as a source of polyphenols to promote metabolic 
health: the case of chamomile and type 2 diabetes.  
 
Botanicals represent a valuable source of polyphenols that can be employed to promote 
metabolic health. Chamomile (Matricaria recutita L) epitomises a remarkable example as 
evidenced by recent human, animal and in vitro studies. Chamomile is widely used 
throughout the world and its consumption in the form of tea has been estimated over 1 
million cups per day (Srivastava and Gupta, 2009). Thus it contributes significantly to 
dietary exposure of polyphenols, particularly the flavone apigenin and its glucoside and 
acylated derivatives which represent the predominant examples (Švehlı́ková et al., 2004). 
In the following sections, the most recent evidence supporting the health effects of 
chamomile and/or apigenin and the potential mechanism involved in metabolic benefits in 
relation to type 2 diabetes will be presented and discussed.  
 
1.5.1 In vivo evidence of the metabolic protection of chamomile and apigenin. 
In recent years, a number of animal studies have suggested the potential of chamomile for 
regulating carbohydrate and lipid metabolism in experimental diabetes (table 1.1). In 
streptozotocin-induced diabetic rats, where diabetes is induced by the irreversible 
destruction of the β-islet cells of the pancreas by streptozotocin (a naturally produced 
antibiotic from Streptomyces achromogenes), the administration of an hydroalcoholic 
chamomile extract (36/64 v/v) for 14 days decrease postprandial hyperglycaemia as 
compared with control diabetic rats, with an overall decreased ranging ~20-25 % 
depending on the dose (5-100 mg/kg) (Cemek et al., 2008). Interestingly, the effect 
observed by chamomile at the highest concentration in diabetic rats was superior to that 
of glibenclamide (5 mg/kg), an antidiabetic drug that stimulates insulin release from the 
pancreas. The authors also observed an improvement of other metabolic parameters 
(doses ranging from 20-100 mg/kg) including reduced levels of oxidative stress as 
evidenced by the lower blood levels of malondialdehyde, along with an increase in the 
activity of antioxidant enzymes (superoxide dismutase, catalase), the levels of dietary 
antioxidants (vitamin C and β-carotene) and protection of β-cell function.  
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Test material*/compound Model Dose
Duration 
(weeks)
Biomarkers postively 
affected
Reference
Chamomile
Streptozotocin-
induced diabetic rats
20 mg/kg/d 2
Fasting blood glucose                                                        
Glucose intolerance         
Eddouks et al. 
(2005)
Chamomile
Streptozotocin-
induced diabetic rats
20-100 mg/kg/d 2
Glucose intolerance       
Malondialdehyde blood levels  
Oxidative stress                                                                                                                              
Cemek et al. 
(2008)
Chamomile
Streptozotocin-
induced diabetic rats
500 mg/kg/d 3 Fasting blood glucose                                                            
Kato et al. 
(2008)
Chamomile
Streptozotocin-
induced diabetic rats
500 mg/kg/d 3 Postprandial blood glucose                                                            
Kato et al. 
(2008)
Apigenin
Streptozotocin-
induced diabetic rats
4 mg/kg/d 1
Fasting blood glucose                                                    
Glucose intolerance                     
Liver injury                                  
Renal dysfunction       
Rauter et al. 
(2010)
Apigenin
Diet-induced obese 
mice (C57BL/6)
100 mg/kg 
(intraperitoneal 
injection)
1
Fasting blood glucose                                                    
Glucose intolerance                  
Blood glucose concentration                                                       
Hepatic triglycerides       
Escande et al. 
(2013)
Chamomile
Diet-induced obese 
mice (C57BL/6)
200 mg/kg/d 6
Fasting blood glucose                                                    
Glucose intolerance                                                                         
Plasma triglycerides                 
Insulin resistance                 
Adipose dysfunction       
Weidner et al. 
(2013)
Chamomile
Lean high-fat fed 
mice (C57BL/6)
200 mg/kg/d 20
Fasting blood glucose                                                    
Glucose intolerance                                                                         
Insulin resistance                         
Hepatic non-esterified fatty 
acids in the liver                                     
Hepatic triglycerides                      
Weidner et al. 
(2013)
Apigenin
Type 2 diabetic 
subjects
3000 mg (20 
mg/mL) 3 
times/day after 
each meal
8
Fasting glucose and insulin                                              
HbA1C                                       
Insulin resistance                        
Plasma cholesterol                   
Plasma triglycerides                  
Plasma LDL-cholesterol    
Malondialdehyde blood levels                          
Oxidative stress                                                            
Rafraf et al. 
(2015) 
Zemestani et 
al. (2016)
Apigenin
Streptozotocin-
induced diabetic rats 
fed with a high-fat 
diet 
50 and 100 
mg/kg/d
6
Fasting glucose and insulin                                              
HbA1C                                       
Insulin resistance                        
Plasma cholesterol                   
Plasma triglycerides                  
Plasma LDL-cholesterol    
Malondialdehyde blood levels                          
Oxidative stress                
Endothelial function                                                           
Ren et al. 
(2016)
*The chemical compostion of the extract used during the study was not reported.
The results described above suggest that chamomile protection is mediated through the 
attenuation of glucose absorption, preventing hyperglycaemia and the associated 
oxidative stress and thus protecting β-cell function. Indeed, the findings of an 
independent subsequent study support the aforementioned pathway. Using the same 
experimental model, Kato et al. (2008) showed that acute chamomile intervention (water 
extract, 500 mg/kg) decreased postprandial glucose peak levels by ~15% after a sucrose 
loading test where the effect was evidenced after 30 min, and reaching baseline levels at 
120 min. In the same study, chronic administration of chamomile for 21 days using the 
same dose reduced fasting glucose levels (~24%) and increased hepatic glycogen content 
(~3.6 fold). 
 
Table 1.1 In vivo studies of the antidiabetic effects of chamomile and apigenin. 
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These results provide more robust evidence about the modulation of glucose by 
chamomile, suggesting an attenuation of glucose absorption in the intestine and a 
direct/indirect effect in the liver through the modulation of gluconeogenesis. 
 
The protective effect of chamomile on peripheral tissues such as the liver and adipose 
tissue has been recently demonstrated in a lean high fat-fed C57BL/6 mice. In this animal 
model, high fat diet is provided in order to induce obesity and the associated metabolic 
disorders (discussed in section 1.3). Chronic chamomile intervention (200 mg/kg/day, 20 
weeks) inhibited the high fat diet-induced insulin resistance by ~35% and the 
accompanying increase in fasting plasma glucose and improved dyslipidaemia evidenced 
by a decrease of circulating free fatty acids and triacylglycerol as compared to control 
mice (Weidner et al., 2013). Although body weight changes were not observed between 
controls and treated mice, hepatic analysis at the functional level suggest that chamomile 
promotes adequate lipid oxidation and utilisation. Hepatic tissue of high fat-fed mice over 
20 weeks showed increases in liver triacylglycerols and non-esterified fatty acids along 
with signs of liver inflammation and fatty liver formation. Chamomile treatment 
efficiently attenuated the metabolic stress caused by the high-fat diet with reductions of 
~72% and ~64% of triacylglycerols and free fatty acids respectively, and a decrease in the 
protein expression of TNF-α (~54%) which attenuated the signs of fatty liver formation 
(reduction of ~64%). 
 
Interestingly, the protective effects of chamomile remained in obese mice which have 
already developed a pathophysiological phenotype (i.e insulin resistance). Chronic 
treatment with chamomile (200 mg/kg/d) substantially reduced insulin resistance (~36%), 
fasting glucose levels and glucose intolerance (~15%), plasma triacylglycerol (~35%), 
free fatty acids (53%), total cholesterol (16%) and LDL/VLDL cholesterol (~43%). Gene 
expression analysis of adipose tissue of mice treated with chamomile showed an 
upregulation of important genes participating in lipid metabolism and so, the 
aforementioned affects could have been mediated by reduction of adipocyte dysfunction 
(Weidner et al., 2013). 
 
Although not conclusive, the most convincing evidence about the potential of chamomile 
to attenuate metabolic dysregulation characteristic of diabetes state comes from a recent 
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human intervention study (Rafraf et al., 2015). In a single blinded, randomized, parallel 
controlled clinical trial, type 2 diabetes subjects consumed one cup of chamomile tea (20 
mg/mL) three times a day immediately after meals for 8 weeks. Compared to baseline 
values, subjects who consumed chamomile tea showed an improvement of metabolic 
parameters characterised by reductions in fasting serum glucose (~11 %) and insulin 
levels (~39%), the levels of glycated haemoglobin (HbA1c, ~5%), and insulin resistance 
(~40%). Similar improvements were observed in lipid profile with reductions of total 
cholesterol, total triglycerides and LDL-cholesterol by ~18, 5.6 and 9 %, respectively. 
These metabolic improvements were related with a reduction of oxidative stress as 
evidenced by lower serum malondialdehyde and higher activity of antioxidant enzymes 
(Zemestani et al., 2016) as previously reported in streptozotocin-induced diabetic rats 
(Cemek et al., 2008).  
 
It is important to mention that during the human study, the type 2 diabetic subjects were 
consuming their normal dose of the antidiabetic drug metformin, indicating that the 
metabolic effects elicited by chamomile were complementary. This highlights the 
potential of botanicals in general, and chamomile in particular, to complement the use of 
antidiabetic drugs and maximise effects while lowering deleterious side effects, providing 
everyday maintenance. 
 
Most of the in vivo evidence on the positive effects of chamomile to prevent and attenuate 
the metabolic dysregulation of diabetic state comes from animal studies. These effects 
seem to be translated in humans, although more studies are needed to validate these 
findings. These studies should consider the dose-response effects as well as to employ 
standardised formulation based on active constituent(s), which is still a matter of 
investigation since all the presented studies failed to provide compositional data. 
Apigenin and its derivatives appears to be strong candidates considering they are present 
in higher amounts than any other polyphenol in chamomile and their bioactivity is 
supported by in vitro studies.  
 
 
 
 
- 15 - 
 
1.5.2 In vitro evidence of the metabolic protection of chamomile and 
apigenin. 
 
The effect of polyphenols on energy metabolism is likely through a variety of different 
mechanisms including reduction on postprandial glucose, enhanced insulin secretion and 
improved insulin sensitivity, modification of hepatic glucose release, activation of insulin 
receptors and glucose uptake and modulation of signalling pathways and gene expression 
and modulation of gut microbiota (Hanhineva et al., 2010; Kim et al., 2016). So how do 
chamomile polyphenols modulate energy metabolism? Most of the mechanistic evidence 
indicates that chamomile works by interacting with transcription factors and the proteins 
of cell signalling pathways affecting gene expression patterns, although careful 
interpretation of the in vitro data needs to be conducted when extrapolating to the effects 
found in vivo.  
 
A study conducted by Weidner et al. (2013) pointed out the protective effects of 
chamomile on type 2 diabetes via activation of fatty acid sensors that control metabolic 
programs and regulate energy homeostasis. In this study, using a combination of in vitro 
assays, the authors showed that the chemical constituents of an ethanolic extract of 
chamomile interact and activate nuclear receptor peroxisome proliferator-activated 
receptors (PPARs). In a competitive binding assay, chamomile extract interacted with 
relatively the same strength with different PPARs with binding constants of ~6, 9 and 10 
μg/mL for PPARγ, PPARβ/δ and PPARα respectively. However, this was not proportional 
to the activation of PPARs where the half-maximal concentration to activate PPARγ was 
~ 14 and 44-fold lower than PPARα and PPARβ/δ respectively in a reporter gene assay.  
 
In adipocytes, chamomile upregulated the expression of genes involved in adipose 
differentiation, lipid uptake and storage and inflammation whereas in hepatocytes, 
increased expression of genes promoting β-oxidation were observed. Knockdown of 
PPARγ and PPARα with siRNA in adipocytes and hepatocytes respectively, led to a 
significant reduction of gene expression by chamomile. Deletion of PPARγ and PPARα 
in mice fed a high-fat diet has been associated with the development of 
hypertriglyceridemia, increased susceptibility to high fat diet-induced steatosis, 
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hyperinsulinemia, and insulin resistance; conversely, their activation with 
pharmacological agents protected mice against these metabolic dysregulations (He et al., 
2003; Su et al., 2014). Thus, PPARγ and PPARα could represent one of the potential 
molecular targets through which chamomile exerts metabolic protection, preserving 
adipose tissue and liver normal functions under metabolic stress conditions (chronic 
overnutrition). However, from this study, it is not clear whether there is a direct activation 
of PPARs or their activation is via modulation of the activity of downstream SIRT1 target 
peroxisome proliferator-activated receptor-coactivator 1α (an activator of PPARs) by 
altering intracellular NAD+ levels. Apigenin (10-40 µM) maintained adequate levels of 
NAD+ by inhibiting CD38 activity and promoting SIRT1 activity in A549 cells and in 
primary CD38 wild-type and knockout mouse embryonic fibroblasts (Escande et al., 
2013). This was associated with improved glucose homeostasis and reduces lipid content 
in the liver of high-fat diet–induced obesity mice. 
 
Obesity and early stages of type 2 diabetes, are characterised by a low-grade systemic 
inflammation and oxidative stress, which in turn are associated with adipose tissue 
dysfunction, insulin resistance, endothelial dysfunction and liver damage. Existing data 
suggest that the metabolic protection observed in in vivo studies with chamomile may be 
complementary mediated through alleviating inflammation and oxidative burst.  
 
In lipopolysaccharide (LPS)-activated RAW 264.7 cells, aqueous chamomile extract 
reduced the synthesis of prostaglandins (PGE2) in a time (0-24 h) and dose-dependent (5-
40 µg/mL) manner. This effect was described to be through the inhibition of the COX-2 
pathway by inhibiting the synthesis and activity of the enzyme (Srivastava et al., 2009) by 
apigenin 7-O-glucoside, which constituted ~90% of the polyphenol content in the extract. 
In support of this, in LPS-THP1 macrophages, apigenin at doses of 10-50 µM drastically 
supressed the release of IL-6, IL-1β and TNF-α (70-90%), however when chamomile 
extract was tested, this effect was nearly supressed owing to the low content of apigenin 
(0.8 µM) (Drummond et al., 2013). In an independent study, apigenin reduced NF-κB 
activation, ICAM-1 mRNA expression and increased insulin-mediated nitric oxide (NO) 
production in endothelial cells after palmitic acid treatment (Ren et al., 2016). Apigenin 
attenuated the protein levels of lectin-like oxidized LDL receptor-1 elicited by high 
glucose and TNF-α in endothelial cells via downregulation of mRNA expression 
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(Yamagata et al., 2011) and reducing phosphorylation of protein kinase C βII, oxidative 
stress and apoptosis along with increased NO levels (Qin et al., 2016); this effect was 
mediated via the PI3K/Akt/eNOS pathway. These in vitro results suggest that 
chamomile/apigenin can confer metabolic protection by mitigating inflammation and 
oxidative stress caused by hyperglycaemia. This antioxidant response could be mediated 
through the Keap1/Nrf2/ARE pathway thus, increasing the expression of antioxidant 
enzymes (Bhaskaran et al., 2013).  
 
Postprandial glycaemia is associated with metabolic dysregulation by altering nutrient 
partitioning, promoting fat storage in metabolic tissues (liver, adipose tissue and skeletal 
muscle), and insulin resistance (Ludwig, 2002; Blaak et al., 2012). An intensive area of 
research on polyphenols and type 2 diabetes has focused on their ability to attenuate 
carbohydrate digestion and absorption which could help to ameliorate metabolic stress 
(Williamson, 2013); this could represent one of the mechanism by which chamomile 
confers metabolic protection. In fact, in human intervention studies (Rafraf et al., 2015; 
Zemestani et al., 2016), chamomile tea was taken after every meal, underlining the 
possibility that the metabolic effects observed can be related with the attenuation of 
postprandial glycaemia. An aqueous chamomile extract inhibited porcine pancreatic α-
amylase and rat maltase and sucrase activity with IC50 values of ~5200, ~2600 and ~900 
µg/mL, respectively (Kato et al., 2008). This represents the only mechanistic study 
looking at the modulation of postprandial glucose by chamomile and so, its potential to 
modulate this metabolic pathway needs further scientific investigation. 
 
Despite the valuable mechanistic information that has been generated on the antidiabetic 
potential of chamomile, most of it is relevant only in a pharmacological context rather 
than in reducing type 2 diabetes risk by a dietary approach. In these studies, chamomile 
extract was directly applied to cells reaching concentrations and chemical forms of 
polyphenols that are not normally expected when they undergo normal metabolism after 
consumption. For instance, the evident inhibition of COX-2 expression and activity was 
observed when chamomile was applied at concentrations of 10 and 20 µg/mL containing 
~40 and ~80 µM of apigenin 7-O-glucoside (Srivastava et al., 2009). This polyphenol is 
unlikely to be present in the blood stream since it undergoes deglycosylation and 
microbial metabolism resulting in the formation of phase II conjugates (Teng et al., 2012) 
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and microbial catabolites such as 3-(4-hydroxyphenyl)propionic acid (Hanske et al., 
2009). Maximum apigenin plasma concentration in rats consuming an oral dose of ~15 
µM was ~ 0.185 µM indicating that only ~1.23 % is bioavailable (Teng et al., 2012). The 
in vitro studies on apigenin report an average effective dose of ~10-50 µM which could 
not possibly have been achieved by the oral administration of chamomile in the in vivo 
studies conducted in rats and mice (assuming that apigenin is present mainly as glycoside 
derivative and underwent mammalian metabolism) and so, they do not support the 
metabolic protection observed in these animal models. This conclusion can be generalised 
for many other in vitro studies employing pure polyphenols and polyphenol-rich extracts 
where the doses applied are not achievable through the diet, and so they do not entirely 
represent what occurs in vivo after repetitive dietary intakes.  
 
Growing scientific consensus converges on the notion that metabolites rather than the 
parent polyphenol (chemical form in planta) are the ones influencing metabolism after 
absorption. Certainly, deciphering the molecular targets and metabolic pathways of these 
metabolites in terms of type 2 diabetes risk prevention is not an easy task, since the 
chemical types and concentrations that reach systemic circulation are a function of the 
individual’s genetic profile and microbiota capabilities. Understanding their true 
mechanism of action requires the development of in vitro models that better represent the 
chronic effect as normally happens after dietary intake, rather than the current 
pharmacological approach adopted for most of the studies so far. As a consequence, we 
have a very limited knowledge of the systemic action of polyphenols and polyphenol-rich 
foods and extracts, and so it certainly will take some few years until we partially define 
robust functional connections between circulating polyphenol metabolites and human 
health and disease state. 
 
Emerging evidence is starting to unmask the contribution and significance that GI 
dysregulation plays on the body’s energy balance, suggesting that it can be a prime target 
for therapeutic actions. Unlike other organs, the knowledge generated on the actions of 
polyphenols and polyphenol-rich foods and extracts including chamomile can be directly 
applied at this site, since postprandial concentrations of parent compounds can reach the 
mM range (Williamson, 2013). Recognition of this therapeutic potential as a core activity 
of these molecules is of primary importance for the development of new products with 
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relevant nutritional characteristics. They can also provide an increase of daily polyphenol 
intake and may guarantee the health benefits attributed to plant-based diets. These 
formulations could provide a window to effective clinical nutrition acting subtly but 
broadly given significant changes in energy balance over a life time period and 
preventing and managing cardiometabolic diseases including type 2 diabetes (Brown et 
al., 2015).  
 
 
1.6 Metabolic regulation by the GI tract: a potential site of action for 
polyphenols and polyphenol rich-foods and extracts on diabetes.  
 
It has started to be widely acknowledged that altered GI function is a significant 
contributor of aberrant metabolism leading to metabolic stress and the subsequent 
progression to type 2 diabetes and associated comorbidities. Intervention studies in 
humans and animals, as well as mechanistic studies in cell models, have provided 
scientific evidence for the protective effects of polyphenols acting at different sites in the 
GI tract, positively influencing physiological processes that protect against type 2 
diabetes. This can be achieved on two main fronts, i) lowering postprandial and total 
glucose excursions and ii) preserving intestinal barrier function. The latter can be 
accomplished by offsetting LPS-mediated inflammation, increasing the expression of 
junctional proteins and remodelling microbiota ecology (Cani et al., 2008; Cani et al., 
2009). Interestingly, some in vitro studies suggests that modulation of these biochemical 
pathways may represent two of the true mechanism by which polyphenols in general, and 
chamomile in particular, confer metabolic protection against type 2 diabetes. However, a 
full discussion of these topics is outside the scope of this thesis, and only the metabolic 
functions of the GI tract in carbohydrate digestion and sugar and the effect of polyphenols 
on these pathways will be discussed.  
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1.6.1 The GI tract in carbohydrate intake and sensing for controlling energy 
homeostasis: the significance of the postprandial state. 
The GI tract contains differentiated specialized cell types including enterocytes, 
enteroendocrine, goblet, and paneth cells. Enterocytes are absorptive cells responsible for 
transporting nutrients into circulation. Enteroendocrine cells coordinate gut functioning 
through specific peptide hormone secretion (GI hormones) which regulate nutrient 
absorption and utilisation while goblet and paneth cells are responsible for protecting 
against chemical damage and modulating the innate immunity respectively (van der Flier 
and Clevers, 2009). The GI tract is thus responsible for the sensing, digestion and 
absorption of nutrients evoking complex neural and endocrine responses that control 
energy metabolism while also functioning as a barrier, preventing antigens and pathogens 
entering the mucosal tissues and potentially causing disease.  
 
Throughout the GI tract, carbohydrates and lipids are sensed via G protein-coupled taste 
receptors (GPCRs) expressed in enteroendocrine cells (originally identified in the oral 
epithelium) increasing intracellular Ca2+ (Sternini et al., 2008; Reimann et al., 2012). 
Intracellular Ca2+ spikes release GI hormones from secretory granules at the basolateral 
membrane which activate nearby vagal- and spinal afferent fibres from neurons and/or 
enter the bloodstream to conduct their hormonal function including the regulation of 
sugar absorption and its metabolism (Sternini et al., 2008; Reimann et al., 2012). GI 
hormones described to regulate these pathways include cholecystokinin (CCK), glucose-
dependent insulinotropic peptide (GIP), glucagon-like peptides (GLPs) and peptide YY 
(PYY).  
 
Upon reaching the upper small intestine, partially hydrolysed carbohydrates activate 
GPCRs expressed on ‘I’ and ‘K’ enteroendocrine cells releasing CCK and GIP 
respectively. CCK induces the secretion of α-amylase from the pancreas (Sternini et al., 
2008), thus achieving efficient carbohydrate digestion by converting starch into smaller 
oligosaccharides, dextrins and disaccharides which require a further step involving the 
action of α-glucosidase enzymes (maltase-glucoamylase and sucrase-isomaltase) to 
produce absorbable glucose. When the dietary sugar is sucrose (glucose linked to 
fructose), the absorbable products are glucose and fructose after hydrolysis by sucrase-
isomaltase. Likewise, released GIP stimulates distal GLP-1 via neural signals in the distal 
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ileum which act together to boost the secretion of insulin from pancreatic β cells 
(Reimann et al., 2012) ensuring efficient buffering of absorbed glucose exported into 
circulation. This is mediated through apically-located transporters SGLT1 (for glucose), 
GLUT2 (glucose and fructose) and GLUT5 (fructose). PPY presents the same biphasic 
release pattern as GLP-1 which seems to be facilitated by CCK (Lin et al., 2000) (Lin and 
Taylor, 2004). Unlike CCK, PYY can reduce carbohydrate digestion and absorption by 
inhibiting pancreatic and intestinal secretion as well as glucose-stimulated insulin 
secretion and sensitivity (Boey et al., 2007). Unabsorbed carbohydrates are further 
catabolised by the microbiota in the distal small intestine and colon producing short chain 
fatty acids (SCFA; mainly acetate, propionate and butyrate) that can stimulate 
gluconeogenesis and DNL in the liver, although the exact mechanism remains elusive 
(Samuel et al., 2008; Marchesi et al., 2016). 
 
During excessive caloric intake (characteristic of the current ‘Western’ lifestyle), lipids 
and sugars presents a metabolic challenge for the body’s bioenergetics, and so the 
metabolic functions of the GI tract are essential for regulating its supply and utilisation in 
the body. The postprandial phase is particularly relevant since during this period, the 
body has to respond with regulatory mechanisms to restore normal energy levels in order 
to maintain homeostasis. High postprandial lipid and sugar excursions can challenge the 
correct functioning of these mechanisms altering the normal transition from the 
postprandial to the postabsorptive state. For instance, in a recent study it was 
demonstrated that an acute and single dose of fat similar to that found in a high fat meal 
such a burger or pizza was sufficient to reduce insulin sensitivity in the whole body of 
healthy individuals by 25 %, altering energy metabolism and promoting hepatic glucose 
release and lipid storage (Hernández et al., 2017). These results indicate that high 
postprandial calorie intake, including high sugar excursions can prepare the path for the 
development of metabolic irregularities. In fact, persistent postprandial glucose spikes 
have been proposed as an independent risk factor of developing type 2 diabetes and 
cardiovascular disease (Barclay et al., 2008; Ceriello and Colagiuri, 2008; Vinoy et al., 
2016). (figure 1.3). 
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Figure 1.3 Postprandial metabolic effects occurred from 2-6 h post-ingestion of high GI 
foods. Postprandial sugar concentrations after the consumption of a high glycaemic food can be 
twice as high as compared with a low GI food with similar levels of nutrients and energy 
(Ludwig, 2002). This rapid flux of glucose exacerbates the secretion of GIP and GLP-1 secretion, 
which along with glucose itself, potentiates insulin release from the pancreas promoting its 
physiological effects on nutrient processing and energy assimilation; as a result, glucose uptake in 
peripheral tissues, glycogenesis and DNL is enhanced while gluconeogenesis is supressed. The 
up-and downregulation of these pathways are maintained even after the total glucose ingested has 
been processed due to the initial boost of insulin, causing a temporal (middle postprandial phase, 
2-4 h) low glucose state or even hypoglycaemic levels (Lev-Ran and Anderson, 1981; Brun et al., 
1995; Ludwig, 2002). Since hyperinsulinemia reduces lipolysis, the fuel levels of the body are 
low and need to be restored. This happens by activating anabolic and catabolic pathways 
including glycogenosis, gluconeogenesis and lipolysis through the secretion of counterregulatory 
hormones ensuing physiological responses that are normally reached after many hours without 
food (Cahill Jr, 1970; Ludwig, 2002). As such, lipolysis and DNL can be overactive in the late 
postprandial phase (4-6 h after ingestion) stimulating chylomicron synthesis and secretion (which 
can be upregulated by glucose, independently of circulating fatty acid levels) (Dash et al., 2015) 
yielding an hyperlipidaemic and inflammatory state, causing vascular injury and the accumulation 
of fat in peripheral tissues. These postprandial metabolic events happen several times a day 
resulting in prolonged and persistent hyperglycaemia, hyperlipidaemia and metabolic stress that,   
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over time supersede the body’s capacity to manage the rise of short and long-term glucose and 
lipid excursions leading to the onset of overt diabetes.  
 
 
Several plausible mechanisms have been proposed for this association including altered 
energy partitioning, increased oxidative stress, low-grade inflammation and endothelial 
dysfunction. For instance, studies conducted in animal models have shown that high GI 
starch diets promote weight gain, visceral adiposity and higher concentrations of 
lipogenic enzymes than do isoenergetic, macro nutrient controlled, low GI-starch. In 
humans, high GI diets promote weight gain as compared with equivalent diets with a low 
GI (Brand-Miller et al., 2002). In healthy, impaired glucose tolerance and type 2 diabetic 
subjects, postprandial hyperglycaemia after ingestion of 75 g of glucose increased 
nitrotyrosine, ICAM-1, VCAM-1, and E-selectin plasma levels, indicating oxidative 
stress and activation of inflammatory pathways (Ceriello et al., 2004).  
 
Decreased endothelium-dependent vasodilation after an oral glucose challenge 
concomitant with a decrease in NO availability was observed in healthy, early stages of 
diabetes and type 2 diabetic individuals (Kawano et al., 1999). Hyperlipidaemia and 
hypertriglyceridaemia are common features of the postprandial state after a high GI diet 
(Harbis et al., 2001; Aslam et al., 2016) and are well known for evoking the production of 
proinflammatory cytokines, recruitment of neutrophils, and generation of oxidative stress, 
thus provoking endothelial dysfunction (Ansar et al., 2011; Nakamura et al., 2016).  
 
The pathological events initiated by hyperglycaemia during the postprandial phase are 
thought to be related to exaggerated hormonal responses caused by the rapid rise and fall 
of blood glucose levels. This is first initiated with the development of an hypoglycaemic 
state due to hyperinsulinemia (Lev-Ran and Anderson, 1981; Brun et al., 1995) that in 
turn triggers glucagon secretion and gluconeogenesis along with overactivation of 
lipolysis and DNL (Ludwig, 2002; Blaak et al., 2012) causing hyperlipidaemia and 
hypertriglyceridemia. These upregulated physiological responses are not observed in 
individuals after having a low GI meal which produce smaller postprandial glucose rise, 
leading to smaller fluctuations in blood glucose levels and more gentle decreases; thus the 
hypoglycaemic state is evaded (Ludwig, 2002) and dyslipidaemia is attenuated (Harbis et 
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al., 2001). The metabolic events during the postprandial phase last for approximately 6 h 
before reaching fasting levels (Ludwig, 2002; Nakamura et al., 2016), so for those who 
consume three meals a day spend most the days and their lives in this phase. Therefore 
persistent postprandial hyperglycaemia can disrupt energy metabolism in peripheral 
tissues and perhaps can be involved in the gradual failure of metabolic control in the GI 
tract. 
 
Recent findings suggest that alteration of endocrine output could occur via chronic 
stimulation of GPCRs with high sugar diets, and it could be an important contributor of 
postprandial metabolic stress. Both, SGLT1 and GLUT2 are regulated through T1R2-
T1R3. High sucrose increased SGLT1 mRNA and protein expression by 2-fold, and 
glucose absorptive capacity in wild-type mice, but not in knockout mice lacking T1R3 
(Margolskee et al., 2007). Activation of T1R2-T1R3 by glucose (75 mM) resulted in a 
rapid 3-fold increase in apical GLUT2 in rat jejunum (Mace et al., 2007) and this effect 
was also observed for sucrose (Gouyon et al., 2003). Importantly, T1R2 expression 
decreases markedly in response to glucose during hyperglycaemia in healthy subjects but 
increased in type 2 diabetics (Young et al., 2013) indicating that disrupted signalling 
under metabolic stress could contribute to the abnormal expression and/or function of 
glucose transporters observed in obesity (Seimon et al., 2013), experimental diabetes 
(Tobin et al., 2008) and type 2 diabetic subjects (Ait-Omar et al., 2011). Moreover, 
metabolic adaptations in the GI tract can occur in response to carbohydrate intake (Perry 
et al., 2007) which will in turn enhance their processing and transport into circulation 
contributing to postprandial metabolic stress. Studies conducted in human vascular cells 
indicates that these adaptations can occur during transient hyperglycaemia and persevere 
even after restoration of normoglycaemia (El-Osta et al., 2008), which can also 
presumably occur in enterocytes. 
  
In addition to promote hyperglycaemia, in vitro and in vivo evidence indicates that high 
flux of glucose into absorptive cells may dysregulate the assembly and export of 
chylomicrons carrying triglycerides and cholesterol during the postprandial phase. 
Luminal cholesterol is taken up by the Niemann-Pick C1 Like 1 (NPC1L1) receptor and 
studies in the intestinal cell model Caco-2 suggest that its expression is modulated by 
glucose concentration and metabolism (Altmann et al., 2004; Davis and Veltri, 2007; Jia 
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et al., 2011) and overexpressed in insulin resistance and type 2 diabetes (Adeli and Lewis, 
2008; Tomkin and Owens, 2011; Veilleux et al., 2014; Tomkin and Owens, 2015). This is 
supported by the established observation that excessive postprandial glucose excursions 
in impaired glucose tolerance and in type 2 diabetics are associated with a cascade of pro-
atherogenic events. Furthermore, enterocytes are capable of storing dietary lipid in the 
cytosol (Chavez–Jauregui et al., 2010; D'Aquila et al., 2016) and subsequently mobilise 
and release them as part of chylomicrons hours after in response to an acute glucose 
stimuli (Robertson et al., 2003). This is in line with the observation that chylomicron 
synthesis in healthy individuals is increased in response to luminal glucose and insulin 
levels (Harbis et al., 2001; Xiao et al., 2013; Xiao et al., 2016).  
 
The atherogenic process has been proposed to be a postprandial event caused by the 
accumulation of remnant cholesterol into sub-endothelial space, leading to inflammation 
and vascular injury (Nordestgaard and Varbo, 2014) increasing the risk of cardiovascular 
disease (Jørgensen et al., 2012; Varbo et al., 2013). Hypertriglyceridaemia, which has 
been suggested to be a marker of circulating remnants rich in cholesterol (Nordestgaard 
and Varbo, 2014) is a common feature of high glucose influx into circulation (Harbis et 
al., 2001; Aslam et al., 2016) evoking the production of proinflammatory cytokines, 
recruitment of neutrophils, and generation of oxidative stress, thus provoking endothelial 
dysfunction (Ansar et al., 2011; Nakamura et al., 2016). Therefore dysregulation of 
cholesterol-rich chylomicrons might be the root cause of the low-grade inflammation and 
endothelial dysfunction observed during the postprandial phase mediated by 
hyperglycaemia and the concomitant hyperinsulinemia. Thus the acute but persistent 
postprandial metabolic disorders such as hyperglycaemia, dyslipidaemia, inflammation 
and endothelial dysfunction could be preceded by sustained and repeated exposure to high 
GI diets which will ultimately lead to chronic insulin resistance and decline of 
cardiometabolic health. 
 
In the light of present eating patterns, the GI tract represents an organ that can drive 
metabolic disorder by increasing energy availability, glycaemic impact and 
dyslipidaemia. Nevertheless, it also represents an opportunity for protection and 
intervention. The low bioavailability of polyphenols entails that they are delivered in the 
GI tract in relatively high concentrations in their native chemical form. This can favour 
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chemical interactions with proteins altering the digestion and absorption processes of 
carbohydrates and sugars, and thus attenuating the hormonal response caused by high 
postprandial sugar excursions and the cluster of metabolic dysregulations. 
 
 
1.6.2 Postprandial glycaemia and polyphenols. 
Reducing or delaying glucose absorption could prevent impaired glucose tolerance in 
healthy individuals while potentially lowering demands on β cells in insulin resistance 
and type 2 diabetic state. This can be achieved by inhibiting the carbohydrate-digesting 
enzymes α-amylase and α-glucosidase and glucose transporters SGLT1 and GLUT2.   
 
Over the past decade, evidence from many in vitro studies has supported the potential of 
polyphenols to attenuate the activity of α-amylase (Nyambe-Silavwe et al., 2015) and α-
glucosidase enzymes (Xiao et al., 2013). Most of these studies have been conducted using 
polyphenol-rich extracts without clearly identifying the active(s) constituents. While this 
approach may be useful to identify potential dietary sources that can attenuate 
postprandial sugar levels, it also constitutes a basis for ambiguity and is prone to 
conflicting results, due to the inherent variability of these molecules in planta. For 
example, significant variation on the inhibition of α-amylase and α-glucosidase activity 
was observed in different cultivars of fig (Wojdyło et al., 2016), apple pulp and peel 
(Barbosa et al., 2010) and grape pomace extracts (Kadouh et al., 2016) while no 
inhibition was also reported for an apple peel extract (Nyambe-Silavwe and Williamson, 
2016). The same discrepancy has been reported for hibiscus extracts on α-amylase and in 
black currant extracts on α-glucosidase were positive (Boath et al., 2012; Ademiluyi and 
Oboh, 2013) and negligible inhibition was observed (Ifie et al., 2016; Nyambe-Silavwe 
and Williamson, 2016). Thus, the literature in this field is overwhelmed by conflicting 
observations of polyphenol-rich extracts that may be capable of reducing carbohydrate 
digestion (Etxeberria et al., 2012; Martel et al., 2016). Whereas the assessment of the 
total extracts considers polyphenol interactions and synergism, it is of interest to examine 
specific compounds that greatly contribute to the total activity, which may guide the quest 
for potent compounds and help to reduce the aforementioned variability in fruit and plant 
extracts.  
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In silico studies have shown that the chemical nature of polyphenols and OH substitution 
pattern and number play a pivotal role in the inhibitory activity against carbohydrate-
digesting enzymes. For human α-amylase, a detailed structure-activity analysis for 
flavonoids described a competitive mechanism where hydrogen bonds between the 
hydroxyl groups of the polyphenol and the catalytic triad, and the formation of a 
conjugated π-system are key for the inhibitory activity (Lo Piparo et al., 2008). As for α-
glucosidases, appropriate in silico studies are more difficult to conduct since the enzyme 
is membrane-bound, so special attention should be paid when extrapolating results from 
studies conducted using non-mammalian enzymes, which have very different specificities 
to human or porcine enzymes (Williamson, 2013). This can mislead the identification of 
molecules that lack physiological relevance and vice versa. However, a similar 
mechanism of inhibition as for human α-amylase has been described using a bacterial 
enzyme (Ahmed et al., 2014). 
 
Docking studies suggest that polyphenols with complex phenolic cores (i.e. high number 
of OH groups and hydrophobic or π interactions) are likely to be effective inhibitors of 
carbohydrate-digesting enzymes. A remarkable example is the strongest α-amylase 
polyphenol inhibitor described so far, ‘montbretin A’ with Ki = 8 nM’ (Tarling et al., 
2008; Williams et al., 2015) which is comprised of a phenolic core of caffeic acid and 
myricetin. Other well-established polyphenol structures where modelling predictions have 
been experimentally verified include quercetin, epigallocatechin gallate (EGCG) and 
luteolin. There are some other polyphenols with reported inhibitory activity of α-amylase 
and α-glucosidase however, as for plant extracts, the data includes contradictory results. 
Cyandin-3-sambubioside was very effective at inhibiting α-amylase and α-glucosidase 
and surprisingly, it was ~48 and 28 times more potent than acarbose for both enzymes 
(Ho et al., 2017). Conversely, it has also been reported to be ineffective at attenuating α-
amylase activity while its inhibition on α-glucosidase was ~200 fold lower than the 
previous report (Ifie et al., 2016). Even for EGCG whose inhibitory potential against α-
amylase is well established, negative results still can be found in the literature (Yasuda et 
al., 2014).  
 
The in vitro studies conducted on the potential of polyphenols and polyphenol-rich 
extracts provide valuable insights about their potential to attenuate α-glycosidase activity. 
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However, recognition and ranking of effective specific compounds or extracts have been 
difficult to establish since there are wide inconsistencies in both assay methods and 
experimental outcomes (see appendix A-C). Very often, synthetic substrates are 
employed to assess the inhibition of polyphenols on α-glycosidase activity. While they 
are useful to assess enzymatic activity, their affinity and binding properties are different 
when compared to physiological substrates (Williamson, 2013) representing a limitation 
for inhibition assays, especially for competitive inhibitors. In the case of inhibition assays 
on α-glucosidase activity, p-nitrophenyl-glucoside is mostly used which indicates a 
general α-glucosidase activity, and no distinction between maltase and sucrase activity 
can be established. Physiologically relevant substrates are also often used however, the 
heterogeneity of assay conditions has led to wide inconsistencies, even when the same 
natural substrate and inhibitor are under study. This irreproducibility of results has been a 
major shortcoming for the translation of polyphenols into nutritional therapeutic 
formulations since there is no robust evidence to relate the effect of a particular 
polyphenol-rich food, plant extract or single compound on this pathway. 
 
The potential of polyphenols to reduce postprandial sugar excursions goes beyond the 
inhibition of digestive enzymes. Polyphenols can form complexes with brush-border 
membrane transporters altering the entry and transport of intestinal sugars across the 
small intestine. The first direct evidence about the interaction of a polyphenol with an 
intestinal sugar transporter dates back to the 1960s where phlorizin, a polyphenol present 
in apple competitively inhibited intestinal glucose transport in everted hamster’s rings 
(Alvarado and Crane, 1962). Further studies on the mechanism of phlorizin inhibition on 
membrane sugar transport led to the identification of the sodium–glucose transport 
mechanism (Vick et al., 1973) and gained its recognition as a specific SGLT inhibitor.  
 
Extending the observation on the similarity with acarbose (an antidiabetic drug that 
inhibits α-amylase and α-glucosidase enzymes) to blunt intestinal glucose absorption, it 
has been demonstrated that acute administration of phlorizin supresses postprandial blood 
glucose levels in mice (Takii et al., 1997; Shirosaki et al., 2012). This finding has been 
further supported by three independent pilot studies in healthy volunteers where apple 
juice (Johnston et al., 2002) and apple extract (Schulze et al., 2014; Makarova et al., 
2015) attenuated postprandial glucose and insulin levels as compared with control meals, 
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which can be mainly attributed to the inhibition of glucose uptake by phlorizin, according 
to in vitro mechanistic studies conducted in intestinal models (Williamson, 2013; Schulze 
et al., 2014). Like phloridzin, there are other example of polyphenols that have been 
described to inhibit intestinal glucose uptake in vitro through their interaction with 
SGLT1 and/or GLUT2 including EGCG, (-)-epicatechin, quercetin, myricetin, 
naringenin, and some of their glucoside derivatives (Kobayashi et al., 2000; Johnston et 
al., 2005; Kottra and Daniel, 2007; Schulze et al., 2014; Schulze et al., 2015). The 
inhibition constants on both transporters have been reported to be in the range of ~10-
1000 µM which are realistic as intestinal intraluminal concentrations (Williamson, 2013). 
Hence, intake of the right polyphenol or polyphenol mixture could possibly inhibit, to 
some extent, the glucose influx into the enterocyte and circulation. The in vitro studies on 
the inhibition of sugar transporters by polyphenols are more limited than those conducted 
for α-glycosidase enzymes and so more studies are needed to validate already reported 
candidates. Although there seems to be a consensus on this matter, conflicting results still 
can be found. For instance, in Caco-2 cells, (-)-epicatechin inhibited SGLT1 mediated 
glucose uptake with an IC50 value of ~100 µM (Johnston et al., 2005) while no inhibition 
was observed in a latter study in the same cell model even at a concentration >500 µM 
(Manzano and Williamson, 2010). 
 
Although there are still some discrepancies when linking the in vitro with in vivo results, 
as to whether polyphenols act synergistically in the various steps of the process of 
carbohydrate digestion and absorption, some evidence from animal studies clearly 
indicate that these compounds limit the postprandial sugar flux into circulation. This has 
been reflected by decreases in postprandial peak and blood glucose and insulin levels 
(Forester et al., 2012; Goto et al., 2012; Murase et al., 2012) and in the secretion of GIP 
incretin hormone (Murase et al., 2012). In particular, the decrease in postprandial glucose 
and insulin along with GIP secretion by an extract of coffee polyphenols was related with 
changes in energy partitioning (Murase et al., 2012), suggesting that polyphenols can 
improve metabolic management of glucose, maintaining an adequate equilibrium between 
the rate of carbohydrate oxidation and utilisation preserving a healthy phenotype.  
 
Most of the effects of polyphenols in postprandial glycaemia were related to the 
inhibition of α-amylase and α-glucosidase enzymes (without distinguishing between 
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maltase and sucrase) with the exception of the study of Goto and co-workers, that also 
related the effects with the inhibition of the sugar transporters SGLT1 and GLUT2 (Goto 
et al., 2012). Surprisingly, when EGCG was co-administered with maltose or glucose to 
mice, no changes were observed in postprandial blood glucose (Forester et al., 2012) 
suggesting no effect on α-glucosidase activity and SGLT1 and/or GLUT2 transporters, 
despite the fact these activities have been reported for this molecule (Hossain et al., 2002; 
Johnston et al., 2005; Nyambe-Silavwe and Williamson, 2016).  
 
Despite the promising results observed in rodents, the answer to the question as to 
whether polyphenols can actually reduce postprandial glucose input with long-term 
metabolic effects in humans remains ambiguous (Suksomboon et al., 2011; de Bock et 
al., 2012; Amiot et al., 2016). For instance, opposing conclusions were obtained in two 
systematic reviews evaluating the association of the consumption of polyphenol-rich 
foods, or beverages, with a carbohydrate source on acute postprandial glycaemia and/or 
insulin concentrations (Burton-Freeman, 2010; Coe and Ryan, 2016). The intake of 
cranberry juice, wild blueberry, strawberry and a fruit meal of banana, kiwi or apple, red 
wine or red wine components did not reduce postprandial glucose levels while mixed 
results were observed regarding insulin, although without reaching significant differences 
in most of the cases (Burton-Freeman, 2010). On the other hand, Coe and Ryan (2016) 
concluded that polyphenol sources such as coffee, black tea, different types of berries, 
apple and aracá juice reduced the peak and early-phase glycaemic and insulin response, 
however with varying degrees of effectiveness depending on the polyphenol–
carbohydrate combination. 
 
The conflicting results presented above can be partially explained by the inconsistent and 
limited characterisation of polyphenol-rich extracts in terms of active constituents, their 
targets and efficacies, restricting the rational design of human intervention studies and 
validation of potential physiological effects. Therefore very few human studies have 
selected individual polyphenols or polyphenol-rich extract with speciﬁc mechanisms of 
effect in mind, yet some examples do exist. For instance, a designed polyphenol-rich meal 
with a combination and concentration of polyphenols capable of inhibiting the different 
stages of starch digestion and absorption as observed in vitro, reduced glucose and insulin 
postprandial levels (~ 50 %) in healthy individuals in a randomised, cross-over 
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intervention (Nyambe-Silavwe and Williamson, 2016). In a similar design, 4 g of green 
tea extract (EGCG content –257.6 mg) with an active concentration of ~0.26 mg/mL 
considering an intestinal volume of 1 L (Nyambe-Silavwe and Williamson, 2016) reduced 
blood glucose by ~30 % after a corn starch meal. In both studies, the concentration of the 
active constituents were at least ~100 times higher than the experimental inhibition 
constants obtained in vitro, which perhaps are needed in order to account for possible 
interactions with other macromolecules if positive results are to be obtained.  
 
Hyperlipidaemia is a common feature during high postprandial glycaemia, probably 
involved in the endothelial dysfunction observed under this condition by promoting 
oxidative stress, atherogenesis and inflammation (Ludwig, 2002; Nordestgaard and 
Varbo, 2014). Due to this intrinsic relationship, the effect of polyphenols on postprandial 
glycaemic impact could attenuate to some extend the levels of circulating lipids and 
cholesterol rich-lipoproteins during the postprandial phase. Indeed, epidemiological 
studies suggest a lower risk of cardiovascular disease by polyphenol intake (Hertog et al., 
1997; McCullough et al., 2012; Kishimoto et al., 2013) and human intervention studies 
indicate that polyphenols regulates postprandial lipid metabolism (Annuzzi et al., 2014). 
For instance, postprandial ApoB48 (a specific marker of chylomicrons and their 
remnants) was reduced by acute non-alcoholic red wine consumption in dyslipidaemic 
postmenopausal woman 6 h after eating (Pal and Naissides, 2004). Similarly, a 
polyphenol-rich diet composed of decaffeinated green tea and coffee, dark chocolate, 
blueberry jam, artichokes, onions, spinach, rocket, and extra-virgin olive oil reduced 
postprandial triglyceride and chylomicron cholesterol in obese/overweight individuals 
after 8 weeks intervention (Annuzzi et al., 2014). Impaired lipid availability in 
enterocytes by the inhibiting digestive lipases and impairing cholesterol solubility has 
been linked with the reduction in intestinal chylomicron production. However, since 
glucose metabolism in enterocytes increase cholesterol absorption, lipogenesis and 
chylomicron assembly and secretion (Robertson et al., 2003; Ravid et al., 2008; Malhotra 
et al., 2013; Xiao et al., 2013), it is possible that attenuation of glucose influx has a knock 
on effect on maintaining a fine tune on this biosynthetic pathway. Therefore, in vitro 
experiments evaluating the effect of polyphenols on postprandial glycaemia should 
contemplate the pleiotropic effect of polyphenols on lipoprotein assembly and secretion 
since there is a plausible association between these metabolic pathways. 
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More studies are needed to validate the effects of polyphenols on postprandial glycaemic 
and lipid response in healthy individuals as well as in those at risk and with type 2 
diabetes. These studies should consider the assessment of standardised preparations based 
on both active constituents and inhibition constants (active concentrations) as well as 
targeting all the steps of the digestion and absorption process, which can potentially give 
subtle but multiple inhibition resulting in a significant overall response. The complexity 
and diversity of polyphenol structures pose a challenge on this matter, which can only be 
overcome with an appropriate chemical characterisation of the polyphenol source that is 
under investigation. This will help to conduct targeted in vitro experiments in order to 
identify the most likely class of molecule(s) responsible for the activity and information 
about potential synergy with other molecules. The in vitro experiments must be 
conducted under the highest standards of methodological rigor if consistent results, and 
recognition on the potential of a particular polyphenol are to be obtained. In this regard, 
the in vitro assays have to be conducted under optimal conditions and using physiological 
substrates which will aid in reducing the current variability that exist in the literature in 
terms of inhibition potencies. By identifying and validating the action of specific 
polyphenols, we will move forward to develop standardised polyphenol-based 
formulations with reproducible actions to achieve an effective clinical nutrition through 
the attenuation of persistent high postprandial glycaemia. 
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1.7 Aim and objectives of the thesis 
 
Plant food supplements are concentrated sources of botanical preparations which could 
provide everyday maintenance. However their use is of concern amongst scientific and 
regulatory communities since there is a lack of scientific substantiation of their bioactive 
constituents and the product itself. The research work of this thesis was developed under 
the framework of the EU project PlantLIBRA with the aim to establish the potential 
health benefits of some plant food supplements using advanced in vitro approaches. 
 
Type 2 diabetes is a growing epidemic and alternatives to reduce the risk of this 
metabolic disease are much needed. In vivo evidence has shown that chamomile can 
positively modulate energy metabolism, suggesting it can be used to provide everyday 
health maintenance. Polyphenols are abundant constituents in chamomile and cumulative 
studies propose they can attenuate the short-term metabolic disturbance caused by high 
postprandial sugar excursions, an important metabolic pathway to maintain long-term 
energy balance. This thesis aimed to investigate whether the in vivo effects of chamomile 
on type 2 diabetes prevention and management can be partially mediated by attenuating 
carbohydrate digestion and sugar absorption and to identify the potential polyphenol 
candidates acting on these pathways by in vitro mechanistic studies. 
 
Hypothesis: Chamomile can attenuate the activity of carbohydrate-digestive enzymes 
and sugar transporters in vitro and these effects are mediated by the most abundant 
polyphenol constituents. 
 
The objectives of this research project were: 
i) Identify and quantify the major polyphenols present in chamomile leading to 
confirm the identity of two abundant hydroxycinnamic acid derivatives 
present.  
ii) Assess the effect of chamomile extract and the most abundant polyphenols to 
attenuate the activity of human salivary α-amylase and rat α-glucosidase 
(maltase, sucrase and isomaltase) employing physiologically relevant 
substrates under optimised assay conditions, identifying individual 
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contributions for each polyphenol. In silico studies were conducted to 
establish the structure-activity relationship. 
iii) Assess the effect of chamomile extract and its major polyphenols to reduce the 
rate of glucose, sucrose and fructose transport using the well characterised 
Caco-2/TC7 cell model and to delineate through mechanistic experiments the 
transporter protein mostly affected and the active compounds. 
iv) Explore the effect of attenuating glucose uptake on cholesterol absorption and 
in the expression of genes regulating cholesterol transporter proteins in Caco-2 
cells. 
- 35 - 
 
Chapter 2 Identification and quantification of major polyphenols in 
chamomile: isolation and structural characterisation of two 
hydroxycinnamic acid derivatives. 
 
2.1 Abstract. 
 
Botanical extracts represent a rich source of bioactive small molecules which can be used 
to provide everyday health maintenance and lower disease risk. Nonetheless, a major 
drawback in this field has been the inadequate determination of the chemical composition 
of the starting plant material resulting in wide inconsistencies across studies. Moreover, 
many of these small molecules remain undiscovered or unexplored for their potential 
biological activity due to their commercial unavailability. Chamomile is a rich source of 
small molecules, especially polyphenols and their chemical characterisation and 
identification is still a work in progress. This chapter summarises the identification and 
quantification of the main polyphenol constituents in a chamomile extract and the 
isolation and chemical characterisation of two hydroxycinnamic acid derivatives whose 
identity was uncertain. LC-MS/MS, LC-QTOF and HPLC-DAD revealed the presence of 
apigenin, apigenin 7-O-glucoside and two hydroxycinnamic acid derivatives as the main 
polyphenol constituents. The two hydroxycinnamic acid derivatives were purified by 
semi-preparative column chromatography, and  identified as (Z) and (E)-2-hydroxy-4-
methoxycinnamic acid glucoside based on accurate mass TOFMS, 1H-13C NMR, nuclear 
Overhauser effect spectroscopy and chemical synthesis of the (E)-methoxycinnamic acid 
skeleton. Quantitative analysis revealed that these compounds are present ~ at the same 
levels as apigenin 7-O-glucoside, the predominant example reported in chamomile until 
now and so, they may contribute to the therapeutic effects of chamomile preparations.  
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2.2  Introduction. 
 
Natural plant extracts provide a rich source for therapeutic discovery which is supported 
by empirical knowledge generated through their use in folklore medicine. Nowadays, 
there is a growing perception that the use of natural bioactive constituents may elicit 
fewer side effects and be similar or more effective than single synthetic chemical entities 
(Gosslau et al., 2011). Thus, they have become a major focus in the field of clinical 
nutritional research to develop multicomponent botanical therapeutic preparations, 
functional foods and nutraceuticals with good safety profiles that can complement 
conventional pharmaceuticals in the treatment and reduction of disease risk. However, the 
development of these safe and effective therapeutic formulations is currently being 
slowed down by the lack of rigorous or poorly documented science, including setbacks in 
their chemical characterisation and biological activity, often resulting in irreproducible 
effects or conflicting results (Raskin et al., 2002; Gosslau et al., 2011; Atanasov et al., 
2015). For instance, green tea extract showed positive effects on reducing postprandial 
glycaemic response (Weber et al., 2008) while no effects were also observed (Josic et al., 
2010) in healthy subjects. 
 
Chamomile it is one of the oldest, most widely used and well-documented medicinal 
plants in the world. It belongs to the Asteraceae/Compositae family and it is represented 
by two common varieties viz. German Chamomile (Matricaria recutita) and Roman 
Chamomile (Chamaemelum nobile) (McKay and Blumberg, 2006; Srivastava et al., 
2010). It is an annual herbaceous plant indigenous to Europe and Western Asia that has 
been naturalised in Australia, UK and the United States and cultivated in Germany, 
Hungary, Russia and other Southern and Eastern European countries for the flower heads 
(Shukla and Gupta, 2010). The recognition of its medicinal properties is exemplified by 
its listing as an official drug in the pharmacopoeias of 26 countries including the UK 
(Ross, 2008). Its medicinal application is mainly established on its anti-inflammatory, 
anti-septic, anti-spasmodic and wound-healing effects, particularly in gastrointestinal 
disorders where its therapeutic effects have been recognised by the German Commission 
E and approved to treat various inflammatory illness (Ross, 2008). Other health effects of 
chamomile that possess scientific substantiation include its chemopreventive (Srivastava 
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and Gupta, 2007; Srivastava and Gupta, 2009; Srivastava et al., 2010) and antidiabetic 
activity (Kato et al., 2008; Weidner et al., 2013; Rafraf et al., 2015).  
  
Several phytochemicals have been identified in chamomile where polyphenols constitute 
the principal group (McKay and Blumberg, 2006). Among them, the flavone apigenin and 
its derivatives (glucosides and acetates) have been reported as the predominant examples 
with levels ~17 % on a dry weight basis of the total flower (Mulinacci et al., 2000; 
Švehlı́ková et al., 2004; Srivastava and Gupta, 2007). Consequently, apigenin and its 
precursor apigenin-7-O-glucoside which are commercially available, have been selected, 
studied and related with some of the biological activities of chamomile including anti-
inflammation (Srivastava et al., 2009) and chemoprevention (Srivastava and Gupta, 2007; 
Srivastava and Gupta, 2009; Matić et al., 2013). However, several hydroxycinnamic acid 
derivatives have been identified and quantified by several independent research groups 
indicating that they are present in higher amounts than total flavonoids, making up to 64.8 
% (dry weight) of the total polyphenol content (Mulinacci et al., 2000; Guimarães et al., 
2013; Matić et al., 2013). In particular, the presence of two of these derivatives makes ~ 
50 % of the total hydroxycinnamic acids and so, they may modulate and/or participate to 
some extent in the biological activity of chamomile preparations; something that remains 
unexplored so far. It is important to underline that the identity of these two compounds is 
debatable and uncertain based on various tentative identifications which have suggested 
several chemical structures such as isomeric and dimeric structures of ferulic acid 
derivatives (Mulinacci et al., 2000; Guimarães et al., 2013) and isomeric structures of 2-
β-D-glucopyranosyloxy-4-methoxycinnamic acid (Weber et al., 2008). Thus the chemical 
information that has been generated and used to characterise and identified the chemical 
structure of these compounds to date remains insufficient and controversial.  
 
The aim of this study was to identify and quantify the major polyphenol constituents in 
German chamomile extract (ChE) and fully and positively identify the two 
hydroxycinnamic acid derivatives to provide adequate compositional data. 
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2.3 Materials and methods. 
 
2.3.1 Materials. 
The ChE and authentic standards of apigenin and apigenin 7-O-glucoside were obtained 
from the plantLIBRA partner PhytoLab Co. KG.h (Vestenbergsgreuth, Germany) as a 
lyophilised powder. 7-methoxycoumarin, LC grade solvents acetonitrile and methanol, 
the analytical reagent formic acid, 1-phenyl-3-methyl-5-pyrazolone, D-mannose, D-
galactose and D-xylose were obtained from Sigma-Aldrich Co., Ltd., Dorset, U.K. The 
analytical reagents D-glucose and TFA were purchased from Fisher Scientific 
(Loughborough, Leicestershire, UK). Distilled water was used for all the experiments 
(Millipore UK Ltd., Hertfordshire, UK). All the reagents were of the highest purity and 
standards were ≥98 % according to the manufacturer. 
 
2.3.2 Methods. 
2.3.2.1 Preparation of ChE for high performance liquid chromatography analysis 
and semi-preparative isolation. 
The ChE was prepared in tubes (14 mL) by adding room temperature water to reach a 
desired concentration of 1 mg/mL. The suspension was mixed vigorously and vortexed 
for 1 min. Then the suspension was centrifuged at 17000 g for 10 min at 4 °C and the 
supernatant was recovered. Thereafter, the supernatant was filtered through 0.2 µm 
syringe-drive PTFE filters and the filtrate used for the subsequent analysis.  
2.3.2.2 Identification and quantification of major polyphenols in ChE. 
Identification and quantification of major polyphenols in ChE was performed on an 
HPLC-DAD system (1200 series; Agilent Technologies, Berkshire, UK) equipped with a 
kinetex C18 analytical column (150x2.10 mm I.D., 2.6μm; Phenomenex, Cheshire, UK) 
maintained at 35 °C. ChE was prepared as previously described in section 2.3.2.1 at 1 
mg/mL and 10 µL was injected and separated using a 41 min gradient of premixed 5 % 
acetonitrile in water (5:95, v/v) (A) and premixed 5% water in acetonitrile (5:95, v/v) (B), 
both modified with 0.1 % formic acid at 0.25 mL/min. The gradient utilized started at 0 % 
solvent B and increased to 10 % (5 min), 25 % (10 min), 35 % (20 min), 50 % (25 min), 
and held at a plateau up to 30 min. The gradient was increased 100 % at 30.5 min and 
returned to 0 % solvent B over 5.5 min before initial starting conditions were resumed for 
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a 6 min column re-equilibration. Double online detection was carried out using 280 and 
320 nm and chromatograms acquired at 320 nm were used for quantification and 
presentation. 
 
Identification of apigenin and apigenin-7-O-glucoside was performed by comparison of 
retention time with those of authentic standards. For the two hydroxycinnamic acid 
derivatives, the identification was based on the deprotonated molecular ions previously 
reported for those compounds at m/z 355 and 711 (Mulinacci et al., 2000; Guimarães et 
al., 2013) on a Shimadzu LC-2010 HT coupled with 2020 quadrupole mass spectrometer 
equipped with an ESI interface under the chromatographic conditions described above. 
Nitrogen was used as nebulizing (45 psig; 1.50 L/min) and drying gas (15.0 L/min); gas 
and vapourizer temperature was 250 °C; detector -1.80 kV, DL temperature 250°C. 
Quantitative analysis of the targeted compounds was conducted by comparison with those 
of authentic standards using an external five-point linear calibration curve (figure 2.1).  
 
Figure 2.1 Representative example of the standard calibration curves generated and used 
for the quantification of apigenin, apigenin 7-O-glucoside (A7G) and hydroxycinnamic acid 
derivatives (HCA) in ChE. Due to its limited solubility, the standard curve of apigenin was 
prepared in the range of 0-50 µM. The values shown are averages of triplicate assays ± SEM. 
Where not visible, error bars are smaller than the size of the data point.  
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The limit of detection (LOD) and the limit of quantitation (LOQ) were calculated by 
LOD=(3.3*intercept)/slope and LOQ=(10*intercept)/slope, respectively for the individual 
polyphenols. 
 
 
2.3.2.3 Method development for the isolation of hydroxycinnamic acid derivatives 
from ChE by semi-preparative RP-HPLC chromatography.  
An ÄKTA Purifier System (GE Healthcare, Fairfield, CT, USA) controlled by a PC 
running GE Unicorn software (5.11), equipped with an UV detector UV-900, 
pH/conductivity detector pH/C-900, fraction collector Frac-950, gradient mixer, and 
pump P-900 was employed. The basic configuration of the system is shown in figure 2.2.  
 
 
  
 
    
  
  
 
 
Figure 2.2 Basic configuration of the AKTA purifier system used to isolate the 
hydroxycinnamic acid derivatives from ChE. The separation unit of the chromatography 
system has four main modules: 1) a binary high performance gradient pump, 2) a multi-
wavelength UV-Vis monitor for simultaneous monitoring of up to 3 wavelengths in the range of 
190-700 nm, 3) a combined monitor for on-line conductivity and pH monitoring and 4) a fraction 
collector with capacity to collect up to 175 fractions. For method optimisation, the sample was 
loaded through a sample loop of 0.1 mL. For isolation, the capacity of the sample loop was 
increased to 1 mL and the flow rate adjusted accordingly (section 2.3.2.4). 
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Two different bonded-phase chemistries were used for the development of the method. 
The first column was a µRPC C2/C18 ST LC column 4.6x100mm I.D. (GE Healthcare, 
Fairfield, CT, USA) which has been demonstrated to be suitable for the determination of 
glycosylated polyphenols (Courts, 2011). The second column was a Gemini C6 phenyl 
column 4.6x150mm i.d. which has a higher selectivity for aromatic compounds 
(Phenomenex, Cheshire, UK). Different chromatographic conditions (flow rate, mobile 
phase, and gradients) were tested using ChE as test sample before the best resolution was 
achieved. This was obtained using the Gemini C6 phenyl column using water containing 
0.1% TFA (solvent A) and acetonitrile (Solvent B) as mobile phase and a gradient 
program as follows:1.5 column volumes (cv), 5–24% B, 1.5 cv, 24% B, 3 cv, 24–38% B, 
3 cv 38-100% B, 1.5 cv, 100% B, 0.1 cv, 100-5% B, 4 cv, 5% B) at 0.8 mL/min (figure 
2.3).  
 
Figure 2.3 Chromatographic separation of polyphenols present in ChE. (A) The separation 
wasconducted using a µRPC C2/C18 column. (B) The separation was done with a phenyl C6 
column. The same chromatographic conditions were employed with both columns and the 
separation was performed using a mobile phase composed of H2O (0.1% TFA) and the separation  
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was performed using a mobile phase composed of H2O (0.1% TFA) and acetonitrile using the 
gradient described in section 2.3.2.3. 
 
 
For the purification of the hydroxycinnamic acid derivatives, solvent B was changed for 
methanol in order to increase the selectivity and separation factor (α) to those polyphenols 
close to the target compounds (figure 2.4).  
 
 
Figure 2.4 Chromatographic separation of polyphenols present in ChE using the C6 phenyl 
column.The chromatogram shows the difference between (A) acetonitrile and (B) methanol as 
mobile phase. The same chromatographic gradient was used for both mobile phases. Targeted 
peaks for isolation are indicated with arrows in panel B. 
 
 
2.3.2.4 Semi-preparative isolation of hydroxycinnamic acid derivatives.  
The two hydroxycinnamic acid derivatives were isolated using the instrument and 
chromatographic conditions previously described in section 2.3.2.3 with the following 
modifications: 1) the system was equipped with a semi-preperative column Gemini C6 
- 43 - 
 
phenyl (250 x 10 mm i.d., 5 μm; Phenomenex, Cheshire, UK), and 2) ChE  (150 mg/mL) 
was loaded manually (1 mL) using a syringe through a sample loop of 1 mL and eluted 
using water containing 0.1% TFA (solvent A) and methanol (Solvent B) at a flow rate of 
2.3 mL/min. The elution was followed at 320 nm and fractions containing the separated 
compounds were collected and analysed for purity by LC-MS (figure 2.5) as described in 
section 2.3.2.2.  
 
Figure 2.5 LC-MS of isolated compounds from ChE.(A) Hydroxycinnamic acid derivative 1 
and (B) hydroxycinnamic acid derivative 2. The spectra obtained for both fractions reveals that 
the compounds were at least >95 % pure at the moment of the isolation as assessed by the total 
ion count in LC-MS. For figure (A) the peak observed presented a m/z (-) of 355 Da while (B) was 
characterised by a predominant m/z (-) of 711 Da.  
 
 
Multiple semi-preparative separations were conducted and the fractions for each peak 
combined, freeze-dried, and stored at -20 °C until use for structure characterisation. 
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2.3.2.5 Chemical characterisation of hydroxycinnamic acid derivatives. 
2.3.2.5.1 HPLC/MS2 and QTOFMS.  
Initial analysis of the purified hydroxycinnamic acid derivatives were carried out using an 
Agilent 1200 HPLC coupled with a 6410-MS triple quadrupole (Agilent Technologies, 
Berkshire, UK) and equipped with a dual spray ESI source operating in negative mode. 
An isocratic separation was conducted with a mixture of water-acetonitrile (4:1 v/v) 
employing reversed phase HPLC using a kinetex C18 analytical column, 150x2.10 mm 
I.D., 2.6μm; Phenomenex maintained at 35 °C. Data were obtained from full-scan MS 
peak spectra acquired in the mass range of m/z 50-1100. Next, manually selected ion 
peaks of the MS spectra were subjected to MS2 analysis under different fragmentor and 
collision energy conditions to characterise the resulting product ion peak spectra from the 
isolated compounds. Complementary LC-QTOFMS analysis were performed by Dr. 
Laszlo Abranko at the Department of Applied Chemistry at the Corvinus University of 
Budapest. The analysis were conducted in a Agilent 1200 series HPLC system (Agilent 
Technologies, Waldbronn, Germany) coupled to an Agilent 6530 Q/TOF mass 
spectrometer (Agilent Technologies, Santa Clara, CA, USA) using the chromatographic 
conditions described above. Elemental formulae of compounds were determined with the 
aid of MassHunter software based on high-resolution (> 20,000 FWHM) accurate mass 
(<5 ppm) data completed with evaluation of isotope abundance matching and isotope 
spacing. Data were obtained from full-scan TOF-only peak spectra acquired in the mass 
range of m/z 50-1100. Next, manually selected ion peaks of the TOF-only spectra were 
subjected to Q/TOFMS analysis and elemental formulae of fragments were determined 
based on accurate mass (<20 ppm) data obtained from product ion peak spectra. Since the 
data obtained with both mass analysers was essentially the same and due to the greater 
mass resolution, sensitivity and accuracy of the TOF analyser, only data acquired with 
this instrument was included to avoid repetition. 
2.3.2.5.2 Acid hydrolysis. 
An aliquot of the purified hydroxycinnamic acid derivative 2 was dissolved in HCl (2 M) 
to reach a concentration of 500 µM (based on the previously reported neutral mass of 356 
Da by Mulinacci et al. (2001)) and subjected to hydrolysis for 2 h at 60 °C. The reaction 
mixture was concentrated to dryness under reduced pressure and reconstituted in water (1 
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mL) and analysed by HPLC-DAD using the chromatographic conditions previously 
described in section 2.3.2.2.  
2.3.2.5.3 Determination of the monosaccharide moiety.  
An aliquot of the hydroxycinnamic acid derivative 2 (200 µM) was subjected to acid 
hydrolysis as previously described in 2.3.2.5.2 and concentrated to dryness. The released 
hexose was chemically tagged with 1-phenyl-3-methyl-5-pyrazolone (PMP) as described 
elsewhere (Shen and Perreault, 1998; Lv et al., 2009) with minor modifications. PMP 
powder was dissolved in methanol containing 0.5 % of HCL (11.65 M) to reach a final 
concentration of 0.5 M. After, 0.5 mL of the PMP solution and 0.5 mL of NaOH (0.3 M) 
were added to the dried hydrolysed sample and heated for 2 h at 70 °C, cooled down to 
room temperature and neutralised with 0.5 mL of HCl (1 M). Thereafter, water (0.5 ml) 
and chloroform were added (1:2, v/v), the mixture was vortexed and the organic phase 
discarded. The process was repeated for approximately six times until the excess of PMP 
was removed. The remaining aqueous phase containing the PMP-hexose complex was 
concentrated to dryness and reconstituted in water (0.25 mL). The derivatised 
monosaccharide was analysed on HPLC-DAD equipped with a C18 analytical column 
(250 x 4.6 mm I.D., 5 µm, Phenomenex, Cheshire, UK) and UV detection at 250 nm. A 
10 µL sample was eluted with 0.1 mM ammonium acetate buffer (pH 5.5)–acetonitrile 
(78:22, v/v) at 1 mL/min. The identification of the monosaccharide component was 
achieve by comparing the retention time with those of authentic standards (D-mannose, D-
glucose, D-galactose and D-xylose) (figure 2.6). 
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Figure 2.6 HPLC-DAD chromatograms of PMP derivatives of standard monosaccharides.  
The four standard monosaccharides were chemically tagged and separated under the experimental 
conditions described. (A) Standard monosaccharides were derivatised and analysed individually, 
(B) Standard monosaccharides were derivatised and analysed as a mixture, Peaks: 1. D-mannose; 
2. D-glucose; 3. D-galactose; 4. D-xylose.  
 
 
2.3.2.5.4 NMR. 
The NMR analyses were performed in collaboration with Ms. Lauren Ford and Professor 
Christopher Rayner from the school of Chemistry at the University of Leeds. Purified 
samples were dissolved in d6 DMSO and placed in a 5 mm OD NMR tube. All NMR data 
were recorded on a Bruker Avance 500 spectrometer (1H frequency 500.573 MHz, 13C 
frequency 125.878 MHz) temperature controlled at 299.3 K. Chemical shifts are 
expressed in ppm and are reported with reference to the residual solvent peak. 
Multiplicities are reported with coupling constants and are given to the nearest 0.1 Hz. 
Where needed, two-dimensional correlation spectroscopy (2D-COSY), heteronuclear 
single quantum coherence spectroscopy (HSQC) and heteronuclear multiple bond 
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correlation spectroscopy (HMBC) and nuclear Overhauser effect spectroscopy (NOESY) 
was performed.  
 
(Z)-2-D-glucopyranosyloxy-4-methoxycinnamic acid present as a mixture of E and Z in a 
~ 1:3 ratio, E peaks eliminated and Z peaks picked at: 1H NMR (501 MHz, DMSO-d6) δ 
7.70 (d, J= 8.5 Hz, 1H, H3), 7.19 (d, J = 12.5 Hz, 1H, cis-alkene, H2), 6.74 (d, J = 2.5 
Hz, 1H, H5), 6.56 (dd, J = 8.5, 2.5 Hz, 1H, H4), 5.78 (d, J = 12.5 Hz, 1H, cis-alkene, H1), 
4.85 (d, J = 7.5 Hz, 1H, anomeric proton, H8), 3.77 (s, 3H, H6), 3.72 (broad d, J= 11.7 
Hz, 1H, H13), 3.47 (broad dd, J= 11.7, 6.0 Hz, 1H, H13’), 3.38 (ddd, J= 10.0, 6.2, 1.6 
Hz, 1H, H12), 3.34-3.29 (m, 2H, H9 & H10)*, 3.16 (apparent t, J= 8.8 Hz, 1H, H11). 13C 
NMR (126 MHz, DMSO-d6) δ 167.7, 161.0, 160.7, 156.7, 136.32, 131.1, 117.53, 116.73, 
101.11, 100.5, 77.24, 76.86, 73.27, 69.81, 60.72, 55.33. *Overlayed by strong signal from 
water. ESI-MS: m/z 355.1035 [M-H]-.  
 
Analysis of pure (E)-2-β-D-glucopyranosyloxy-4-methoxycinnamic acid: 1H NMR (501 
MHz, DMSO-d6) δ 12.00 (s, 1H, H7), 7.82 (d, J = 16.2 Hz, 1H, trans-alkene, H2), 7.62 
(d, J = 8.7 Hz, 1H, H3), 6.76 (d, J = 2.4 Hz, 1H, H5), 6.62 (dd, J = 8.6, 2.4 Hz, 1H, H4), 
6.39 (d, J = 16.2 Hz, 1H, trans-alkene, H1), 5.16 (broad s, 1H (OH)), 4.98 (d, J =7.5 Hz, 
1H, anomeric proton, H8), 4.89 (broad s, 2H (OH)), 4.58 (broad s, 1H, (OH)), 3.78 (s, 
3H, H6), 3.72 (broad d, J= 11.7 Hz, 1H, H13), 3.47 (broad dd, J= 11.7, 6.0 Hz, 1H, 
H13’), 3.38 (ddd, J= 10.0, 6.2, 1.6 Hz, 1H, H12), 3.34-3.29 (m, 2H, H9 & H10)*, 3.16 
(apparent t, J= 8.8 Hz, 1H, H11). 13C NMR (126 MHz, DMSO-d6) δ 168.08, 162.08, 
157.07, 138.76, 129.32, 116.73, 116.05, 108.03, 101.11, 100.02, 77.24, 76.86, 73.27, 
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69.81, 60.72, 55.33. *Overlayed by strong signal from water. ESI-MS: m/z 355.1035 [M-
H]-.  
 
2.3.2.5.5 Synthesis of (E)-2-hydroxy-4-methoxycinnamic acid.  
7-Methoxycoumarin (0.44 g) was dissolved in an aqueous solution of 0.5 M NaOH (20 
mL, 2.5 mM) and stirred for 4 h at room temperature. Aliquots were taken and showed 
full conversion to the trans carboxylate by NMR in D2O. The solution was then acidified 
with 1 M aqueous HCl and extracted with dichloromethane (3 × 10 mL). The solvent was 
then evaporated and eluted with ethyl acetate on a flash silica column. This yielded the 
(E)-2-hydroxy-4-methoxycinnamic acid (32 mg, 0.165 mM, 6.6 % yield). The low yield 
was due to the ring closing to reform the coumarin in acidic conditions. The schematic 
representation of the chemical synthesis of shown below. 
 
 
 
 
1H NMR (500 MHz, Acetone) δ 9.25 – 9.21 (broad s, 1H, H7), 7.95 (d, J = 16.1 Hz, 1H, 
H2), 7.54 (d, J = 8.5 Hz, 1H, H3), 6.40 (d, J= 2.2 Hz, 1H, H5), 6.37 (dd, J= 2.2, 8.5 Hz, 
1H, H4) 6.33 (d, J= 16.1 Hz, 1H, H1), 3.66 (s, 3H, H6). The synthesised compound was 
analysed by HPLC-DAD. ESI-MS: m/z 193.06 [M-H]-  (figure 2.7). 
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Figure 2.7 HPLC-DAD and LC-MS analysis of chemically synthesised (E)-2-hydroxy-4-
methoxycinnamic acid. The synthesised standard was dissolved in 5 % acetonitrile in water 
(5:95, v/v) and analysed under the conditions described in section 2.3.2.2 for both HPLC-DAD 
and LC-MS. The insert shows the deprotonated molecular mass of the synthesised compound.  
 
 
 
 
2.3.3 Statistical analysis. 
Statistical analyses were performed by one-way analysis of variance using the Number 
Cruncher Statistical System version 6.0 software (NCSS, LLC). Significant differences 
were assessed with the Tukey–Kramer multiple comparison test (p<0.05). The data are 
expressed as the mean±SEM of at least three independent experiments with three 
technical replicates each. 
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2.4 Results and discussion. 
 
2.4.1 Analytical and semipreparative HPLC-DAD analysis. 
Initial detection of the major polyphenols in ChE was based on previous analysis 
conducted in ChE where apigenin, apigenin 7-O-glucoside and two peaks with [M-H]- ion 
masses at m/z 355 and 711 showed the highest intensity among the polyphenols detected 
(Villa‐Rodriguez et al., 2017). Table 2.1 shows the polyphenol profile of the ChE used in 
this study as reported in Villa-Rodriguez et al. (2017).  
 
                            Table 2.1 Polyphenol profile of aqueous ChE.  
Compound [M-H]- MS
2
Protocatechuic acid 153 109
Umbelliferone aglycone* 161 133
Ferulic acid* 193 149
Apigenin* 269 151
Luteolin* 285 133
Kaempferol* 285 151
Quercetin* 301 151
Isorhamnetin 315 300
Coumaroyl quinic acid 337 191
4-O -CQA 353 173
3-O -CQA 353 179
5-O -CQA 353 191
cis/trans ferulic acid hexoside 355 193
5-O - feruloylquinic acid 367 194
Dimethoxy-cinnamic acid hexoside 369 189
Luteolin 7 O -glucoside* 447 285
Quercetin 3 O -glucoside* 443 301
Quercetin 3 O -glucuronide 477 301
Myricetin O -hexoside 479 317
Luteolin O -acylhexoside 489 285
di-CQA* 515 353
Kaempferol 3 O -rutinoside 593 285
Quercetin 3 O -rutinoside 609 301
FA hexoside dimer 711 355, 193  
The polyphenols were identified using authentic standards when available (*). Otherwise, the 
identification was conducted by comparing the characteristic transition ions with those reported in 
the literature (Mulinacci et al., 2000; Lin and Harnly, 2012; Guimarães et al., 2013). 
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Rt Concentration LOD LOQ
 (min)  (µM) (µM) (µM)
  1* 8.7 257.0 ± 2.2 0.42 1.32
2 10.5 200.9 ± 2.0 0.46 1.43
3 12.1 148.7 ± 2.0 2.62 8.18
4 15.8 12.22 ± 0.08 2.48 7.75
Compound
Figure 2.8A shows an HPLC-DAD chromatographic analysis of ChE demonstrating the 
presence of four major polyphenols previously identified (Villa‐Rodriguez et al., 2017) 
and targeted in this study; their descriptive characteristics are presented in table 2.2.  
 
Figure 2.8 Analysis of polyphenols in ChE. (A) HPLC-DAD chromatogram of polyphenols in 
ChE. Compounds are referred according to the retention time sequence, 1) hydroxycinnamic acid 
derivative (HCA) 1; 2) HCA 2; 3) apigenin 7-O-glucoside; 4) apigenin. The peaks indicated with 
arrows were tentatively identified as apigenin acetyl derivatives according to LC-MS analysis 
(data not shown). (B) UV-Vis spectrum of the abundant HCAs (peaks 1 and 2).  
 
Table 2.2 Identification and quantification of targeted polyphenols in ChE. 
 
 
 
*The quantification was conducted with the isolated standard with an estimated purity of >80 % 
based on quantitative information of compound 2. An isomerisation reaction took place where the 
hydroxycinnamic acid derivative changed to the most thermodynamically stable form (trans) 
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which accounts for the impurity detected. There were significant differences (p<0.05) in the 
content of the polyphenols in ChE.  
 
 
In line with previous observations, apigenin 7-O-glucoside and its derivatives were the 
predominant examples in chamomile (Mulinacci et al., 2000; Švehlı́ková et al., 2004; 
Guimarães et al., 2013; Villa‐Rodriguez et al., 2017). Additionally, we detected two 
abundant peaks with UV-Vis absorption spectra of those previously shown to have [M-
H]- ion masses at m/z 355 and 711 (Mulinacci et al., 2000) and which are characteristic of 
hydroxycinnamic acid derivatives (compound 1 and 2). An important work reporting the 
presence of these compounds was conducted by Mulinacci et al. (2000) who assigned 
their identity as ferulic acid-1-O-glucoside and ferulic acid-7-O-glucoside and their work 
has served as a reference for the identification of these compounds in further studies (Lin 
and Harnly, 2012; Matić et al., 2013). LC-MS by itself usually does not provide sufficient 
structural information for unambiguous identification of a particular chemical constituent 
in a plant extract. Therefore it is intriguing to considerer how Mulinacci and co-workers 
assigned the identity of these compounds based solely on spectroscopic analysis and 
comparison with structurally-related compounds without complementary analytical 
techniques. Similarly, Guimarães et al (2013) tentatively identified these compounds as 
ferulic acid derivatives and they suggested the presence of a ferulic acid hexoside dimer 
based on the predominant deprotonated molecular ion peak observed at m/z 711 which 
gives a mass difference of 355 units. On the other hand, Weber et al. (2008) reported the 
presence of isomeric structures of 2-(glucosyloxy)-4-methoxy-cinnamic acid which 
possess the same deprotonated molecular mass of the isomers of ferulic acid previously 
identified in the work of Mulinacci and co-workers. Since the exact identity of these 
molecules is controversial, here the isolation of the hydroxycinnamic acid derivatives on 
a semi-preparative scale was conducted in order to establish their chemical identity, their 
content in ChE and their potential bioactivity (described in chapter 3 and 4). 
 
The two hydroxycinnamic acid derivatives were successfully semi-preparatively 
separated (figure 2.9), isolated and concentrated, yielding enough material to perform 
chemical analysis and future in vitro experiments. The purity after pooling the collected 
fractions and freeze-dried concentration, was >80 % for compound 1 and >99 % for 
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compound 2. Moreover, the quantitative analysis revealed that compound 1 and 2 are 
present at higher levels than apigenin 7-O-glucoside suggesting that they might contribute 
to certain extent to the biological activity of chamomile. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9 Semi-preparative purification of the two hydroxycinnamic acid derivatives 
(HCA) from ChE using the AKTA system. The chromatographic separation was conducted 
using the gradient described in section 2.3.2.4. Isolated peaks are highlighted with dashed lines. 
 
 
2.4.2 Chemical characterisation of the hydroxycinnamic acid derivatives. 
The identity of the hydroxycinnamic acid derivatives was assigned based on HPLC-
DAD/QTOFMS, 1H and 13C NMR, NOESY and chemical synthesis. The full-scan TOF 
spectra of both compounds showed prominent ions at m/z 355.1035 and 711.2136, which 
were assigned as [M-H]- and [2M-H]- respectively (table 2.3). This assignment could be 
further confirmed by the appearance of the [M+Cl]- ion at m/z 391.0801 in the spectrum 
of hydroxycinnamic acid derivative 2. The (neutral) elemental formula of the two 
hydroxycinnamic acid derivatives was established as C16H20O9. Both compounds showed 
identical fragment ions in the Q/TOF product ion spectra at m/z 193.0506 [M-hexosyl-H]- 
and 149.0608 [M-hexosyl-CO2]
- (table 2.3). These results clarified that neither of the 
compounds are dimeric ferulic hexosides as suggested by Guimarães et al. (2013) based 
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on the predominant ion at m/z 711 for the hydroxycinnamic acid derivative 2 but a 
pseudo-molecular created in the interface during the ionisation process.  
 
Table 2.3. Q/TOF-MS/MS of isolated hydroxycinnamic acid derivatives (HCA) from 
ChE. 
Compound [M-H]-              MS
2 Elemental formula Measured m/z Exact mass Error (ppm)
355 [M-hexosyl-CO2]-         C9H9O2 149.0599 149.0608 -6.04
355 [M-hexosyl]-         C10H9O4 193.0496 193.0506 -5.18
355 [M-H]-         C16H19O9 355.1017 355.1035 -5.07
711 [M-hexosyl]-         C10H9O4 193.0497 193.0506 -4.66
711 [M-H]-         C16H19O9 355.1029 355.1035 -1.69
711 [2M-H]-         C32H39O18 711.2152 711.2136 2.25
355 [M-hexosyl-CO2]-         C9H9O2 149.0599 149.0608 -6.04
355 [M-hexosyl]-         C10H9O4 193.0493 193.0506 -6.73
355 [M-H]-         C16H19O9 355.1034 355.1035 -0.28
711 [M-hexosyl]-         C10H9O4 193.0494 193.0506 -6.22
711 [M-H]-         C16H19O9 355.1022 355.1035 -3.66
711 [2M-H]-         C32H39O18 711.2114 711.2136 -3.09
1
2
 
 
It is noted that covalently bound ‘dimeric ferulic acids’ are well characterised 
compounds, which act as polysaccharide cross-linking agents in cell walls (Kennedy et 
al., 1999; Andreasen et al., 2000). Thus their (di)glycosides structures also can be 
theoretically expected in plant extracts. However, their predicted ion formula should be 
[C32H37O18]
- resulting in a monoisotopic ion mass of m/z 709.1985 in negative ion mode. 
Confirmatory Q/TOF fragmentation of the m/z 711.2136 was performed that provided 
fragments only at m/z 355 and 193 (table 2.3, figure 2.10) lending further support to the 
original assumption that the elemental formula of the two hydroxycinnamic acid 
derivatives is C16H20O9.  
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Figure 2.10 Fragmentation pattern of isolated ion at m/z 711.(A) hydroxycinnamic acid 
derivative 1 and (B) hydroxycinnamic acid derivative 2. The resulting ions are due to i) the 
cleavage of the glycosidic bond between the hydroxycinnamic acid and glucose (m/z 193), ii) 
cleavage of the pseudo-molecular deprotonated dimer ion formed ([2M – H]–) in the interface 
during the ion generation (m/z 355). 
 
 
Nevertheless, these results did not invalidate the presumed isomeric structures of ferulic 
acid glucosides previously reported (Mulinacci et al., 2000). The diagnostic MS2 
fragments displayed by these polyphenols logically suggest that they are ferulic acid 
glycosides. However, acid hydrolysis of these compounds did not result in the release of 
ferulic acid (figure 2.11A) but a compound with a m/z of 193 eluting at 13.4 min with an 
UV-Vis spectra characteristic of hydroxycinnamates was detected (figure 2.11B). We also 
observed a peak with a UV-Vis spectra distinctive of coumarins (figure 2.11B) (Cho et 
al., 2009) eluting at 15.3 min which was later confirmed as 7-methoxycoumarin by 
comparison with the authentic standard (figure 2.12). 
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Figure 2.11 Analysis of hydroxycinnamic acid derivative 2 (HCA 2) after acid hydrolysis. 
(A) HPLC-DAD chromatogram of the hydrolysed fraction and comparison of the resulted 
compounds with ferulic acid standard. Released products after the hydrolysis are marked as 
compound 1 and 2. (B) UV-Vis spectra of ferulic acid standard and compounds resulting from 
acid hydrolysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.12 Acid hydrolysis of hydroxycinnamic acid derivative 2 (HCA 2).The products 
resulting from the hydrolysis were identified as (E)-2-hydroxy-4 methoxycinnamic acid (2-E-
MCA) and 7-methoxycoumarin by comparison with authentic standards. 
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The presence of 7-methoxycoumarin was indicative of the release of a O-
hydroxycinnamate after hydrolysis where part of it underwent intramolecular cyclization 
catalysed by the acid conditions (Cho et al., 2009). A previous study (Weber et al., 2008) 
identified the presence of (Z) and (E)-2-β-D-glucopyranosyloxy-4-methoxycinnamic acid 
(Z and E-MCAG) in chamomile which possesses the same molecular mass of the isolated 
hydroxycinnamic acid derivatives; this would explain the compounds detected after 
hydrolysis and their mistaken identification as ferulic acid derivatives. Moreover, these 
compounds have been reported to be the precursor of 7-methoxycoumarin (Repčák et al., 
2001) which clarify the appearance of this molecule after acid hydrolysis. Indeed, further 
confirmation of the identity of the cinnamate moiety was obtained by chemical synthesis 
and comparison with the released aglycone after acid hydrolysis (figure 2.12) indicating 
that the compound with a deprotonated molecular mass of 193 is an isomer of ferulic acid 
identified as 2-hydroxy-4-methoxy-trans-cinnamic acid. 
  
The 1H-NMR data displayed spectroscopic signals for a free carboxylic group, which was 
identified from the detection of the signal at δ 12.00. The presence of a (Z) and (E)-alkene 
group in the structure of hydroxycinnamic acid derivative 1 and 2 were identified from 
the signals at δ 7.19 and 5.78 (J=12.7 Hz), and δ 7.82 and 6.39 (J=16.2 Hz), respectively. 
The spectrum also showed three aromatic protons in the ABD substitution pattern 
characteristic of the coupling constants of J=8.5-8.6 (ortho) and J=2.4-2.5 (meta) (Weber 
et al., 2008). Acid hydrolysis of both compounds resulted in the release of D-glucose 
(figure 2.13). The 1H chemical shift in the range 4.85 (Z-isomer) and 4.98 (E-isomer) with 
coupling constants of J=7.5 Hz from the anomeric protons indicate a β-glycosidic linkage 
and the location of the D-glucose moiety was assigned at the phenolic ring by the 
observed NOE enhancements (figure 2.14).  
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Figure 2.13 Comparison of the resulting compounds after acid hydrolysis with authentic 
standards of monosaccharides.The hexose was identified as D-glucose (for elution pattern see 
figure 6). HCA 1: hydroxycinnamic acid derivative 1; HCA 2: hydroxycinnamic acid derivative 2. 
 
 
The NOE enhancements gave an indication of the position of the other functional groups 
around the ring. The 13C NMR data showed 16 carbon resonances for the phenolic moiety 
in isolated compound 2, suggesting the presence of (Z) and (E)-2-β-D-
glucopyranosyloxy-4-methoxycinnamic acid (Z and-E-MCAG) as previously reported by 
Weber et al. (2008).  
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Figure 2.14 NOESY analysis of hydroxycinnamic acid derivative 2.(A) Key NOESY 
correlations are indicated with arrows and circles. The colour of the circles represents the protons 
interacting in (B). (B) Key NOESY correlations are indicated with arrows and percentage 
enhancements. 
 
 
A 
B 
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In the present study conclusive evidence is provided that demonstrates unambiguously the 
chemical identity of the two hydroxycinnamic acids. The combination of analytical 
techniques indicates that the identity of the two hydroxycinnamic acid derivatives is (Z) 
and (E)-MCAG. This information adds to the previous one reported by Weber et al. 
(2008) who did not state the adduct formation [2M-H]- with a deprotonated molecular 
mass of m/z 711 for both compounds, which is crucial for efficient data-mining. 
Moreover, it has been demonstrated through acid hydrolysis and the use of an authentic 
standard that Z-MCAG is the precursor of 7-methoxycoumarin, commonly known as 
herniarin. The characteristic chromatographic pattern observed after acid hydrolysis along 
with their formation of 7-methoxy coumarin and distinctive UV spectrum of the MCA 
can be used to identify the presence of these compounds in the absence of authentic 
standards.  
 
Insufficient evidence regarding the analytical information obtained to identify and 
characterise the hydroxycinnamic acids in previous publications is perhaps the main 
reason why the identity of the hydroxycinnamic acid derivatives in chamomile remained 
obscure. In this sense, it is important to mention that the presence of these compounds 
was first described more than 20 years ago (Ohe et al., 1994; Repčák et al., 2001) but 
without fully providing the chemical information obtained to assigned their chemical 
identity (HPLC, LC-MS and NMR). This tendency has continued in some recent 
publications where the presence of (Z) and (E)-MCAG has been described in chamomile 
without giving enough chemical information (Kováčik and Repčák, 2008; Avula et al., 
2014).  
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2.5 Conclusion 
 
The combination of analytical techniques used in this study confirmed that the m/z(-) at 
711 is a pseudo-molecular dimer ion formed in the interface from both compounds. The 
hydroxycinnamic acid derivatives were identified as (Z) and (E)-MCAG and the 
quantitative analysis revealed for the first time that they can be present at higher levels 
than apigenin 7-O-glucoside. For (Z)-MCAG, the content can vary according to 
chamomile handling since deglycosylation results in 7-methoxycoumarin formation. In 
addition, the content of these major polyphenols in chamomile can be affected by 
different stresses, locations, climates, microenvironments and physical and chemical 
stimuli altering any activity resulting from their interaction. Therefore, suitable 
characterisation of botanical preparations from chamomile is mandatory to unravel and 
assure reproducible biological activity in screening assays.  
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Chapter 3 Assessment of the inhibition of carbohydrate-digesting 
enzymes by polyphenols and chamomile extract in vitro: 
optimisation of α-amylase activity using the 3, 5-dinitrosalicylic acid 
method and determination of molecular interactions in silico. 
 
3.1 Abstract. 
 
Botanical preparations, functional foods and nutraceuticals offer the possibility to 
modulate the absorption of sugars, leading to benefits for healthy individuals and 
diabetics. As part of the characterisation of such foods, inhibition of carbohydrate-
digesting enzymes (acarbose-like activity) is used to assess components for their potential 
ability to modify the postprandial glycaemic response. Many publications on polyphenols 
as potential inhibitors report widely varying assay conditions leading to variable estimates 
of inhibition. The first part of this chapter describes the optimisation of an in vitro human 
salivary α-amylase inhibition assay and, in particular, it is show the importance of 
removing certain polyphenols after the enzymatic reaction when using 3,5-dinitrosalicylic 
acid solution since they interfere with this reagent. There was a substantial ~5-fold effect 
on acarbose IC50 values when working outside optimal conditions. This shows that 
inappropriate assay parameters, such as excess of enzyme, greatly influence inhibition 
constants and could explain some discrepancies in the current existing literature.  
 
The optimised α-amylase inhibition assay along with a α-glucosidase assay were used to 
assess the acarbose-like activity of ChE and identified the active polyphenols 
participating in this metabolic pathway. The four major polyphenols inhibited human 
salivary α-amylase, with apigenin exhibiting the strongest effect (competitive inhibition, 
Ki = 17 µM) followed by apigenin 7-O-glucoside (competitive inhibition, Ki = 146 µM) 
while (Z) and (E)-MCAG presented mild inhibitory activity (maximum ~25 % at 100-500 
µM). When the four polyphenols were combined at the concentrations equivalent to those 
present in the ChE, the activity was enhanced by ~20 % as compared with the whole 
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extract. Molecular docking was performed to investigate the interactions taking place 
between the polyphenols and the enzyme and rationalise the inhibition observed for all 
the tested molecules. The rat intestinal maltase activity was modestly inhibited; neither 
ChE nor the individual polyphenols reached 50 %, while no inhibition of rat intestinal 
sucrase and isomaltase activities was observed. These results suggest that ChE as a herbal 
plant extract that combines (Z)-(E)-MCAG, apigenin and apigenin 7-O-glucoside, can 
potentially help to attenuate postprandial hyperglycaemia.  
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3.2 Introduction. 
 
Persistent high postprandial glucose spikes have been proposed as independent risk 
factors for developing insulin resistance and progression to type 2 diabetes (Barclay et al., 
2008; Vinoy et al., 2016). Plausible mechanisms suggested for this association include 
acute altered energy partitioning (Brand-Miller et al., 2002), increased oxidative stress 
(Ceriello et al., 2004), low-grade inflammation (Ceriello et al., 2004) and endothelial 
dysfunction (Kawano et al., 1999) that, over time, orchestrate a coordinated breakdown in 
cellular functions. Therefore, the modulation of absorption of sugars in the intestine has 
now been seen as a therapeutic target for reducing insulin resistance and type 2 diabetes 
risk (Ceriello and Colagiuri, 2008; Vinoy et al., 2016).  
 
The attenuation of carbohydrate digestion in the intestine by the antidiabetic drug 
acarbose (figure 3.1) has shown to reduce the risk of type 2 diabetes and cardiovascular 
events by 25 and 49 % respectively (Chiasson et al., 2002; Chiasson et al., 2003), proving 
the clinical relevance of this approach to manage blood glucose levels. Unfortunately the 
use of this drug very often is marked with severe GI side-effects including abdominal 
pain, meteorism, flatulence and diarrhea (Chiasson et al., 2002; Bethel et al., 2015) 
resulting in poor patient compliance and adherence to the treatment. This highlights the 
need for the identification of new small molecules that could decrease not only 
carbohydrate digestion but also sugar uptake in the gut which can be used as an 
alternative to acarbose or act as coadjuvants. Furthermore, considering the current 
western lifestyle patterns, the incorporation of these small molecules in foods represent a 
technical advantage over the use of low GI foods since postprandial glycaemic goals can 
be achieved without altering the carbohydrate and sugar composition of diets. Therefore 
these molecules can aid to control hyperglycaemia not only in persons with a 
pathophysiological phenotype, but also in healthy individuals.  
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Figure 3.1 Steps involved in the digestion of starch and the disaccharides sucrose and lactose 
leading to the appearance of glucose in circulation.Starch is a polysaccharide formed of 
amylose and amylopectin. Amylose is made of linear chains of glucose molecules, joined by α-1–
4 linkages whereas amylopectin is constituted of branched chains of glucose, joined by both α-1–
4 and α1–6 linkages (Guzmán‐Maldonado et al., 1995). Partial hydrolysis of starch is 
accomplished by salivary α-amylase, with major cleavage provided by human pancreatic α-
amylase in the gut, generating malto-oligosaccharides (two or more α-1,4-linked glucose units) 
and dextrins (α-1,6-linked glucose units along with attached α-1,4-linked glucose units) 
(Butterworth et al., 2011). These resulting products from starch hydrolyses as well as sucrose and 
lactose are in turn broken down to glucose by maltase-glucoamylase and sucrase-isomaltase 
(generally known as α-glucosidases) that are attached to the epithelium of the small intestine 
(Robayo–Torres et al., 2006). Both enzymes are composed of duplicated catalytic domains 
showing overlapping substrate specificities for α-1,4-oligosaccharides. In addition, sucrase-
isomaltase shows specificity for α-1,2 and α-1,6-glycosidic bonds and so, it mediates the 
conversion of sucrose and isomaltose respectively to the corresponding monosaccharides glucose 
and fructose (Sim et al., 2010). The drug acarbose reduce and slows-down plasma glucose levels 
by inhibiting α-amylase and α-glucosidases. 
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Many reports indicate that polyphenol-rich extracts inhibit α-amylase (reviewed in 
Nyambe-Silavwe et al. 2015, appendix A-C). However, these studies used different 
methods of detection and assay conditions (reaction time and temperature, pH, enzyme 
concentration and source, substrate concentration and source) which have a pronounced 
impact on the reported data. The most commonly used method for measuring α-amylase 
activity involves the 3,5-dinitrosalicylic acid (DNS) reagent for detection of reducing 
sugars. The presence of a free carbonyl group in reducing sugars enables them to 
participate in an oxidation-reduction reaction with DNS (figure 3.2). However, due to the 
reducing potential of polyphenols, they could interfere with the development of the colour 
and thus the results of the assay. Therefore the development and optimisation of bioassays 
with high levels of reliability is essential to evaluate the acarbose-like activity of 
polyphenols and polyphenol-rich extracts in order to consider them as real candidates for 
attenuating hyperglycaemia. For instance, recent reports have indicated positive effects of 
chamomile in experimental diabetes and type 2 diabetic subjects (Cemek et al., 2008; 
Weidner et al., 2013; Rafraf et al., 2015; Zemestani et al., 2016). However it is yet 
elusive whether the antidiabetic and in particular, the antihyperglycaemic effect of 
chamomile is partially mediated through the modulation of carbohydrate metabolism at 
the small intestinal site.  
 
 
 
 
 
 
Figure 3.2 Reaction of DNS with reducing sugars. The aldehyde functional group of the 
reducing sugar (highlighted in circle) is oxidized into a carboxyl group and the 3, 5-
dinitrosalicylic acid is reduced to 3-amino-5-nitrosalicylic acid. This reaction cause a colour 
change from yellow to orange or red, depending on the concentration of the reducing sugars 
present in the sample. By reading absorbance of the resulting reducing sugars, the amount of 
maltose equivalents can be calculated using a standard curve with different concentrations of 
maltose. 
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The in vitro results can be complemented with computational methods to provide 
mechanistic investigation by predicting the interaction between polyphenols and α-
amylase. Molecular docking is a widely used computational method which allows to 
characterise the behaviour of small molecules in the binding site of target proteins 
through the use of efficient sampling algorithms and scoring functions (Kitchen et al., 
2004).The algorithms generate a predicted binding pose by exploring the ligand 
conformational space and interactions within a pocket of the protein surface. The binding 
modes associated with the lowest energy scores are predicted to be the binding modes, 
and the corresponding energy scores are used to evaluate the binding affinity and to 
predict the biological activity (Kitchen et al., 2004; Meng et al., 2011). Therefore 
molecular docking allows to model the interaction between a protein and small molecules 
including polyphenols, pointing out important features of the structure of the ligand that 
could be very useful to rationalise structure-activity relationships and to guide 
experimental research. 
 
With a view to identify potential inhibitors of carbohydrate digestion, and to elucidate 
whether the antidiabetic effects of chamomile can be partially mediated by acting at this 
pathway, the combination of the two optimised in vitro assays along with molecular 
docking was used to assess the inhibitory activity of different classes of polyphenols 
including those in chamomile on α-amylase and α-glucosidase enzymes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 68 - 
 
3.3 Materials and methods. 
 
3.3.1 Materials. 
3,5-Dinitrosalicylic acid reagent, potassium sodium tartrate, chromatographically purified 
human salivary α-amylase type IX-A (A0521), acetone extract of rat intestine (i1630), 
hesperidinase from Aspergillus niger (H8137), pancreatin from porcine pancreas (P3292), 
maltose, epigallocatechin 3-O-gallate, quercetin, amylose and amylopectin from potato, 
D-sucrose, D-maltose, D-glucose, glucose hexokinase and Bradford reagent were all 
purchased from Sigma-Aldrich. Co., Ltd., Dorset, UK. Phloridzin, quercetin-3-O-
glucoside and luteolin were purchased from Extrasynthase, Genay, France. Gallic acid 
was obtained from Alfa Aesar, Lancashire, UK. Green tea, ChE, apigenin and apigenin 7-
O-glucoside were obtained from PhytoLab Co. KG.h while Z and E-MCAG were purified 
from the ChE according to the procedure described in chapter 2, section 2.3.2.4. Oasis 
MAX cartridge 1 mL (30 mg) and 3 mL (60 mg) were purchased from Waters 
Corporation Ltd., Milford, MA, U.S.A. The DNS reagent solution was prepared by 
adding to 12 mL water, 20 mL of 96 mM DNS in water and 5.3 M sodium potassium 
tartrate solution (12 g in 8 mL of 2 M sodium hydroxide). All the reagents were of the 
highest purity and standards were ≥98 %. 
 
3.3.2 Methods. 
3.3.2.1 Determination of Km and Vmax.  
The kinetic parameters Km and Vmax were determined by using a chosen enzyme 
concentration and incubation times giving linear rates of reaction where enzyme activity 
is determined accurately. The substrate concentrations ranged from 0 to 1 mg/mL in the 
final assay volume. Maltose standard curve was obtained by adding 1 mL of the DNS 
reagent to a total volume of 500 µL of different maltose concentrations (0-1.5 mg/mL,) 
and then heated (100 °C for 10 min). The absorbance was recorded at 540 nm in a 
PHERAstar FS microplate reader (BMG Labtech, Inc., Cary, NC, USA), and the amount 
of maltose produced was calculated against a five-point linear calibration curve (figure 
3.3). The Lineweaver-Burk plot was used to calculate Km and Vmax. 
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Figure 3.3 Representative example of maltose standard calibration curve. The calibration 
curve was used to quantify the reducing sugars (mainly maltose) produced from amylose and 
amylopectin after hydrolysis with human salivary α-amylase. Each data point represents the 
average of at least three independent determinations ± SEM. Where not visible, error bars are 
smaller than the size of the data point. 
 
 
3.3.2.2 Enzyme concentration and reaction time.  
Optimal enzyme units and incubation time were determined by using different enzyme 
concentrations (0.5, 1.0, 1.5 and 2.0 U/mL). Assay mixtures were incubated for different 
times (0, 3, 6, 9, 12 and 15 min) and the results were plotted as absorbance versus time to 
obtain a combination that would give a linear relationship. 
 
3.3.2.3 Effect of polyphenols on colour reagent. 
The interference of polyphenols on the development of the colour by the DNS was 
determined by adding 1 mL of DNS reagent to an assay mixture containing 450 µL 
phosphate buffer saline (PBS, 0.01 M, pH 6.9) and 50 µL of different concentrations of 
different polyphenols (0-1 mM). The absorbance was recorded as described in section 
3.2.2.2.  
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3.3.2.4 Retention efficiency of Solid Phase Extraction cartridges by HPLC-PDA. 
HPLC analysis for efficiency of retention of polyphenols by the Oasis MAX solid phase 
extraction (SPE) cartridge was carried out with EGCG by Dr. Idolo Ifie (figure 3.4). The 
analysis were performed in a UFLCXR Shimadzu system (Shimadzu, Japan) consisting of 
binary pump, a photodiode array with multiple wavelength SPD-20A and a LC-20AD 
solvent delivery module coupled with an online unit degasser DGU-20A3/A5 and a 
thermostat autosampler/injector unit SIL-20A (C). The column used was a 5 µm Gemini 
C18 (250 x 4.6 mm, i.d.) with a flow rate of 1 mL/min, column temperature set at 35 
0C 
with an injection volume of 10 µL and detection at 280 nm. A two phase gradient system 
consisting of water with 0.1% TFA as mobile phase A and acetonitrile containing 0.1 % 
TFA as mobile phase B. The gradient conditions were as follows: the initial conditions 
started with 92% A and increasing to 18 % solvent B at 3.50 min, 32% B at 18 min, 60% 
B at 28 min reaching to 100% B at 32 min for 4 min, returning to the initial conditions for 
3.5 min. 
 
Figure 3.4 Retention efficacy of OASIS solid phase extraction cartridges. The efficiency was 
tested using EGCG as the test sample. (A) HPLC analysis of EGCG standard (200 µM) SPE. (B) 
HPLC analysis of EGCG standard after solid phase extraction. 
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3.3.2.5 Human α-amylase inhibition assay. 
For α-amylase, 1 “Sigma-defined” unit will liberate 1.0 mg of maltose from starch in 3 
min at pH 6.9 at 20 °C, and this was the basis of the initial experiments to optimise the 
assay. The enzyme preparation on this basis contained 276 Sigma-units per mg protein as 
estimated by Bradford assay. The assay contained 200 µL each of substrate (amylose or 
amylopectin) and enzyme, 50 µL PBS and 50 µl of inhibitor of different concentrations. 
For the control assay, the inhibitor was replaced by an equal volume of PBS. Stock 
amylose and amylopectin solutions (2.5 mg/mL) were prepared in water by heating at 90 
°C on a hot plate until it was dissolved (normally 5-10 min). A second stock solution of 
amylopectin was prepared at 0.925 mg/mL. Human salivary α-amylase stock solution 
(1.25 U/mL) was prepared in PBS. The enzyme stock solution and the assay mixture 
containing the inhibitor, PBS and substrate were pre-incubated at 37 °C for 10 min and 
the reaction was started by adding the enzyme to the assay solution. The reaction was 
carried out at 37 °C for 10 min with α-amylase at 0.5 U/ mL, substrate at 1 mg/mL and 
varying concentrations of the inhibitor up to 1 mM (depending on solubility). The 
reaction was stopped by placing the samples in a water bath at 100 °C for 10 min where 
no further reaction occurred, transferred to ice to cool down to room temperature and 
centrifuged for 5 min at 14000 g. The resulting sample was used for SPE to remove 
polyphenols before adding the DNS reagent. Thereafter, 1 mL of the DNS reagent was 
added and heated at 100 °C for 10 min. After cooling to room temperature, 250 µL from 
each sample was placed in a 96 well plate (Nunc A/S., Roskilde, Denmark) and the 
absorbance was recorded at 540 nm. Figure 3.5 summarises the different stages involved 
in the human salivary α-amylase protocol. 
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Figure 3.5 Schematic representation of human α-amylase inhibition assay. Critical steps that 
were optimised in order to get reliable inhibition constants include the concentration of enzyme 
and the removal of polyphenols to avoid interferences with the DNS reagent solution.  
 
The rate of enzyme inhibition was calculated as a percentage of the control (without 
inhibitor) using the formula: 
% = ((Abs Control − Abs sample)/ Abs control) × 100 
The half maximal inhibitory concentration (IC50) was calculated graphically by dose-
dependent inhibition. For Ki values, the Dixon plot method was employed (Dixon, 1953). 
Ki values were obtained by calculating the intersection point having an associated 
standard deviation supplying the uncertainties on the estimate using the following 
equations: 
 
                                                                     (Assuming n non-parallel regressions)  
Intersections (xij, yij) of each pair-wise combination i,j; 
 nicxmy iiii ,..,3,2,1, 
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This provides precisely                            = N, unique, i.e. non-repetitive pair-wise 
combinations. 
Defining the mean (x,y) and standard deviations (sx, sy) of the unique intersection 
coordinates xij, yij, as  
 
 
 
 
provides the expected intersection point of the regressions and associated standard 
deviation to supply the uncertainties on the estimate. The lines of each data point were 
fitted to the intersection point obtained from the equation. This mathematical equation 
was designed with the collaboration of Dr. Melvin Holmes from the School of Food 
Science and Nutrition at the University of Leeds.  
 
The α-amylase inhibition assay was employed to test the potential of ChE and its major 
polyphenols to attenuate carbohydrate digestion. ChE contained 50 % maltodextrin 
consisting of a variable length of D-glucose units linked by α-1,4 glycosidic bonds. 
Therefore, maltodextrin represent a substrate for intestinal enzymes and can interfere with 
the measurement of inhibition. The procedure employed to remove maltodextrin is 
described in the next section. For the α-amylase inhibition assay, ChE stock solution free 
of maltodextrin was reconstituted in DMSO while the individual polyphenols were 
prepared in a water-ethanol solution (50:50, v/v). The maximum concentration of the 
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organic solvents in the assay solution was 2 and 1 % for DMSO and ethanol respectively, 
which did not affect the activity of the enzyme as assessed in control incubations.  
 
In order to evaluate the possibility of the release of 2-E-MCA after hydrolysis by 
digestive enzymes in the gastrointestinal tract and therefore its potential role as inhibitor 
of carbohydrate-digestive enzymes, 2-E-MCA was subjected to enzymatic hydrolysis 
using hesperidinase and acetone extract from rat small intestine. The enzymatic 
hydrolyses were conducted with 50 mg/mL of the respective enzyme (the enzyme 
solution was prepared in PBS as described for α-amylase) and the reaction was conducted 
for 3 h at 37 °C. The released products were analysed by HPLC under the 
chromatographic conditions described in chapter 2, section 2.3.2.2. Kaempferol 3-O-
glucoside was used as positive control. 
 
3.3.2.6 Preparation of maltodextrin-free ChE.  
The maltodextrin in the chamomile preparation was removed using the ÄKTA Purifier 
System described in Chapter 2 section 2.3.2.3. ChE was loaded manually using a syringe 
through a sample loop of 0.1 mL and eluted using water containing 0.1% TFA (solvent 
A) and acetonitrile (Solvent B) at a flow rate of 0.75 mL/min as follows: 0-3 min linear 
gradient from 5 to 24 % B; 3-6 min isocratic at 24 % B; 6-18 min linear gradient to 40 % 
B; 18-24 isocratic at 40 %B, 24-30 min linear gradient to 100 %B: 30-35 min isocratic at 
100 %B, 35-38 min linear gradient to 5 %B, 38-41 min isocratic at 5 %B. The elution was 
followed at 280 nm and the polyphenol fraction was collected yielding a maltodextrin-
free extract. Multiple semi-preparative collections were done, combined, freeze-dried, 
and stored at -20 °C until the enzymatic assays were conducted. 
 
 
3.3.2.7 Inhibition of α-glucosidase activity by ChE and its individual major 
polyphenols. 
For α-glucosidase activity, maltase, sucrase and isomaltase were assessed. The assay was 
optimised for linearity in terms of enzyme and substrate concentration by other members 
of the laboratory (Aydin, 2015; Nyambe-Silavwe, 2016) as described for human salivary 
- 75 - 
 
α-amyalse. The apparent Km values for maltose, sucrose and isomaltose were 3, 16 and 6 
mM respectively as determined using the Lineweaver–Burk plot with a chosen enzyme 
concentration and incubation times giving linear rates of reaction. These concentrations 
were used to conduct the enzymic assays.  
 
Acetone extract from rat small intestine was used as the enzyme source and inhibitors 
were prepared as described for human salivary inhibition assay. The reaction mixture 
contained 0.2 mL of enzyme solution (4 mg/mL powder in 0.01 M PBS, pH 7·0 for 
maltase and 20 mg/mL for sucrase and iso-maltase), 0.2 mL of substrate (3 mM maltose, 
16 mM sucrose and 6 mM isomaltose), 0.05 mL of inhibitor (varying concentrations) and 
0.05 mL of PBS. In the control sample, inhibitor was replaced by an equal volume of 
PBS. The enzyme solution and the assay mixture containing the maltose, inhibitor and 
PBS were pre-incubated at 37 °C for 10 min and the reaction started by adding the 
enzyme to the assay mixture. The reaction was carried out and stopped as reported for α-
amylase assay after 20 min reaction time and cooled down to room temperature before the 
inhibitors were removed by solid phase extraction (polyphenols interfere with the 
enzymatic determination of glucose probably by enhancing NADH production yielding 
erroneous absorbance readings in their presence). The glucose produced was determined 
enzymatically (figure 3.6 and 3.7) by placing 0.01 mL of the reaction mixture in 96 well 
plate (Chimney well, Germany), adding 0.25 mL of hexokinase reagent, incubating for 15 
min at 30 °C and recording the absorbance at 340 nm according to Encarnação (2015). 
 
Enzyme inhibition (%) was calculated according to the equation:  
 
% = ((Abs Control − Abs sample)/Abs control) × 100 
 
where Asample is absorption of the sample and Acontrol is absorption of the control (without 
inhibitor). The inhibition constants were calculated as previously described for human α-
amylase.   
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Figure 3.6 Enzymatic determination of glucose by hexokinase-linked reaction. Glucose is 
phosphorylated by adenosine triphosphate (ATP) in the reaction catalysed by hexokinase. 
Glucose- 6-phosphate (G6P) is then oxidized to 6-phosphogluconate in the presence of oxidized 
nicotinamide adenine dinucleotide (NAD) in a reaction catalysed by glucose-6-phosphate 
dehydrogenase (G6PDH). During this oxidation, an equimolar amount of NAD+ is reduced to 
NADH. The consequent increase in absorbance at 340 nm is directly proportional to glucose 
concentration.  
 
 
 
 
 
 
 
 
 
Figure 3.7 Representative example of glucose standard calibration curve. The calibration 
curve was used to quantify the glucose produced from maltose, sucrose and isomaltose after 
hydrolysis with acetone extract from rat small intestine. Each data point represents the average of 
at least three independent determinations ± SEM. When not visible, the error bars are smaller than 
the data point. 
 
 
 
 
 
- 77 - 
 
3.3.2.8 Molecular Modelling.  
We investigated the interactions of polyphenols with human salivary and pancreatic α-
amylase using the three-dimensional crystal structure 1MFV (Ramasubbu et al., 2003) 
and 1CPU (Brayer et al., 2000) deposited in the RCSB Protein Data Bank 
(http://www.rcsb.org/pdb/home/home), respectively. They contain a modified form of the 
α-amylase inhibitor acarbose that was co-crystallised in the binding pocket. The 1MFV 
and 1CPU were superimposed applying the CLC drug discovery workbench 3.0.2 
molecular modelling program (CLC Bio-Qiagen, Aarhus, Denmark) and the binding site 
residues were located in similar conformation for both enzymes. The α-amylase structures 
were prepared for docking by removing from the crystallographic structures water 
molecules and any other co-crystallised ligand. No constraints were introduced and the 
default parameters were used in this study (binding site: within 13 Å radius around 
acarbose, scoring function: PLANTSPLP score, genetic algorithm: 100% search 
efficiency). The score mimics the potential energy change (ΔG), when the protein and the 
ligand (acarbose or polyphenol) come together. This means that a very negative score 
corresponds to a strong binding and vice versa. These interactions consist of (i) hydrogen-
bond interaction, (ii) lone-pair metal ion interactions and (iii) non-polar interactions. The 
number of docking iterations for evaluation of the preferred binding pose was set at 500. 
This was optimised for the search space, as the binding poses generated after 500 
iterations did not change. The ten best docked poses per docking calculation were 
analysed based on their docking score and the top ranked pose for each ligand was 
selected for further analysis. Ligand-receptor interactions were visualised within the CLC 
workbench and Discovery Studio (BIOVIA, Client version 2016). 
 
Validation of the docking parameters was performed by docking the co-crystal modified 
structures of acarbose into the active site of each protein. The molecular mechanical 
energy of the extracted structures were minimised using the impact energy minimization 
option of Avogadro graphical interface applying the conjugate gradient algorithm before 
conducting the docking. For the co-crystal structure extracted from 1CPU, hydrogen 
atoms were added. The corresponding ligand was successfully docked in the binding 
pocket of 1MFV and 1CPU (1MVF= −74.07 and 1CPU= -73.99 Kcal/mol) with a root 
mean square deviation (RMSD) of 1.36 and 1.11 Å respectively, and establishing similar 
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Figure 3.8 Validation of the docking 
parameters using the crystal 
structure analyses of human α-
amylases. (A) human salivary (1MFV) 
and (B) human pancreatic α-amylase 
(1CPU) protein complexed with a 
modified acarbose ligand, showing the 
superimposition of native conformation 
(in grey) with the docked one (in 
turquoise and purple) in the active site. 
The RSMD of both docked structures 
were within the acceptance deviation 
with values of 1.36 and 1.11 Å for 
salivary and pancreatic α-amylase 
respectively. The small spheres in blue 
(calcium) and green (chlorine) represent 
cofactors. Figures on the right shows 
the H-bond formed between the co-
crystal structures of (C) salivary and 
(D) pancreatic α-amylase in the binding 
pocket. H-bonds are indicated with blue 
dotted lines. 
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similar interactions (figure 3.8). Docking programs are considered reliable if they are able 
to return the re-docked pose below the RMSD value of 2 Å (Murumkar et al., 2013). 
These results indicate that the CLC workbench was capable of reproducing the native 
crystallised pose of the ligands. After validation of the docking parameters, the atomic 
structure of each polyphenol molecule was obtained from PubChem database and the 
mechanical energy minimised before docking studies. 
 
3.3.3 Statistical analysis. 
Statistical analyses were performed by one-way analysis of variance using the Number 
Cruncher Statistical System version 6.0 software (NCSS, LLC). Significant differences 
were assessed with the Tukey–Kramer multiple comparison test (p<0.05). The data are 
expressed as the mean ± SEM of at least three independent experiments with three 
technical replicates each. 
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3.4 Results and discussion. 
 
3.4.1 Effect of enzyme and substrate concentration on inhibition. 
There are many in vitro examples of positive results on the inhibition of digestive 
enzymes by pure polyphenols and polyphenol-rich extracts. However the recognition and 
ranking of specific molecules and extracts have been difficult to establish since there are 
wide inconsistencies in both assay methods and experimental outcomes (Nyambe-
Silavwe et al., 2015).  
 
The IC50 of an inhibitor is very dependent on the assay conditions including enzyme 
concentration, type of substrate, reaction time, temperature and pH. While temperature 
and pH have been standardised in most of the published studies on α-amylase inhibition 
to 37 °C and 6.9 respectively, there is no consensus regarding the other parameters. In 
this regard, the effect of acarbose, a well-known α-amylase inhibitor, was tested under 
two different assay conditions to determine the effect on the inhibition constant. 
Concentrations of 0.5 and 3.0 U/mL of enzyme were chosen to conduct this experiment 
where the former represents a suitable concentration of enzyme (linear range) and the 
latter a sub-optimal condition (where the substrate is rapidly mostly consumed during the 
mixing and/or starting procedure) under this experimental setting. This experiment was 
conducted on amylose and amylopectin as substrate (figure 3.9). 
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Figure 3.9 Time-dependence rate of hydrolysis by human α-amylase. The rate of hydrolysis at 
different incubation times was measured using two different substrates (A) amylose and (B) 
amylopectin. The hydrolysis of both substrates was measured by the amount of maltose-produced 
at four different concentrations of enzyme. Each data point represents the mean ± SEM of three 
independent experiments conducted in triplicate (n = 3). When not visible, the error bars are 
smaller than the data point. 
 
As depicted in figure 3.10, the two different enzyme concentrations had an effect 
(p<0.05) on the apparent IC50 value exhibited by acarbose, and this was more pronounced 
when amylopectin was used as substrate. The IC50 value of acarbose under non-optimal 
conditions was ~7 to 8-fold higher than that obtained under optimal conditions for both 
substrates. Reducing the concentration of amylopectin from 1 mg/mL to 0.37 mg/mL to 
give the same ratio of Km value versus concentration in comparison to amylose also 
caused an apparent increase in the inhibitory activity of acarbose, and the same pattern 
was observed for green tea (lower IC50) (table 3.1). These results demonstrate that any 
enzymatic inhibition assay must be performed within the area of the initial linear 
progression of the reaction since the following non-linear phase will produce misleading 
results (Bisswanger, 2014). Furthermore, changes in the type of substrate and 
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concentration affect the apparent potency of an inhibitor due to the varying catalytic 
efficiencies (Km) of the enzyme for the substrate, as exemplified with acarbose, EGCG 
and green tea extract.   
 
 
Figure 3.10 Inhibition of human α-amylase by acarbose. The experiment was conducted using 
amylose and amylopectin at a concentration of 1 mg/mL. Amylase activity inhibition varied 
according to the units utilized during the enzymic assay (units defined as described in section 
1.3.2.5). Results are expressed as % compared to the reducing sugars produced in control 
incubations (no inhibitor; normalised to 100 %). Each data point represents the mean ± SEM of 
three independent experiments conducted in triplicate (n = 3). When not visible, the error bars are 
smaller than the data point. 
 
Table 3.1 Experimental IC50 values of acarbose, selected polyphenols and green tea 
extract.  
Amylose Amylopectin        Amylopectin
(1 mg/mL) (1 mg/mL)  (0.37 mg/mL)
Acarbose 3.5 ± 0.3 10 ± 1 6.7 ± 0.8
EGCG 5 ± 0.6 72 ± 2 10 ± 4
Quercetin 20 ± 0.3 83 ± 7 22 ± 1 
Luteolin 28 ± 0.3 75 ± 1 42 ± 9
Green tea 9 ± 0.6 60 ± 2 25 ± 1
Inhibitor 
Substrate
 
      The IC50 value of pure compounds is expressed in µM while for green tea is µg/mL. 
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3.4.2 Kinetic studies on amylose and amylopectin 
The time-dependence hydrolysis assessed for different concentrations of enzyme was 
linear for up to 15 min for amylose and up to 12 min for amylopectin using 0.5 U of 
enzyme as depicted in figure 3.9. Therefore, 10 min and 0.5 U of enzyme were chosen as 
the optimum assay conditions to obtain the kinetic parameters, with 1 mg/mL substrate 
concentration. Using Lineweaver–Burk plots (figure 3.11), the values obtained are: 
amylose, Km = 12.9 mg/mL and Vmax = 1.67 mmol/min per mg of protein; amylopectin, 
Km = 4.8 mg/mL and Vmax = 0.67 mmol/min per mg of protein. 
 
 
Figure 3.11 Lineweaver–Burk plot for action of human α-amylase. The kinetic parameters of 
α-amylase were calculated with using amylose and amylopectin as substrates with concentrations 
that ranged from 0-2 mg/mL (2 mg/mL was the maximum soluble concentration for both 
substrates). Each data point represents the mean ± SEM of at least three independent experiments 
conducted in triplicate (n = 3). When not visible, the error bars are smaller than the data point. 
 
 
The results obtained for the human α-amylase inhibition show the importance of 
determining the effect of enzyme concentration and the kinetic parameters Km and Vmax 
before measuring inhibition constants. These parameters are then used for assay 
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optimisation and are critical to the interpretation of correct and comparable IC50 values 
(Acker and Auld, 2014). For instance, reducing the concentration of amylopectin from 1 
mg/mL to 0.37 mg/mL to give the same ratio of Km value versus concentration in 
comparison to amylose caused an apparent increase in the inhibitory activity of acarbose, 
and the same pattern was observed for green tea (lower IC50).   
 
3.4.3 Interference of polyphenols with the DNS reagent. 
The use of the DNS reagent is one of the most widely reported methods to quantify the 
content of reducing sugars, and it has been largely applied to measure the inhibition of α-
amylase from activity from different species by many compounds including polyphenols. 
For the optimisation of the assay, three different classes of polyphenols with different 
reduction potentials were tested to corroborate this fact (figure 3.12). Significant 
differences (p<0.05) were observed between EGCG, gallic acid and phlorizin. EGCG 
caused the most interference with the DNS reagent solution in a dose-dependent manner, 
followed by gallic acid and phlorizin. The extent of the interference strongly correlates 
with the number of OH groups in the chemical structure of the polyphenol (figure 3.13), 
which also partially predicts their reduction potential (Rice-Evans et al., 1996). This 
result implies that polyphenol molecules with high reduction potential (antioxidant 
activity) will interfere with the assay. Indeed, EGCG which contains the highest number 
of OH groups of the tested compounds, gave the greatest effect and ferulic acid, with the 
lowest number of OH groups did not react. 
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Figure 3.12 Reaction of selected polyphenols with the DNS reagent solution. For establishing 
the interference, different polyphenols with varying reduction potentials (judged by the number of 
OH groups in the chemical structure (Rice-Evans et al., 1996)) were tested in the absence of any 
reducing sugar. Each data point represents the mean ± SEM of at three independent experiments 
conducted in triplicate (n = 3). When not visible, the error bars are smaller than the data point. 
 
Figure 3.13 Relationship between the number of OH groups and colour development by 
DNS reagent solution. The Pearson correlation coefficient of linear regression between the num- 
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-ber of OH groups and absorbance at 100, 500 and 1000 µM of selected polyphenols gave a 
strong correlation (r2= 0.98; R2= 0.9892). Each data point represents the mean ± SEM of three 
independent experiments conducted in triplicate (n = 3). When not visible, the error bars are 
smaller than the data point. 
 
 
While this relationship may not hold for all polyphenols, their removal should be 
considered in pre-tests involving the DNS reagent solution. This is something that has 
been ignored in many published studies and may account for the variation in the reported 
inhibition of α-amylase for EGCG (reviewed in Nyambe-Silavwe et al. 2015), since it 
interacts very strongly with the DNS reagent. Ignoring this contribution would decrease 
the apparent inhibition, i.e. raise IC50 and Ki values. This may explain the discrepancy 
between data in the literature, where, for example, EGCG was estimated to be far less 
potent compared with the result of this study with an IC50 value of 1.5 mM using the DNS 
reagent as detection method (Koh et al., 2009).  
 
 
3.4.4 Inhibitory effect of selected polyphenols on human α-amylase activity. 
Assays under optimal conditions of enzyme concentration and incubation time were 
carried out to test the inhibitory activity of selected polyphenols using amylose and 
amylopectin as substrate and compared to those reported in the literature for those 
compounds (summarised in appendix A-C). Polyphenols were removed from the reaction 
solution using SPE, and the efficiency is shown in figure 3.4 for EGCG as an example. 
The same procedure was carried out with quercetin and luteolin with the same removal 
efficiency. All of the tested polyphenols showed dose-dependent inhibition of α-amylase 
activity on both substrates, and therefore the IC50 values could be calculated (figure 3.14).  
The inhibitory activity of quercetin, EGCG and luteolin was higher when amylose was 
used as substrate. EGCG showed the highest inhibition with maximum inhibition at 20 
µM and no significant difference (p>0.05) was observed above that concentration. For 
quercetin and luteolin, the highest inhibition was recorded at the highest concentration 
tested (100 µM) owing to limits in solubility, showing significant difference (p<0.05) 
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among the tested concentrations. No differences (p>0.05) were observed between the 
three tested polyphenols at a concentration of 100 µM using amylose as substrate. 
 
Figure 3.14 Inhibition of human α-amylase by polyphenols. Selected polyphenols were 
assessed for their inhibition of human salivary α-amylase using (A) amylose and (B) amylopectin 
as substrate at 1 mg/mL. The IC50 is indicated by the dotted line in (A) and (B). Different trends 
of inhibition are observed according to the substrate used which is due to the difference in the 
substrate/Km ratio (using the same ratio gave very similar inhibition values). Results are expressed 
as % compared to the reducing sugars produced in control incubations (no inhibitor; normalised to 
100 %). Data points represent the mean ± SEM of three independent experiments conducted in 
triplicate (n = 3). When not visible, the error bars are smaller than the data point. For visualisation 
purposes, statistical significance are not indicated in the graph, instead they are described in the 
main text. 
 
 
With amylopectin as substrate, IC50 values were higher. The differences in the inhibition 
behaviour of the polyphenols on α-amylase between amylose and amylopectin could be 
related to the differences in the affinity (Km) for each type of substrate. This is another 
variable that partially explain the discrepancy in the literature regarding the inhibitory 
- 88 - 
 
-20 0 20 40 60 80 100
0.00
0.05
0.10
0.15
0.20
0.25
 0.5 mg/mL
 0.6 mg/mL
 0.8 mg/mL
 0.9 mg/mL
 1.0 mg/mL
Equation
Weight
Residual Sum 
of Squares
Pearson's r
Adj. R-Square
V
W
X
Y
Z
   
   
   
   
1/
v 
(1
/
m
o
l/m
in
/m
g
 
   
  o
f 
p
ro
te
in
)
Concentration (M)
B
potential of polyphenols. Even for acarbose which is an established α-amylase inhibitor, 
the reported differences in the IC50 values ranged from 0.9 to 23,100 µM, and when 
results are compared with same-source enzymes, the range vary from 0.9– 6.9 and 1.24–
23,079 µM for human and porcine, respectively (Nyambe-Silavwe et al., 2015). Hence 
the need to calculate the Ki which, for competitive inhibition, represents the dissociation 
constant of the enzyme–inhibitor complex independently of substrate employed. There 
was no significant difference (p>0.05) between Ki values for amylose and amylopectin 
(figure 3.15) suggesting that the Ki should always be considered for measuring the 
inhibition efficacy of pure compounds in order to minimise some of the potential 
differences between laboratories. 
 
                
                      
Figure 3.15 Dixon plot kinetic analysis of EGCG on human α-amylase. The kinetic analysis 
were conducted on both amylase substrates (A) amylose and (B) amylopectin at varying 
concentrations as indicated in the figure legend. The mean intercept value represents –Ki which 
was calculated according to the equation described in section 1.3.2.5. The Ki are shown as inserts 
below the EGCG 2D chemical structure illustration. Data points represent the mean ± SEM of th- 
A) Ki = 0.28 +/- 0.64 
B) Ki = 4.50 +/- 4.53 
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-ree independent experiments conducted in triplicate (n = 3). When not visible, the error bars are 
smaller than the data point. 
 
 
Most of the research regarding the inhibition of α-amylase activity by polyphenols has 
been carried out using an enzyme from porcine pancreas, which possesses 14 % different 
amino acid composition to that of human origin (Brayer, Luo, & Withers, 1995), and data 
on the effect of polyphenols on human α-amylase are much more limited when compared 
to porcine (Lo Piparo et al., 2008). In a previous study, acarbose, luteolin and quercetin 
competitively inhibited human salivary α-amylase with IC50 of ~1, 18 and 21 µM 
respectively, similar to those obtained in this study when amylose was used as substrate 
(Lo Piparo et al., 2008). Lo Piparo and co-workers utilised the same type of substrate 
(potato starch high in amylose to amylopectin ratio) as in this study which may partially 
explain the similarity of the results for the polyphenols and acarbose. These results 
indicate that when similar assay conditions are used, the experimental outcomes do not 
vary greatly.  
 
 
3.4.5 Inhibitory effect of ChE and individual major polyphenols on human 
salivary α-amylase and α-glucosidase activity. 
The inhibitory effect of ChE and individual polyphenols against human salivary α-
amylase and rat α-glucosidase activity are shown in figure 3.16 and 3.17. The addition of 
ChE resulted in a dose-dependent inhibition of human salivary α-amylase activity by ~35, 
45, 61 and 60 % at concentrations of 0.125, 0.25, 0.5 and 1 mg/mL respectively. The IC50 
value for human α-amylase was 0.29 ± 0.052 mg/mL (figure 3.16A).  
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Figure 3.16 Inhibition of human α-amylase activity by ChE and polyphenols.(A) Dose-
dependent inhibition of ChE. IC50 for acarbose was obtained and used as positive control. (B) 
Combined and individual inhibition effect of polyphenols at concentrations equivalent to those 
present in the ChE: (Z)-MCAG, 257 µM; (E)-MCAG, 200 µM; apigenin 7-O-glucoside (A7G), 
148 µM; apigenin, 12 µM. (C) Dose-dependent inhibition of individual polyphenols. (D, E) 
Dixon plot showing the kinetic analysis of apigenin and A7G against human salivary α-amylase. 
The intercept value represents –Ki. In panel A-C, results are expressed as % compared to the 
reducing sugars produced in control incubations (no inhibitor; normalised to 100 %).  Data points 
represent the mean ± SEM of three independent experiments conducted in triplicate (n = 3). When 
not visible, the error bars are smaller than the data point. Different letters denotes significant 
difference among treatments.  
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For the individual polyphenols, apigenin and its precursor apigenin 7-O-glucoside 
exhibited the most potent inhibition against human salivary α-amylase with IC50 of ~22.8 
and 248 µM respectively (figure 3.16C). However, when the four polyphenols were 
combined at concentrations equivalent to those quantified in the extract, apigenin 7-O-
glucoside showed the highest contribution (p<0.05) (figure 3.16B). Moreover, the 
combination of the four polyphenols resulted in an increase on the inhibitory activity by 
~20 % as compared to the whole ChE. This result highlights that even when subtle 
inhibition is observed by a particular compound, any additive/synergistic effect can 
potentiate the overall response.  
 
In order to gain a better understanding of the inhibitory effects of apigenin and apigenin 
7-O-glucoside on human salivary α-amylase, a kinetic assessment was performed. Ki 
values were calculated at ~17 and 146 µM for apigenin and apigenin 7-O-glucoside 
respectively from the intercept of a Dixon plot (figure 3.17D and E). The potential 
inhibition of 2-(E)-MCA on carbohydrate-digestive enzymes was not assessed since this 
chemical form is very unlikely to be present in the small intestine given that E-MCAG 
was resistant to digestive hydrolytic enzymes (figure 3.17).   
 
The final step of starch digestion is catalysed by α-glucosidases (maltase-glucoamylase 
and sucrase-isomaltase). Their combined catalytic activities hydrolyse linear and 
branched malto-oligosaccharides after the action of pancreatic α-amylase (Sim et al., 
2010); in addition, sucrase-isomaltase hydrolyses sucrose, producing glucose and 
fructose. Their inhibition can provide complementary action for blunting the rise of these 
readily absorbable sugars whose intake increase the prospect of type 2 diabetes onset (Te 
Morenga et al., 2013; Imamura et al., 2015). The results indicate only a modest inhibition 
on maltase-glucoamylase activity using maltose as substrate while no inhibitory effect 
was observed on sucrase and isomaltase (figure 3.18A). Even at a concentration of 2 
mg/mL, rat maltase was inhibited only by ~33 %. As expected, maltase-glucoamylase 
was weakly inhibited by the individual polyphenols (figure 3.17B and C). A dose 
response inhibition was observed and apigenin 7-O-glucoside was the principal 
contributor (p<0.05), although apigenin seems to have a more potent inhibitory effect, its 
poor solubility did not allow testing at higher concentrations (figure 3.17C). Neither the 
individual polyphenols nor their combination reached 50 % inhibition.   
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Figure 3.17 Enzymatic hydrolysis of kaempferol 3-O-glucoside (positive control) and (E)-
MCAG. Kaempferol 3-O-glucoside standard (300 uM). (B) Kaempferol standard (100 µM) (C) 
Kaempferol 3-O-glucoside hydrolysed with hesperidinase. (D) Kaempferol 3-O-glucoside 
hydrolysed with acetone rat intestinal extract. (E) Kaempferol 3-O-glucoside hydrolysed with 
pancreatin. (F) (E)-MCAG (500 uM) hydrolysed with hesperidinase. (G) (E)-MCAG (500 uM) 
hydrolysed with acetone rat intestinal extract. Three independent experiments in triplicate were 
conducted (n = 3). Representative chromatograms of the hydrolysis of each compound were 
randomly selected and presented in this figure. 
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Figure 3.18 Inhibition of rat maltase activity by ChE and polyphenols.(A) Dose-dependent 
inhibition of ChE. IC50 for acarbose was obtained and used as positive control. (B) Combined and 
individual inhibition effect of polyphenols at concentrations equivalent to those present in the 
ChE: (Z)-MCAG, 257 µM; (E)-MCAG, 200 µM; apigenin 7-O-glucoside (A7G), 148 µM; 
apigenin, 12 µM. (C) Dose-dependent inhibition of individual polyphenols. Results are expressed 
as % compared to the reducing sugars produced in control incubations (no inhibitor; normalised to 
100 %). Data points represent the mean ± SEM of three independent experiments conducted in 
triplicate (n = 3). When not visible, the error bars are smaller than the data point. 
 
 
There is limited studies designed at identifying potential inhibitors of carbohydrate 
digestion in chamomile (Kato et al., 2008). In contrast to the present study, Kato and co-
workers reported a more potent inhibition on α-glucosidase (IC50 = 2.6 mg/mL and 
sucrase = 0.9 mg/mL) than α-amylase activity (IC50 = 5.2 mg/mL) by chamomile. 
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However as reported here, apigenin showed the strongest effect although the inhibition 
was ~17 times lower (42 % at 400 µM). As for α-glucosidase, the authors suggest that 
this effect was driven by the presence of esculetin (maltase IC50 = 534 μM; sucrase IC50 = 
72 μM) and quercetin aglycone (maltase IC50 = 216 μM; sucrase IC50 = 71 μM). 
However, other data on chamomile composition indicate that these compounds, if present 
at all, are unlikely to be effective since they are several orders of magnitude below the 
concentrations necessary for inhibition (Raal et al., 2012; Guimarães et al., 2013; 
Guimarães et al., 2013).  
 
There are several reasons that can explain the conflicting results which are related to the 
assay parameters as well as the ChE itself. First, the authors did not report the assay 
conditions to perform the inhibition with the exception of the pH. Consequently, the assay 
cannot be replicated and therefore it is difficult to ascertain whether the assays where 
conducted under optimal conditions. Second, the inhibition assays were conducted using 
different sources of enzyme. While human α-amylase and a commercial acetone rat 
intestinal powder for α-glucosidase was employed in the present study, Kato and co-
workers used pancreatic porcine α-amylase and brush border membranes prepared from 
rat small intestine. Since kinetic parameters were not reported, it is impossible to have an 
idea of the specific activity and so the performance of the enzyme preparations. Third, as 
pointed out in chapter 2, the composition and content of the plant material must be 
reported. Kato and co-workers did not give any information on the phytochemical profile 
and content of the ChE tested and so, it is possible that the opposite results are due to 
variations in the chemical constituents. A caveat of failing to report compositional data is 
the identification of compounds that lack any physiological relevance (e.g. negligible or 
low levels as compared with the inhibition constants obtained) in plant extracts.   
 
 
3.4.6 Modelling studies. 
Molecular docking studies were further carried out to get a molecular insight of the 
interactions that occur between the tested ligands, human and pancreatic α-amylase in 
order to support the experimental findings. In general, all the docking scores were in line 
with the experimental results where the most potent inhibitors showed the lowest binding 
energy (table 3.2). A remarkable exception was apigenin 7-O-glucoside that showed a 
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Molecule
Hydrogen 
bond score
Metal 
interaction 
score
Steric 
interaction 
score
Ligand 
conformation 
penalty
Total score
1MFV
A7G -14 0.00 -59.74 2.1 -71.46
Acarbose -18.35 0.00 -63.03 10.34 -71.04
EGCG -16.37 0.00 -57.67 5.6 -68.44
Luteolin -9.7 0.00 -55.44 1.34 -63.79
Quercetin -11.91 0.00 -51.36 1.41 -61.87
Apigenin -7.86 0.00 -53.12 1.3 -59.68
(E )-MCAG -24.57 0.00 -35.61 2.44 -57.75
(Z )-MCAG -16.63 0.00 -40.55 3.92 -53.25
1CPU
Acarbose 20.03 0.00 -56.28 7.35 -68.97
A7G -14.49 0.00 -55.2 3.66 -66.02
EGCG -13.6 0.00 -50.84 3.98 -60.46
Luteolin -11.32 0.00 -48.15 1.47 -58
Quercetin -13.31 0.00 -45.6 1.32 -57.6
Apigenin -8.19 0.00 -48.27 1.6 -54.86
(E )-MCAG -15.91 0.00 -40.33 0.94 -55.31
(Z )-MCAG -9.38 0.00 -45.56 6.04 -48.9
very similar score to acarbose for both enzymes but its experimental inhibition value was 
~71.5-fold times lower. 
 
    Table 3.2 Docking scores of polyphenols on human salivary and pancreatic α-amylase. 
 
 
 
 
 
 
 
 
 
The contribution from hydrogen bond interactions is presented as ‘hydrogen bond score’. The 
contribution from lone-pair-metal ion interactions is listed as ‘metal interaction score’. The non-
polar interactions, non-polar–polar contacts, and the repulsive contacts are combined in the ‘steric 
interaction score’. The software punishes internal heavy atom clashes in the ligand and strain 
resulting from non-favourable bond rotations and is listed as ‘Ligand conformation penalty’. 
A7G: apigenin 7-O-glucoside. 
 
 
A drawback of the scoring function is that it takes into account all the interactions 
between the ligand and the receptor, and so a large ligand can get a better score than a 
small one. Therefore docking score does not necessarily reflect the potency of a particular 
inhibitor as is the case of apigenin 7-O-glucoside. This is something to bear in mind 
specially when conducting a virtual docking screening to identify potential inhibitors for a 
particular receptor, where a combination of docking score and most importantly, the 
binding interactions within the catalytic pocket (if competitive inhibitors are assessed) has 
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to be considered. Luteolin showed slightly better score than quercetin and apigenin, 
however among them, it presented the higher IC50 (lower inhibition activity). 
Nonetheless, this cannot be considered a bias from the software since both the docking 
scores and the experimental IC50 values were very close to each other (quercetin= 20 µM; 
apigenin= 23; luteolin= 28 µM). Moreover, although the ligands were not experimentally 
tested on human pancreatic α-amylase, the binding energy scores and the comparison of 
the binding cavity and orientation of the catalytic residues (Asp197, Glut233 and Asp300) 
suggest that the enzyme can be inhibited to the same extent by the polyphenols (table 3.2, 
figure 3.19).  
 
The docking studies revealed that strong inhibitors of salivary α-amylase activity 
(arbitrarily defined as molecules with IC50 <100 µM) bind in the active site next to, and 
interacting with, the catalytic residues Asp197 (nucleophile), Glu233 (acid-base) and Asp300 
(acid-base) through H-bonds (figure 3.20). These interactions occur between OH groups 
present in position R3′ and R4′ of the B ring in the flavonoid skeleton. The number of H-
bond formed varied among polyphenols and they seem to predict the potency of the 
inhibitor according to the in vitro results. For instance, the R3′ and R4′-OH groups of 
quercetin form H-bonds with Asp197 residue (figure 3.20B) while luteolin and apigenin 
form only one H-bond through the OH group of R4′ and R3′ positions, respectively 
(figure 3.20D, E and I). A similar conclusion can be drawn for the most potent inhibitor 
identified in this study ‘EGCG’ where the R3′-OH and R4′-OH group form an H-bond 
with Asp197 and Asp300 respectively.  
 
From the selected conformations, the binding pose of EGCG, quercetin, apigenin and 
luteolin to the catalytic pocket of human salivary α-amylase is characterised by 
intramolecular hydrophobic π-π stacking interactions between the A, B and C-ring of the 
flavonoid core and the aromatic ring of Tyr62 and the indole ring of Trp59 (a 3D 
illustration of the π-π stacking interactions is shown in figure 3.20B). These hydrophobic 
interactions are thought to be critical for the inhibition of salivary (Lo Piparo et al., 2008) 
and human pancreatic α-amylase (Williams et al., 2015) by polyphenols since they 
provide optimal alignment of the OH groups for prime hydrogen bonding with the 
catalytic residues (Williams et al., 2015). A final feature of potent inhibitors is that they-
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Figure 3.19 Structural comparison between the residues forming chemical interactions with the co-crystal structures of human salivary 
(1MFV) and human pancreatic α-amylase (1CPU).(A) Structural conformation of the binding pocket of salivary α-amylase. (B) Structural 
conformation of the binding pocket of pancreatc α-amylase. (C) Structural alignment of the binding pocket salivary (in turquoise) and pancreatic 
α-amylase (in dark green). As can be observed from the individual figures and from the superimposition, the only residue that has a different pose 
is Tyr62 (spherical red dotted line in panel C).  
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Figure 3.20 The binding pose and chemical 
interactions of polyphenols with human 
salivary α-amylase. 
 (A) and (B) Close-up 3D view illustrating the H-
bond and π-π stacking interactions of EGCG 
adjacent to α-amylase active site residues 
respectively. (C-J) Charge surface representation 
(in blue and red) of α-amylase binding cavity 
with respective ligands displayed in stick format 
(in purple); (C) EGCG, (D) quercetin, (E) 
luteolin, (F) (Z)-MCAG, (G), (E)-MCAG, (I) 
apigenin and (J), apigenin 7-O-glucoside. Next to 
each 3D complex are schematic representations 
of the 2D interactions between each ligand and 
α-amylase amino acid residue including the 
length of each interaction (in Å) as displayed by 
Discovery Studio software.  
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occupy the same binding subsites in the catalytic pocket on salivary α-amylase (figure 
3.21B and C). In these binding conformations, the flavonoid skeleton of EGCG, 
quercetin, apigenin and luteolin is directed towards subsites -1 and -2 according to the 
established nomenclature for  acarbose substructures oriented in the active site spanning 
subsites -3 to +2 (Brayer et al., 2000) (figure 3.21A).  
 
EGCG shows a slightly different pose which favours a better orientation towards subsite -
2. Subsites -1, -2 and -3 have been reported to be the centre of the catalytic reaction in 
human pancreatic α-amylase (Brayer et al., 2000). This, along with the number of H-
bonds formed with catalytic residues and the strength of the interaction (indicated by the 
length of the H-bonds) would explain the stronger effect observed in the in vitro 
experiments of EGCG to reduce human salivary α-amylase activity. Additional H-bonds 
were observed between the strong inhibitors with other residues that are not directly 
involved in the catalytic activity including Gln63, His305 and Gly306 (figure 37).  
 
Figure 3.21 Subside binding pose of strong polyphenol inhibitors of human salivary α 
amylase. (A) Illustration of the co-crystal modified acarbose molecule showing the binding 
subsites according to the reported nomenclature (Brayer et al., 2000; Lo Piparo et al., 2008; Al‐
Asri et al., 2016). Binding subsites are denoted with negative and positive numbers. (B) Superim- 
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-position of the docking pose of quercetin  (in purple), apigenin (in turquoise), luteolin (in dark 
green) and the docking pose of quercetin  (in purple), apigenin (in turquoise), luteolin (in dark 
green) and (C) EGCG with the modified acarbose structure in amylase binding cavity. 
Surrounding residues are showed and labelled. Variable sizes of amino acid labelling correspond 
to their depth in the binding pocket. 
 
 
Analysis of the docking conformation of polyphenols that presented modest inhibitory 
activity ((Z)-(E)-MCAG and apigenin 7-O-glucoside)) showed that they occupy the cavity 
in a completely different pose (figure 3.20F, G and J). Notably, (Z) and (E)-MCAG are 
able to form H-bonds with the catalytic residues. However, unlike apigenin, the H-bonds 
are formed mainly with the OH groups present in the glucose moiety and as might be 
expected, are weaker (as judged by the distance of H-bonds formed). Strong H-bonds 
would stabilise the substrate, keeping it in place and interfering with the catalytic activity.  
 
In (Z)-MCAG, an H-bond is formed between the 6-OH group of the glucose unit with 
Asp197 while (E)-MCAG present a more complex interaction. In (E)-MCAG, 2 covalent 
bonds are formed between the carbon at position 2 and Asp197 (indicated as carbon-
hydrogen bond in figure 3.20). Additionally, H-bond interactions occur between the 6-OH 
group and Glu233 and Asp300 and an additional H-bond is formed between the Glu233 and 
the OH-present in the carboxylic group of the phenolic skeleton. These additional 
interactions would explain the slightly higher inhibition observed by the (E)-isomer in 
vitro, and perhaps they account for its stability in the binding pocket due to the lack of π-π 
stacking interactions.  
 
Apigenin 7-O-glucoside is able to form π-π stacking interactions with Trp59 and Tyr62 
however, it does not form the H-bond with the catalytic residue Asp197 resulting in a ~ 8-
12-fold decrease in its inhibitory activity as compared with luteolin, apigenin and 
quercetin and ~45-fold with EGCG. The side chain residue of Asp197 is believed to act as 
nucleophile during the catalytic reaction of α-amylase and its substitution dramatically 
decreased (106-fold) its catalytic activity (Brayer et al., 2000) which explains its lower 
potency as observed in vitro. Thus, H-bond between OH groups of B ring and catalytic 
residues and π-π staking interactions appear to be requirements for an optimal inhibition 
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of human α-amylase by polyphenols acting via a competitive mechanism. Indeed, in a 
previous study, Lo Piparo et al. (2008) observed similar features; polyphenols showing 
IC50 <100 µM were anchored in the active through π-π interactions with Trp59 and formed 
H-bonds with residues Asp197 and Glu233 through OH groups in A and B ring. This 
mechanism is further supported by X-ray structural analyses of the polyphenols myricetin 
and montbretin A with human pancreatic α-amylase (Williams et al. 2012: Williams et 
al., 2015).  
 
Taken together, the combination of in vitro and molecular docking studies has revealed 
that apigenin and apigenin 7-O-glucoside are primarily responsible for the inhibition of 
ChE. This arises from (a) their ability to form H-bonds between the R3′ and R4′-OH 
groups of B ring and the catalytic residues, mainly Asp197, (b) the formation π-π stacking 
interactions with Trp59 and Tyr62 and (c) their stacking at the binding subsides -1 and -2.  
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3.5 Conclusion. 
 
Chamomile provide an interesting mixture of polyphenols and recent scientific evidence 
support its effectiveness against hyperglycaemia and other metabolic abnormalities 
observed in type 2 diabetes. The results of this study shows that ChE as botanical extract 
that combines (Z)-(E)-MCAG, apigenin and apigenin 7-O-glucoside can potentially be 
used to modulate postprandial blood glucose levels by restricting starch degradation in the 
GI tract. To further explore the potential of ChE and polyphenols to blunt sugar 
absorption at the GI site, the inhibition on sugar transport was next assessed (chapter 4).      
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Chapter 4 Chamomile, apigenin and apigenin 7-O-glucoside attenuate 
monosaccharide transport across Caco-2/TC7 cell monolayers: a 
mechanistic study for the identification of the target transporter.  
 
4.1 Abstract. 
 
Persistent high postprandial glycaemia has been associated with the development of 
insulin resistance and type 2 diabetes. A strategy to reduce postprandial sugar levels is to 
partially reduce glucose and fructose transport from the gut lumen to the blood stream. 
This chapter focuses on characterising the effect of ChE and its major individual 
polyphenols on monosaccharide transport using the well characterised differentiated 
Caco-2/TC7 cell model. Apigenin 7-O-glucoside was a very effective inhibitor of D-[U-
14C]-glucose (IC50 = 175 µM) and D-[U-
14C]-sucrose (IC50 = 194 µM) apical to 
basolateral transport while moderate inhibition was observed for D-[U-14C]-fructose (IC20 
at 200 µM). A stronger inhibition was observed under Na+-depleted conditions suggesting 
an interaction mainly with the GLUT2 transporter. Both (Z) and (E)-MCAG did not 
inhibit D-[U-14C]-glucose, D-[U-14C]-sucrose or D-[U-14C]-fructose transport. 
Mechanistic studies using specific inhibitors binding at the exofacial and endofacial site 
of GLUT2 transporter indicate interaction of apigenin and apigenin 7-O-glucoside at the 
exofacial-binding site. Moreover, the effect appears to be solely acute since chronic co-
incubation of chamomile, apigenin and apigenin 7-O-glucoside did not affect the rate of 
D-[U-14C]-glucose across the cell monolayers. These findings highlight the effect of 
chamomile containing apigenin and apigenin 7-O-glucoside on attenuation sugar 
transport and its potential application in dietary and/or complementary strategies to 
manage postprandial hyperglycaemia.  
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4.2 Introduction. 
 
The gastrointestinal tract represents the first site of interaction between energy-dense 
nutrients such as glucose and fructose and the host. The small intestine absorbs ~ 90 % of 
these nutrients (Chan and Leung, 2015) initiating crucial negative feedback systems to 
control whole body energy homeostasis through the action of other metabolic tissues such 
as the liver, adipose tissue and skeletal muscle (discussed in chapter 1). Therefore 
attenuation of postprandial sugar levels at the small intestinal site has been seen as a 
prominent strategy to prevent and manage metabolic dysregulations. In addition to the 
reduction or delay of glucose release from starch by intestinal enzymes, the inhibition of 
transporters responsible for absorption of dietary monosaccharides (figure 4.1) is another 
promising strategy to blunt postprandial hyperglycaemia and the two mechanisms 
together could provide an effective way to manage postprandial sugar levels.  
 
 
Figure 4.1 Schematic representation of glucose and fructose absorption in the small 
intestine. Glucose uptake from the intestinal lumen is mediated through SGLT1expressed in the 
apical membrane of enterocytes which utilises the energy derived from moving Na+ down its 
concentration gradient. The Na+ that enters the cell is then transported out into blood via de portal 
vein by the Na/K-pump in the basolateral domain, so maintaining the driving force for glucose 
transport (Wrigh et al., 2007, Cura and Carruthers, 2012). The resulting accumulation of cytoplas- 
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-mic glucose allows for the facilitative transport of glucose down a concentration gradient across 
the basolateral domain via GLUT2 (Wright et al., 2007). Fructose is taken up from the intestinal 
lumen by the apically-located transporter GLUT5 (Cura and Carruthers, 2012, Burant et al., 
1992). Since GLUT2 also transport fructose, its localisation at the basolateral domain provides the 
exit pathway for fructose into the bloodstream (Cheeseman, 1993). The discovery of apical 
GLUT2 in diabetic rats (Corpe et al., 1996) along with the observation that GLUT2 can 
translocate from the basolateral to the apical domain (Helliwell et al., 2000; Tobin et al., 2008)) 
and that it poses a high transport constant led to hypothesised that GLUT2 provides the main 
route for glucose uptake during the postprandial phase in humans (Kellett et al., 2008). Studies in 
animal models have shown that at postprandial luminal concentrations (>30 mM), GLUT2 is 
translocated to the apical membrane and mediates the uptake of ~75 % of glucose and fructose 
(Gouyon et al., 2003). 
 
 
There are not yet commercially available glucose-lowering agents targeting 
monosaccharide transporters. Some pharmacological compounds are under development 
which have shown promising results in lowering postprandial glucose with overall 
positive effects on metabolic biomarkers. For instance, the compound LX4211 improved 
glycaemic control, lowered triglycerides and produced downward trends in weight over 4 
weeks of once-daily dosing in type 2 diabetic subjects (Zambrowicz et al., 2012). These 
effects were mediated through the inhibition of SGLT1 activity which attenuated the 
postprandial glucose appearance after an oral glucose challenge in both healthy and type 
2 diabetics (Zambrowicz et al., 2013b, Zambrowicz et al., 2013a). Like the compound 
LX4211, some polyphenols interact with intestinal transporters and could potentially 
blunt sugar absorption (discussed in chapter 1, section 1.7.2) suggesting that either as 
food components or their co-administration with foods could help to attenuate high 
postprandial sugar excursions and hormonal responses.  
 
Despite the promising progress achieved on the potential of polyphenols to interact with 
sugar transporters, some gaps still remain to be explored. For example, the information of 
which intestinal glucose transporters are inhibited by different polyphenols, polyphenol-
rich foods and extracts is scarce and uncertain, which polyphenols are the most potent 
inhibitors of glucose transport and their active concentrations, and whether there is 
selectivity for inhibition of transport of different substrates have not been established. 
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Furthermore, most of the studies on the characterisation of polyphenols to blunt sugar 
postprandial rise has focused on studying a single metabolic pathway of the carbohydrate 
digestion and absorption process and so, information of compounds capable of acting at 
different steps of this pathway is lacking.  
 
The generation of this information would serve as the foundation for the rational design 
of human intervention studies to study the effectiveness of polyphenols on sugar 
absorption, and to establish the potential mechanism of action of polyphenol-rich foods 
and extracts that have shown positive effect in relevant biomarkers. For instance apigenin, 
a major polyphenol constituent of chamomile have shown antihyperglycaemic effects in 
type 2 diabetic rats in both baseline and postprandial glucose levels and decreased insulin 
resistance after 6 weeks of treatment (Ren et al., 2016). Therefore, it is possible that the 
antihyperglycaemic effect of chamomile observed in animal models and humans (Kato et 
al., 2008; Weidner et al., 2013; Rafraf et al., 2015; Zemestani et al., 2016) is mediated 
mainly through the presence of apigenin and its derivatives, and such effect can be 
partially elicited by their complementary action on both carbohydrate digestion (described 
in chapter 3) and sugar absorption.  
 
Here, the potential of apigenin and other three major polyphenol constituents of 
chamomile to blunt intestinal glucose absorption in Caco-2/TC7 cells was assessed. 
Transporter specificity was delineated by the use of well-established SGLT1 inhibitor and 
GLUT2 while GLUT5 inhibition and specificity was assessed with the use of fructose. 
The Caco-2/TC7 cell model have been extensively characterised, and have been utilised 
for studies on sugar transport as a model for the small intestine, since the expression and 
membrane location of GLUTs and SGLT1 is well known under a wide variety of 
conditions (Robayo–Torres et al., 2006; Sim et al., 2010). 
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4.3 Materials and methods. 
 
4.3.1 Materials. 
The ChE and authentic standards of apigenin and apigenin 7-O-glucoside were obtained 
from PhytoLab as a lyophilised powder. D-glucose, D-sucrose, D-fructose, cytochalasin B 
from Drechslera dematioidea, 4,6-O-Ethylidene-α-D-glucose and Dulbecco's Modified 
Eagle's Medium, (including 1000 and 4500 mg glucose/L, L-glutamine, NaHCO3 and 
pyridoxine HCl) and Bradford reagent were all purchased from Sigma-Aldrich. Co., Ltd., 
Dorset, UK. D-[U-14C]-Glucose and D-[U-14C]-sucrose were purchased from Perkin 
Elmer (Boston, USA) and D-[U-14C]-fructose was obtained from American Radiolabelled 
Chemicals (St. Louis, MO, USA). Cy3-conjugated donkey anti-rabbit IgG was obtained 
from Jackson Immuno Research (West Grove, USA), fluorescein conjugated wheat germ 
agglutinin (WGA) from Vector laboratories (Burlingame, USA), ProLong Gold anti-fade 
reagent mounting medium from molecular probes (Life Technologies, Paisley, UK) and 
GLUT2 polyclonal antibody from Abcam (ab95256), Cambridge, U.K. GLUT5 
monoclonal antibody was from Santa Cruz Biotechnology. Claudin-1 (2H10D10) 
antibody, SLC2A5 and TATA-box binding protein (TBP) FAMTM-labelled TaqMan 
primers (Hs01086390_m1) were from Fisher Scientific, Leicestershire, UK. RNAqueous-
4PCR (AM1912) and a high capacity RNA-to cDNA master mix kits were obtained from 
Applied Biosystems, Warrington, UK. The Caco-2/TC7 cell line was obtained from Dr 
M. Rousset, U178 INSERM, Villejuif, France. Caco-2 cells (HTB-37) were obtained 
from the American Type Culture Collection (LGC Promochem, Middlesex, UK). 
Distilled water was used for all the experiments (Millipore UK Ltd., Hertfordshire, UK). 
All the reagents were of the highest purity and standards were ≥98 %. 
 
4.3.2 Methods. 
4.3.2.1 Preparation of ChE for bioactivity studies. 
ChE was prepared as previously described in chapter 2 section 2.3.2.1. 
 
4.3.2.2 Cell culture. 
Caco-2 and Caco-2/TC7 cells were cultured in a humidified CO2 incubator (Sanyo, 
MCO-18AIC) in an atmosphere of 10 % CO2–90 % air at 37 °C. Cells were routinely 
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grown in Dulbecco's Modified Eagle's Medium (1000 and 4500 mg/L glucose), 
supplemented with 20 % heat-inactivated fetal calf serum, 2 % L-alanyl-L-glutamine, 200 
mM, 2 % non-essential amino acids and 100 U/mL penicillin-streptomycin. Every other 
day, the growth medium was replaced with fresh medium. When cells reached 80-90 % 
confluence, they were detached from the flask using 0.25% trypsin-EDTA solution and 
propagated in new 75 cm2 cell culture plastic flasks at a ratio of 1.2 x 106 cells/flask. All 
experiments were carried out on cells of passage number from 36 and 50 and 30 to 42 for 
Caco-2 and Caco-2/TC7 respectively. 
 
4.3.2.3 Transport assay of monosaccharides in Caco-2/TC7 cells. 
The effect of ChE and polyphenols to blunt sugar absorption was investigated in Caco-
2/TC7 cells. These cells undergo a process of spontaneous differentiation leading to the 
formation of a cell monolayer expressing several morphological and functional 
characteristics of human enterocyte, and more homogenous expression of differentiation 
traits and stability than the parent cell line Caco-2 (Robayo–Torres et al., 2006). Both 
Caco-2 and Caco-2/TC7 cells are considered as one of the most appropriate in vitro 
models for the investigation of a number of intestinal functions including the uptake and 
transport of nutrients such as sugars, ions, lipids, vitamins, polyphenols and drugs (for a 
comprehensive review see Sambuy et al. (2006)). Multiple studies have shown that Caco-
2 and Caco-2/TC7 differentiated monolayers are fully appropriate for the study of 
glucose, sucrose and fructose absorption (Tobin et al., 2008; Manzano and Williamson, 
2010; Grefner et al., 2012; Zheng et al., 2012) since they express the apically-located 
proteins SGLT1, sucrase-isomaltase and GLUT5 (Robayo–Torres et al., 2006; Hayeshi et 
al., 2008). Importantly, when seeded on porous filters (Transwell), Caco-2/TC7 cells 
permit access to both sides of the bipolar intestinal epithelium. The apical and basolateral 
compartments represent the intestinal lumen or serosal circulation respectively (figure 
4.2), better reproducing the steric conditions of the intestine in vivo. Therefore, the Caco-
2/TC7 cell model has been recognised to be a good alternative to human and animal 
studies to predict in vivo intestinal uptake and transport and to study mechanistic aspects 
of nutrient absorption, such as the case of polyphenols and sugar transporters. 
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Figure 4.2 Schematic representation of Transwell® permeable support. The inserts provide 
independent access to both sides of the cell monolayer which allows study of the transport of 
nutrients and other molecules in vitro. 
 
 
Transport experiments were performed according to the method published by Manzano 
and Williamson (2010) with minor modifications. Briefly, Caco-2/TC7 cells were seeded 
to 12-well plates (Costar, polycarbonate membrane, pore size 0.4 mm, 12 mm diameter) 
at 7 x 104 cells/well and cultured for 21-23 d at 37 °C. After 7 days, cells were changed to 
asymmetric conditions with a serum-free medium in the apical side for the remainder of 
the culturing period. Glucose transport was assessed by replacement of growth medium 
with transport buffer solution (TBS). TBS contained 5.4 mM KCl, 4.2 mM NaHCO3, 137 
mM NaCl, 20 mM HEPES buffer solution and 1.8 mM CaCl2 and pH was adjusted to 7.4. 
After washing cells, 1 mL TBS was added to both apical and basolateral sides and the 
plate was pre-incubated for 30 min at 37 °C under a humidified atmosphere. After 
equilibration, TEER values were recorded to assess the integrity of the monolayer and the 
TBS was carefully aspirated to waste from the apical and basolateral sides. For 
experiments, 0.5 mL TBS containing 5 mM glucose, sucrose or fructose including D-[U-
14C]-glucose 0.15 µCi/mL, D-[U-14C]-sucrose 1.8 µCi/mL, or D-[U-14C]-fructose 1.0 
µCi/mL with or without inhibitor at varying concentrations (adjusted pH 7.4 with HCl or 
NaOH) was added to the apical side (for asymmetric transport, solution was added at the 
basolateral side) and 1 mL TBS to the basolateral compartment. Then, cells were 
incubated for 25 min for glucose and 60 min for sucrose and fructose at 37 °C and 
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transport was stopped by washing each membrane twice with ice-cold PBS. Transport 
values were obtained by adding the apical and basolateral solution to scintillation vials 
containing 5 mL of scintillation liquid. The radioactivity was estimated from an 8-point 
linear calibration curve using scintillation counting (Packard Liquid Scintillation 
Analyser 1600TR). A schematic representation of the method used to assess 
monosaccharide transport is depicted in figure 4.3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Schematic representation of the experimental design for assessing the inhibition 
of D-[U-14C]-monosaccharide transport across differentiated Caco-2/TC7 cell monolayers. 
The assay was conducted with and without inhibitors and the D-[U-14C]-glucose and D-[U-14C]-
fructose transported from apical to basolateral was quantified using a standard of the 
corresponding radiolabelled monosaccharide. 
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4.3.2.4 Differential mRNA and protein expression levels of GLUT5 in CaCo-2 and 
CaCo-2/TC7 cells.  
For GLUT5 mRNA and protein expression analysis, Caco-2 and Caco-2/TC7 cells were 
seeded onto solid supports (6.43 x 104 cells/cm2) and maintained for 23 days before 
harvesting for expression analysis. RNA isolation was performed using an RNAqueous-
4PCR kit and its quality (260/280 ratio) and quantity (280 nm) determined with a 
Nanodrop 1000ND spectrophotometer (Thermo Scientific, Labtech, East Sussex, UK). 1 
µg of RNA was reverse transcribed to cDNA using a High Capacity RNA-to cDNA 
master mix kit. Quantitative gene expression was conducted using a QX100 Droplet 
digital PCR (ddPCR) system (Bio-Rad). In brief, 20 µL of stock sample containing 9 µL 
of transcribed DNA (21.5 ng), 1 µL SLC2A5 FAMTM-labelled TaqMan primer and 10 µL 
of digital droplet PCR Supermix for Probes (Bio-Rad) were introduced in the assay well. 
TBP was used as a reference. Droplets were generated according to the manufacturer’s 
procedure with the QX100 Droplet generator (Bio-Rad) before cycling in a C1000 Touch 
thermal cycler (Bio-Rad) at optimal temperature for every primer for 30 min followed by 
95 °C (10 min), 40 cycles of 94 °C (0.5 min) followed by 60 °C (60 min), and 98 °C (10 
min). The average number of accepted droplets was 14781 ± 981 (see example in figure 
4.4) and the concentration of the target DNA in copies/µL was calculated from the 
fraction of positive reactions using Poisson distribution analysis. The Data was analysed 
with the QuantaSoft software (Kosice, Slovakia). The ddPCR data for each target gene 
are captured independently based on fluorescence signal and copy numbers are reported 
for all (figure 4.4). Thus, the housekeeping gene expression can be monitored but is not 
essential for data evaluation and quantitative determination. Since Caco-2 and Caco/TC7 
cells showed high variation in TBP expression, the quantitative data is presented as copy 
numbers/ng of cDNA and TBP was used solely as a reference for the same group of 
samples to compare performance between ddPCR runs.  
 
For analysis of GLUT5 protein levels, Caco-2 and Caco-/TC7 cells were washed three 
times with ice-cold PBS, scraped from trans well filters and lysed in RIPA buffer 
containing 0.5% protease inhibitor mixture by gently rocking the samples on ice for 30 
min. The lysate was centrifuged at 14,000 g for 10 min, and the total protein 
concentration of the supernatant was determined by BCA microplate assay according to 
the manufacturer’s instructions. GLUT5 protein levels were quantified using the 
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automated capillary ProteinSimple system “Wes” (figure 4.5) according to the protocol of 
the manufacturer with primary antibody incubation time of 30 min. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Representative example of ddPCR data viewed as a 1-D plot with each droplet 
from a sample plotted on the graph of fluorescence intensity vs droplet number. All positive 
droplets, those above the threshold (red line), are scored as positive and each is assigned a value 
of 1. All negative droplets, those below the red threshold line, are scored as negative and each is 
assigned a value of 0. QuantaSoft™ software measures the number of positive and negative 
droplets for each fluorophore in each sample. The software then fits the fraction of positive 
droplets to a Poisson algorithm to determine the starting concentration of the target DNA 
molecule in units of copies/µL. (A) In blue are the positive droplets obtained for a Caco-2 cell 
lysate containing GLUT5. (B) In green are the positives droplets obtained for a Caco-2 cell lysate 
containing TBP.   
 
 
 
 
 
 
A 
B 
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Figure 4.5 Schematic representation of the integration of all steps equivalent to a traditional 
Western blot in the automated capillary ProteinSimple system ‘Wes’. Samples and reagents 
are loaded into an assay plate and placed in the system and proteins are resolved as they migrate 
through a stacking and separation matrix in capillary columns based on size. After separation, the 
proteins are immobilized onto the interior wall by a proprietary photoactivated cross-linkage. 
Thereafter, the matrix is removed by the rinsing step and the capillary lumen is filled with 
primary antibody against the target protein, followed by the incubation of horseradish peroxide 
(HRP)-conjugated secondary antibody. Chemiluminescent signal representing the protein of 
interest is generated by HRP-catalysed reaction as it occurs in traditional Western blot. The 
diagram was adapted from proteinsimple website (https://www.proteinsimple.com). 
 
 
Different concentrations of cell lysates were tested for linearity of GLUT5 and Claudin-1 
antibodies (both antibodies used with a dilution of 1:50) and a standard curve was 
generated for both cell lines (figure 4.6).  
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Figure 4.6 Concentration-dependent detection of multiplexed claudin-1 and GLUT5 in 
whole cell lysate. Panel A and B show the standard curve of multiplex claudin-1 and GLUT5. 
The concentration-dependent detection of Claudin-1 and GLUT5 is shown as electropherograms 
in panel C and D. Panel E and F shows the data as gel-like image. For quantitative analysis, 0.25 
and 0.05 mg/mL were selected as the optimal lysate concentration for for Caco-2 and Caco/2 TC7 
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cells respectively. A, C and E- differentiated Caco-2 cells; B, D and F-differentiated Caco-2/TC7 
cells. NSI: non- specific interaction. Three biological replicates in two seeding experiments were 
pooled and analysed four times. Data is expressed as mean ± SEM. When not visible, the error 
bars are smaller than the data point. 
 
 
Optimal loading concentration was 0.1 and 0.05 mg/mL for Caco-2 and Caco-2/TC7 
cells, respectively (figure 4.6A and B). For assigning the molecular weight of target 
proteins, assay samples contained molecular weight fluorescence-labelled standards 
which were loaded and run in individual capillaries. Quantification of peak areas and gel-
like image transformations were carried out using ProteinSimple Compass software. 
Given the large difference in protein expression of Claudin 1 between the two cell lines 
(13-fold), for quantitation, the peak areas of GLUT5 in CaCo-2 and CaCo-2/ TC7 cells 
are presented without normalisation to Claudin 1, but normalised to total protein. 
 
4.3.2.5 Characterisation of the main glucose transporter in Caco-2/TC7 cells and 
its inhibition by ChE, apigenin and apigenin 7-O-glucoside. 
D-[U-14C]-glucose transport experiments were conducted as previously described in 
section 4.3.2.2. The assays were conducted under Na+ and Na+-free conditions to 
ascertain the involvement of SGLT1 and GLUT2 on glucose transport respectively. To 
validate the model, phloridzin and phloretin, well known inhibitors of SGLT1 and 
GLUT2 respectively, were used to determine the specific contribution of each transporter 
to the total glucose transport across Caco-2/TC7 cell monolayers.  
 
4.3.2.6 Detection of GLUT2 in Caco-2/TC7 cells by immunofluorescence staining. 
Caco-2/TC7 cells were seeded on 12 well Millicell cell culture inserts (PET 0.4 mm pore 
size, Millipore) at 7 x 104 cells/well and cultured for 21-23 d at 37 °C. For staining, cells 
were fixed with 4% para-formaldehyde in PBS and incubated with wheat germ agglutinin 
(WGA, 1 mg/mL) for 10 min at 37 °C. Following permeabilisation with 0.1% Triton-
X100 for 20 min at room temperature, cells were incubated without (control) and with 
GLUT2 antibody at a dilution of 1:50 for 1 h. After washing with PBS, cells were further 
incubated with Cy3-conjugated donkey anti-rabbit IgG at a 1:300 dilution. Cell layers 
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were stained with 0.002 mg/mL 4,6-diamidino-2-phenylindole (DAPI) and mounted on 
microscopy slides with ProLong Gold antifade reagent mounting medium and imaged 
using a Zeiss LSM700 confocal microscope. 
 
4.3.2.7 In vitro conversion of apigenin 7-O-glucoside to apigenin by Caco-2/TC7 
cells. 
Cells were seeded on 6-well plates (Costar, 22.1 mm diameter) at 2.4 x 105 cells/well and 
cultured for 21-23 d at 37 °C under the conditions previously described. Cells were 
exposed to 150 μM apigenin 7-O-glucosid for 25 and 60 min. After the treatment, media 
was collected and subjected to HPLC analysis as described in chapter 2, section 2.3.2.2. 
 
4.3.3 Statistical analysis. 
Statistical analysis was performed by one-way analysis of variance using the Number 
Cruncher Statistical System version 6.0 software (NCSS, LLC). Significant differences 
were assessed with Tukey-Kramer multiple comparison test (p<0.05). Independent 
samples t test was used to compare means of the contribution of apigenin 7-O-glucoside 
and apigenin to the total inhibition of sugar transport and between incremental 
concentration of inhibitors. Data are expressed as the mean ± SEM.  
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4.4 Results and discussion. 
 
4.4.1 Inhibitory effect of ChE and polyphenols on glucose, sucrose and 
fructose transport. 
 
Excess dietary sugars such as glucose and fructose are responsible for altering whole 
system energy balance contributing to a coordinate breakdown of cellular functions.  In 
order to be absorbed, glucose and fructose must be transported from the intestinal lumen 
into the blood, and so the small intestine has been suggested as a prime target for 
preventive and therapeutic actions against metabolic diseases by attenuating the activity 
of sugar transporters (Williamson, 2013; Stringer et al., 2015).  
In the presence of Na+ where the three sugar transporters SGLT1 and facilitated 
transporters GLUT2 and GLUT5 are active, Caco-2/TC7 cells transported 0.08 mmol of 
D-[U-14C]-glucose from the apical to basolateral compartment across the cell monolayers 
(figure 4.7A).  
 
Figure 4.7 Monosaccharide transport under Na+ conditions across differentiated Caco-
2/TC7 cells monolayers. (A) Transport D-[U-14C]-glucose and D-[U-14C]-sucrose in the absence 
of inhibitors. (B) Dose-dependent inhibition of D-[U-14C]-glucose and D-[U-14C]-sucrose transport  
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by ChE. (C) Inhibition of D-[U-14C]-fructose by ChE at a single concentration (1 mg/mL). For D-
[U-14C]-glucose and D-[U-14C]-sucrose transport the IC50 values were calculated as 0.24 ± 0.02 
and 0.91 ± 0.06 mg/mL respectively. For D-[U-14C]-fructose the maximum inhibition at the 
concentration tested was 28 %. Each data point represents the mean ± SEM of at three 
independent experiments with six technical replicates each (n = 3). In figure (B), the reduction of 
D-[U-14C]-sugar transport is expressed as % compared to the transported sugars in control 
incubations (no inhibitor normalised to 100 %). When not visible, the error bars are smaller than 
the data point. In figure (B) statistical difference is indicated vs incremental concentration of ChE. 
*p<0.05, **p<0.01.  
 
D-[U-14C]-sucrose has to be hydrolysed by brush border sucrase and the resulting 
products, fructose and glucose, are transported across the cells. After incubation with D-
[U-14C]-sucrose, Caco-2/TC7 cells transported 0.035 mmol from the apical to the 
basolateral compartment (figure 4.7A).  
 
The addition of ChE to Caco-2/TC7 cells led to a dose-dependent inhibition of D-[U-14C]-
glucose transport and labelled-derived sugars from D-[U-14C]-sucrose, with maximum 
inhibitions of ~ 78 and 55 % respectively at the highest concentration tested (1 mg/mL). 
The IC50 value of ChE for D-[U-
14C]-glucose transport was ~0.24 mg/mL while the 
inhibition when D-[U-14C]-sucrose was added was ~3.8-fold lower with an IC50 value of 
0.91 mg/mL (figure 4.7B). On the other hand, although D-[U-14C]-fructose was also 
transported in the apical to basolateral direction, the addition of 1 mg/mL of ChE did not 
reach 50 % of the inhibition (figure 4.7C); the addition of ChE had a lower but significant 
inhibitory effect (~28 %, p<0.05). 
 
A previous study has been conducted in an attempt to identify plant extracts with the 
potential to attenuate monosaccharide uptake and transport in the intestinal cell line Caco-
2 (Aydin, 2015). While the IC50 values obtained for the inhibition D-[U-
14C]-glucose 
(IC50= 0.32 ± 0.05) and D-[U-
14C]-sucrose (IC50= 0.32 ± 0.05) transport were similar to 
those obtained in the clone cell line Caco-2/TC7, a different trend was observed for the 
inhibition of D-[U-14C]-fructose transport. Contrary to the experimental results obtained 
in this work, the addition of ChE inhibited the transport of D-[U-14C]-fructose (1 mM) 
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from apical to basolateral compartment in a competitive manner in Caco-2 cells (figure 
4.8).  
 
Figure 4.8 Inhibition of D-[U-14C]-fructose transport by ChE across differentiated Caco-2 
cell monolayers.(A) Inhibition of D-[U-14C]-fructose transport by the addition of 1 mg/mL of 
ChE at different concentrations of apical fructose. (B) Lineweaver-Burk plot for transport of D-
[U-14C]-fructose with and without ChE at 1 mg/mL; the intercept suggests competitive inhibition. 
The graph was adapted from Villa-Rodriguez et al. (2017). 
 
 
The discrepancies in the inhibition values are likely due to differences between the 
protein expression levels of GLUT5 among the intestinal cell lines, since the 
morphological and functional phenotype tend to vary among cell lines from different 
passages and different clones (Sambuy et al., 2005). Therefore, differences in the mRNA 
and protein expression levels of fructose transporter GLUT5 were investigated in 
Caco2/TC7 cells and in the parental cell line Caco-2 to clarify the differences in the 
inhibition obtained (figure 4.9). In accordance with the D-[U-14C]-fructose transport 
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observation, GLUT5 mRNA expression levels were ~2.5-fold higher (p<0.01) in the 
Caco-2 TC7 clone (figure 4.9A), which is translated into a ~2.0-fold increase (p<0.01) in 
GLUT5 protein levels in the apical membrane (figure 4.9B).  
 
Figure 4.9 Differential mRNA and protein expression levels of GLUT5 in differentiated 
Caco-2 and Caco-2/TC7 cell monolayers. (A) Exact copy numbers of GLUT5 are shown per ng 
of cDNA since changes were also observed for TBP copy numbers (insert figure) when 
multiplexed with each cell line. (B) GLUT5 protein levels as quantified by automated capillary 
Western, with optimal protein lysate concentrations based on standard curves of multiplexed 
GLUT5 and Claudin-1 for both cell lines. (C) Data is shown as electropherograms. (D) Data is 
shown as gel-like image at equal concentration of cell lysate (0.1 mg/mL). Three biological 
replicates in two seeding experiments were pooled and analysed six times. Data is expressed as 
mean ± SEM. *p<0.05, **p<0.01. 
 
 
These data indicate that the differences in the inhibition constants obtained between the 
two cell lines regarding D-[U-14C]-fructose transport from the apical to the basolateral 
compartment is due to a higher transport capacity due to a higher expression of GLUT5 
transporter protein. The apical protein expression levels of GLUT5 in the Caco-2 cell line 
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has been shown to be similar to that noted in an adult small intestine (Mahraoui et al., 
1992), thus the inhibition value obtained for fructose in the Caco-2 cell line is 
underestimated.    
 
In order to elucidate whether the four major polyphenols in ChE were responsible and /or 
participate in the inhibition of monosaccharide transport, they were tested for their 
potential to attenuate D-[U-14C]-monosaccharide flux across Caco-2/TC7 cell monolayers. 
Among individual polyphenols tested, apigenin 7-O-glucoside was a very effective 
inhibitor of D-[U-14C]-glucose and D-[U-14C]-sucrose transport, and IC50 values were 
obtained. Apigenin 7-O-glucoside dose-dependently inhibited (0-200 µM) D-[U-14C]-
glucose transport with a maximum inhibition of ~60 % and IC50 of ~173 µM. The same 
range of concentrations were effective to attenuate D-[U-14C]-sucrose transport and the 
IC50 was obtained around the highest concentration tested (IC50= 197 uM) (figure 4.10A).  
 
Figure 4.10 Inhibition of monosaccharide transport under Na+ conditions across 
differentiated Caco-2/TC7 cell monolayers by individual polyphenols. (A) Concentration-
dependent inhibition of D-[U-14C]-glucose and D-[U-14C]-sucrose by apigenin 7-O-glucoside 
(A7G). (B) Inhibition of D-[U-14C]-glucose and D-[U-14C]-sucrose by apigenin at a single 
concentration (50 µM). (C) Inhibition of D-[U-14C]-fructose by A7G and apigenin at a single con- 
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-centration; A7G (200 µM), apigenin (50 µM). Results are expressed as % compared to the 
transported sugars in control incubations (no inhibitor: normalised to 100%). Each data point 
represents the mean ± SEM of three independent experiments with six technical replicates (n = 3). 
In figure (A), statistical significance is indicated between incremental concentrations of A7G. 
*p<0.05.  
 
 
Apigenin was also an effective inhibitor of D-[U-14C]-glucose and D-[U-14C]-sucrose 
transport, although IC50 values could not be obtained at the highest soluble concentration 
tested (50 µM). However it can be deduced that it is a more potent inhibitor based on the 
substantial ~3-fold higher-effect when compared with apigenin 7-O-glucoside at the same 
concentration (figure 4.10B). On the other hand, as expected, apigenin and its precursor 
apigenin 7-O-glucoside weakly inhibited the transport of D-[U-14C]-fructose across the 
cell monolayers with maximum inhibitions of ~21 and 13 % at the maximum soluble 
concentrations tested (figure 4.10C). (Z) and (E)-MCAG did not inhibit D-[U-14C]-
glucose, D-[U-14C]-sucrose nor D-[U-14C]-fructose transport.  
 
To test whether apigenin and apigenin 7-O-glucoside were solely responsible for the 
inhibition of monosaccharide transport observed by the ChE, they were combined at the 
concentrations equivalent to those present in the extract and transport experiments were 
carried out. As depicted in figure 4.11, apigenin and apigenin 7-O-glucoside were 
responsible for ~62 %, 80 and 89 of the total D-[U-14C]-glucose, D-[U-14C]-sucrose and 
D-[U-14C]-fructose transport inhibition respectively. 
 
The results on monosaccharide transport clearly show that ChE has the potential to 
attenuate the amount of glucose and, to a lesser extent, the amount of fructose that can be 
transported across the enterocytes, which is mainly driven by the presence of apigenin 
and apigenin 7-O-glucoside. This activity represents an advantage over acarbose which 
acts primarily (and perhaps solely) by inhibiting starch and disaccharide digestion (shown 
in chapter 2), thus decreasing and delaying the subsequent amount of free 
monosaccharides available for absorption. However, a previous study has indicated a 
direct effect of acarbose on free glucose absorption in the jejunal epithelium of rats (Hirsh 
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et al., 1997). Therefore acarbose was next assessed for its potential to attenuate D-[U-
14C]-glucose, D-[U-14C]-sucrose and D-[U-14C]-fructose transport across Caco-2/TC7 cell 
 
 
Figure 4.11 Inhibition of monosaccharide transport by ChE and combined inhibition of 
apigenin and apigenin 7-O-glucoside (A7G). D-[U-14C]-sugar transport assay was conducted 
under Na+ conditions. Apigenin, 12 µM; A7G 148 µM. Results are expressed as % compared to 
the transported sugars in control incubations (no inhibitor; normalised to 100 %). Each data point 
represents the mean ± SEM of three independent experiments with six technical replicates 
(n = 3).*p<0.05; **p<0.01. 
 
 
monolayers at varying concentrations ranging from 0-500 µM. Acarbose inhibited D-[U-
14C]-sucrose transport effectively in a dose-dependent manner with an IC50 value of ~7 
µM (figure 4.12), but did not inhibit glucose nor fructose transport across cells 
monolayers even at a concentration of 500 µM. These results show that the enzyme 
sucrase, located at the apical membrane of Caco-2/TC7 cells, is sensitive to acarbose but 
neither SGLT1, GLUT2 nor GLUT5 are, since D-[U-14C]-glucose and D-[U-14C]-fructose 
transport was unaffected by its presence. The lack of effect of acarbose on GLUT2 and 
GLUT5 has been further confirmed in Xenopus Oocytes expressing the transporter 
proteins where acarbose did not attenuate the uptake of D-[U-14C]-glucose or D-[U-14C]-
fructose up to a concentration of 5 mM (Villa-Rodriguez et al. 2017). Moreover, these 
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data suggest that the inhibition observed for D-[U-14C]-sucrose is due to the interaction of 
ChE constituents, apigenin and apigenin 7-O-glucoside, with the glucose transporter 
SGLT1 and/or GLUT2 since they showed a modest effect at impairing α-glucosidase 
activity (discussed in chapter 3, section 3.4.5).  
 
Figure 4.12 Concentration-dependent inhibition of D-[U-14C]-sucrose transport by the 
antidiabetic drug acarbose across differentiated Caco-2/TC7 cell monolayers. Insert shows 
the chemical structure of acarbose and the calculated IC50 value. Each data point represents the 
mean ± SEM of three independent experiments with six technical replicates (n = 3). Results are 
expressed as % compared to the transported sucrose in control incubations (no inhibitor; 
normalised to 100 %). When not visible, the error bars are smaller than the data point. Statistical 
difference is indicated vs incremental concentration of acarbose. *p<0.05, **p<0.01. 
 
4.4.2 Identification of the main glucose transporter protein in Caco-2/TC7 
cells and the effect of ChE, apigenin and apigenin 7-O-glucoside on its 
activity.    
At low concentrations, the uptake of glucose and fructose is via SGLT1 and the facilitated 
transporter GLUT5, respectively. However, after a high sugar meal, their concentration 
may be elevated to 50-300 mM, and consequently it has been suggested that the 
facilitated transporter GLUT2 is translocated to the apical membrane, and then accounts 
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for ~75 % of glucose and ~60 % of fructose total uptake (Gouyon et al., 2003; Kellett et 
al., 2008). To delineate whether the inhibition observed by ChE, apigenin and apigenin 7-
O-glucoside on D-[U-14C]-glucose transport was predominantly through their interaction 
with SGLT1 or GLUT2, transport assays were carried out under Na+ (where both 
transporters are active) and Na+-free conditions (only GLUT2 is active).  
 
Caco-2/TC7 cells transported 0.075 mmol of D-[14C]-glucose when Na+ was present. 
Removing Na+ from the TBS reduced the transport of D-[14C]-glucose to 0.049 mmol 
(figure 4.13A), implying that SGLT1 was responsible for ~35 % of the total D-[U-14C]-
glucose transported across the monolayer. This was corroborated by two observations; 
phloridzin (a well-known specific inhibitor of SGLT1 transporter) showed no inhibition 
of D-[U-14C]-glucose transport under Na+-free conditions (Figure 4.13A) and D-[U-14C]-
glucose transport was dose-dependently affected by phloretin (Figure 4.13B). Both 
findings also attest to the role of GLUT2 as the main glucose transporter in Caco-2/TC7 
cells.  
 
Figure 4.13 Characterisation of the main D-[U-14C]-glucose transporter in Caco-2/TC7 cell 
monolayers. (A) D-[U-14C]-glucose transport with and without Na+ and Na+-free with co-incuba-  
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-tion of 200 µM phlorizin. (B) Dose-dependent inhibition of D-[U-14C]-glucose by phlorizin and 
phloretin with TBS containing Na+. (C) Chemical structures of phlorizin and phloretin and their 
respective inhibition constants. Each data point represents the mean ± SEM of three independent 
experiments with six technical replicates. When not visible, the error bars are smaller than the 
data point. In figure (B) statistical difference are indicated between phloridzin and phloretin. 
*p<0.05, **p<0.05.  
 
 
The inhibition of D-[U-14C]-glucose transport by ChE, apigenin and apigenin 7-O-
glucoside under Na+ conditions suggest that they interact mainly with GLUT2 transporter 
protein since these values were all above the maximum D-[U-14C]-glucose transported 
through SGLT1. Indeed, when D-[U-14C]-glucose transport was assessed under Na+-free 
conditions and ChE, apigenin or apigenin 7-O-glucoside were added as inhibitors, an 
increase in the inhibitory activity (~50 %) was observed as evidenced by the decrease in 
their inhibition constants when compared in the presence of Na+ (figure 4.14). 
 
 
Figure 4.14 Inhibition D-[U-14C]-glucose transport across differentiated Caco-2/TC7 cell 
monolayers under Na+-free conditions. (A) Concentration-dependence inhibition of ChE, IC50 = 
0.138 ± 0.018 mg/mL. (B) Concentration-dependence inhibition of apigenin and apigenin 7-O-glu  
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-coside (A7G) respectively. (C) Chemical structures of apigenin and A7G and their respective 
inhibition constants. (D) Combined inhibition of apigenin and A7G; apigenin, 12 µM; A7G, 148 
µM. Each data point represents the mean ± SEM of three independent experiments with six 
technical replicates (n = 3). Results are expressed as % compared to the transported sugars in 
control incubations (no inhibitor; normalised to 100 %). When not visible, the error bars are 
smaller than the data point. In figure (A) and (B) statistical difference is indicated vs incremental 
concentration of each inhibitor. *p<0.05, **p<0.05.  
 
 
The IC50 values for ChE, apigenin and apigenin 7-O-glucoside under Na
+-free conditions 
were 0.13 mg/mL, 29 and 100 µM respectively. Moreover, when tested in combination, 
apigenin and apigenin 7-O-glucoside were responsible for ~80 % of the inhibitory activity 
(figure 4.14D). This indicates that there are other compound(s) present in the ChE which 
are responsible for the remaining inhibitory activity and are active on both SGLT1 and 
GLUT2 transporters. Nonetheless, overall apigenin and apigenin 7-O-glucoside are the 
main active compounds since they are the main contributors under Na+ and Na+-free 
conditions.  
 
Next, it was evaluated whether Caco-2/TC7 cells have the capability to convert apigenin-
7-O-glucoside to apigenin. Glycosylated polyphenols can be hydrolysed by exogenous 
(luminal) β-glucosidase enzymes, such as lactase phlorizin hydrolase, present in the brush 
border of the enterocytes, and the aglycone released. Therefore, there was a possibility 
that the inhibition observed by apigenin-7-O-glucoside was due to the presence of 
apigenin after enzymic release. For these studies, Caco-2/TC7 cells were incubated with 
150 µM apigenin 7-O-glucoside for 25 and 60 min as in the inhibition assays. Figure 4.15 
shows that the in vitro conversion of apigenin 7-O-glucoside to apigenin is negligible at 
both incubation times confirming that both polyphenols interact with GLUT2 transporter 
protein. This is of primary importance since the release of apigenin from apigenin 7-O-
glucoside in the small intestine is expected in humans which may increase the efficacy.  
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Figure 4.15 In vitro conversion of apigenin 7-O-glucoside to apigenin by Caco-2/TC7 cells. 
(A) Apigenin 7-O-glucoside standard (150 µM). (B) Incubation of apigenin 7-O-glucoside (150 
µM) with Caco-2/TC7 cells/TC7 cells for 25 min. (C) Incubation of apigenin 7-O-glucoside (150 
µM) with Caco-2/TC7 cells/TC7 cells for 60 min. The detection of apigenin at both incubation 
times is indicated with the arrow. 
 
 
Studies were conducted to explore the binding affinities of apigenin and apigenin 7-O-
glucoside to GLUT2 in order to get a better insight on their interaction. Immunostaining 
of GLUT2 showed that the protein was present on both apical and basolateral sides of 
differentiated Caco-2/TC7 cell monolayers (figure 4.16). This was also confirmed by 
functional assays where the rate of D-[U-14C]-glucose transport under Na+-free conditions 
was the same from apical to basolateral compartments and vice versa (figure 4.17A). 
Having confirmed the localisation of GLUT2, inhibition constants for the exofacial 
glucose transporter inhibitor 4,6-O-ethylidene glucose and the endofacial glucose 
transporter inhibitor cytochalasin B on asymmetric D-[U-14C]-glucose transport were 
compared to those for apigenin and apigenin 7-O-glucoside (figure 4.17B,C and D). The 
results suggest that the two polyphenols apigenin and apigenin 7-O-glucoside bind at the 
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exofacial cavity of the transport channel since a 4-fold lower maximum inhibition was 
observed when the D-[U-14C]-glucose transport was assessed from basolateral to apical 
side which was also hold for the exofacial inhibitor 4,6-O-ethylidene glucose.  
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Figure 4.16. Immunofluorescence detection of GLUT2 
in differentiated Caco-2/TC7 cell monolayers. Row 1 
shows control cell layer incubated with 4’,6-diamidino-2-
phenylindole (DAPI) and Cy3-conjugated donkey anti-
rabbit secondary antibody only. In rows 2-4 cells were 
incubated with DAPI, membrane marker wheat germ 
agglutinin (WGA), GLUT2 primary antibody and Cy3-
conjugated donkey anti-rabbit secondary antibody. 
GLUT2 is shown in red, appearing orange when co-
localising with DAPI and WGA shown in blue and green 
respectively. Staining revealed the presence of GLUT2 in 
the lateral and basal plasma membrane. Scale bars (10 
µm) are shown in the lower left corner of DAPI images. 
Scale bar applies to all the images corresponding to each 
row. Images are representative examples of 3 
independent immunostaining experiments (n=3).   
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Figure 4.17 Characterisation of the potential binding site of apigenin and apigenin 7-O-
glucoside (A7G) on GLUT2. Transport experiments were conducted under Na+-free conditions. 
(A) Asymmetric D-[U-14C]-glucose transport without inhibitor. (B) Asymmetric D-[U-14C]-
glucose transport in the presence of cytochalasin B and inhibition constants. (C) Asymmetric D-
[U-14C]-glucose transport in the presence of 4,6-ethylidene glucose and inhibition constants. (D) 
Inhibition of asymmetric D-[U-14C]-glucose transport by apigenin and A7G. Dotted line 
represents the inhibition values obtained at the maximum concentration tested when D-[U-14C]-
glucose transport was assessed from apical (a) to basolateral (b) (data replotted from Fig 6C-2). 
Each data point represents the mean ± SEM (n = 3). In panel (B-C) results are expressed as % 
compared to the transported glucose in control incubations (no inhibitor; normalised to 100 %). 
When not visible, the error bars are smaller than the data point. In panel (B) and (C) statistical 
difference is indicated against incremental concentration of cytochalasin B and 4,6-ethylidene 
glucose respectively. *p<0.05, **p<0.05.  
 
 
Intestinal cells have the ability to adapt functionally to environmental stimuli such as diet 
(Drozdowski and Thomson, 2006). Therefore, ChE and apigenin was administered to 
Caco-2/TC7 cells for 96 h in order to assess whether the chronic treatment would affect 
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the D-[U-14C]-glucose transport by altering the intestinal expression of glucose 
transporters. Figure 4.18 shows that D-[U-14C]-glucose transport was unaffected implying 
that ChE and apigenin can potentially have an antihyperglycaemic effect exclusively by 
attenuating the activity of sugar transporters through physical interaction (acute effect). 
This means that an effect on postprandial glycaemia would only be possible when 
consumed at the same time as the carbohydrate or sugar source. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18 Effects of ChE and apigenin on D-[U-14C]-glucose transport across differentiated 
Caco-2/TC7 cell monolayers.Caco-2/TC7 cells were incubated with media (5 mM glucose) 
without (control) and with ChE (1 mg/mL) and apigenin (50 µM) for 96 h (every 24 h, the media 
was replaced with fresh one). After the incubation period ended, media was discarded D-[U-14C]-
glucose transport was assessed as described in section 4.3.2.2. Each data point represents the 
mean ± SEM of three independent experiments with six technical replicates. No significant 
differences were found between control incubations and treatments. 
 
 
The inhibition constants observed for apigenin and apigenin 7-O-glucoside on D-[U-14C]-
glucose and D-[U-14C]-sucrose transport are realistic as intestinal intraluminal 
concentrations of polyphenols where they can be present in the mM range (Williamson, 
2013). For instance, if 3 g of chamomile flowers are typically added to ~100 ml boiling 
water, then the concentration of extracted matter in the drink would be about 3 mg/mL 
assuming at least 10 % extraction. This would yield a content of apigenin and apigenin 7-
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O-glucoside 60 and 20-fold higher than the necessary for 50% inhibition respectively. In 
the case of designed supplements and functional foods, the concentrations can be 
significantly higher depending on the type and the dose consumed. Thus, the individual 
intake of apigenin and apigenin 7-O-glucoside or their mixture as a botanical preparation 
(i.e. chamomile) could possibly inhibit, up to some extent, the glucose and fructose influx 
into the enterocyte and circulation, and could partially contribute to the positive effects 
recently observed by chamomile in type 2 diabetics subjects (Rafraf et al., 2015; 
Zemestani et al., 2016) and experimental diabetes (Cemek et al., 2008; Weidner et al., 
2013).  
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4.5 Conclusion. 
 
The findings of this work provide some mechanistic insights about the potential 
antidiabetic effects of chamomile, apigenin and apigenin 7-O-glucoside acting at the 
small intestinal site. Such a mechanism is mediated by acting at the different steps of 
carbohydrate digestion (described in chapter 3) and absorption. It is show here that the 
drug acarbose do not affect glucose and fructose transport, and so would be ineffective 
against fructose and glucose absorption from, for example, high fructose corn syrups 
composed of free glucose and fructose and widely used as sweetener in fruit juices and 
beverages. Therefore botanical preparations such as chamomile and/or individual 
polyphenols such as apigenin and apigenin 7-O-glucoside can be exploited to develop 
food-based nutritional approaches which will diversified solutions spanning from 
preventive and complementary approaches for managing hyperglycaemia.   
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Chapter 5 Glucose stimulates cholesterol uptake in Caco-2 cells via 
upregulation of NPC1L1 protein receptor and this response is 
attenuated by the acute inhibition of glucose absorption by 
Chamomile and apigenin 7-O-glucoside.  
 
5.1 Abstract. 
 
Cholesterol uptake and chylomicron synthesis, which contribute to dyslipidaemia and 
cardiovascular risk factors, have been shown to be upregulated by high glucose levels in 
both healthy and diabetic individuals during the postprandial phase. The goal of this study 
was to determine the role of reducing glucose availability with polyphenols on Niemann-
Pick C1 Like 1 protein expression and cholesterol uptake in simulated postprandial 
conditions using the intestinal cell model Caco-2. Cells incubated with glucose 
concentrations >5 mM showed an increase in [4-14C-]-cholesterol uptake, however no 
significant differences were observed in concentrations ranging from 10-25 mM. Time-
dependent studies indicated that this response is acute since the raise of [4-14C-]-
cholesterol uptake was observed at least 3 h post-incubation. The glucose-mediated 
increased uptake was parallel to an upregulation of Niemann-Pick C1 Like 1 protein 
receptor and this response was attenuated by the use of GLUT2 inhibitors ChE and 
apigenin 7-O-glucoside in a dose-dependent manner. Caco-2 cells did not express the 
efflux cholesterol transporter proteins ABCG5/G8 indicating that the attenuation of [4-
14C-]-cholesterol uptake relied solely on Niemann-Pick C1 Like 1. These data indicate 
that attenuation of intestinal glucose uptake with polyphenols may have pleiotropic 
effects on chylomicron-rich cholesterol synthesis with potential positive effects on 
postprandial lipemia in health and disease states.              
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5.2 Introduction. 
 
Cholesterol is an indispensable component in the body as it forms part of most biological 
membranes. It plays a fundamental role in several physiological functions such as 
embryonic development, cell differentiation, nerve conduction and membrane fluidity; it 
also serves as precursor for the synthesis of steroid hormones and bile acids (Ge et al., 
2008; Yu et al., 2014). However, high circulating levels of cholesterol cause severe 
problems including cardiovascular disease (Grundy et al., 2004) and may be involved in 
liver (deOgburn et al., 2012) and adipose tissue dysfunction (Aguilar and Fernandez, 
2014). Blood cholesterol levels are regulated by several processes, including de novo 
synthesis from acetyl-CoA, cholesterol uptake from the intestinal lumen, and biliary 
clearance and excretion (figure 5.1). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Cholesterol metabolism in the human body. After solubilisation in the mixed-
micelles, dietary and biliary cholesterol is transported across the unstirred layer towards the 
brush-border membrane to facilitate its uptake by the apically-located receptor NPC1L1 (Wang, 
2007). Both luminal free cholesterol and that produced by de novo synthesis (HMG-CoA-
mediated) can either be exported back to the lumen via ABCG5/8 transporter proteins or move to 
the endoplasmic reticulum where it undergoes esterification by ACAT2. Cholesteryl esters are 
incorporated into ApoB-48 and exported to the lymph forming part of chylomicron particles 
(Dash et al., 2015). Once in circulation, the chylomicron-triglyceride component is hydrolysed by 
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LPL expressed on the surface of adipocytes, myocytes, and macrophages, producing cholesterol 
remnants. The triglyceride component is used for energy production, stored in the liver or 
adipocytes via lipogenesis or exported back into circulation as a VLDL component (Bays et al., 
2016). Cholesterol remnants are conjugated with ApoE and cleared by the liver via the ApoE 
receptor (Tomkin and Owens, 2011). In the liver, cholesteryl esters are either exported back to the 
lumen through the enterohepatic circulation of bile acids or excreted as VLDL with Apo-B100 as 
the solubilising protein. As chylomicrons, VLDL are hydrolysed by LPL giving rise to LDL 
which are taken back into the liver by LDLr, representing another source of cholesteryl esters and 
cholesterol for further processing (Tomkin and Owens, 2011; Bays et al., 2016). NPC1L1: 
Niemann-Pick C1 Like 1 protein receptor; HMG-CoA: 3-hydroxy-3-methylglutaryl-CoA; 
ACAT2: acetyl-CoA:cholesterol acyltransferase isoform 2; MTP: microsomal transfer protein; 
LPL: lipoprotein lipase; FAO: fatty acid oxidation; LDLr: low density lipoprotein receptor; 
ApoEr: ApoE receptor. 
 
 
The use of statin, a drug reducing the de novo synthesis of cholesterol by inhibiting the 
activity of 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA), has been widely 
prescribed to reduce the levels of low density lipoprotein cholesterol (LDL-C) in subjects 
at risk of atherosclerosis or coronary heart disease (Kastelein, 2014; Nordestgaard and 
Varbo, 2014). However, in a substantial number of cases, statin therapy does not lower 
LDL-C levels to the desired goal and residual risk factors such as high levels of remnant 
cholesterol remain (Nordestgaard and Varbo, 2014; Kones and Rumana, 2015). It is well 
established that there is a positive and significant correlation between circulating levels of 
LDL-C and dietary and biliary cholesterol absorption (Wang, 2007), pointing out the 
importance of this metabolic pathway to manage whole body cholesterol homeostasis, 
independently of de novo synthesis.  
 
NPC1L1transmembrane protein receptor located on apical enterocytes has been identified 
as a critical player to take up readily available cholesterol the from gut lumen across 
species (Altmann et al., 2004; Davis and Veltri, 2007; Jia et al., 2011). NPC1L1-deficient 
mice demonstrated a drastic reduction of dietary cholesterol absorption (~70 %) (Altmann 
et al., 2004). Like other transmembrane protein transporters, NPC1L1 activity is 
influenced by surrounding nutrients and cell-intrinsic nutrient sensors. For instance, in 
vitro studies have shown that NPC1L1 is translocated from the endocytic recycling 
- 138 - 
 
compartment to the apical membrane after cholesterol depletion (Yu et al., 2006; Brown 
et al., 2007); this response is thought to be controlled by the sterol response element 
binding protein 2 (SREBP2) (Alrefai et al., 2007) which senses cholesterol levels and 
activates appropriated intracellular responses to maintain homeostasis (Horton et al., 
2002). 
 
Like cholesterol, glucose also controls the expression of NPC1L1 gene and protein levels. 
In Caco-2 cells, chronic treatment with high glucose (25 mM, 24 h) upregulated the apical 
localisation of NPC1L1 resulting in an increased cholesterol uptake (~30-50 %) compared 
to cells incubated under physiological fasting glucose levels (Ravid et al., 2008). In a 
subsequent study using the same in vitro model, it was shown that glucose directly 
modulates NPC1L1 expression via transcriptional mechanisms and this effect was 
dependent of glucose metabolism (Malhotra et al., 2013). These studies were inspired by 
the recognised feature of dyslipidaemia in diabetics where NPC1L1 expression, 
concomitant with chylomicron production, is increased (Lally et al., 2006; Adeli and 
Lewis, 2008), and this has been proposed as an important risk factor for cardiovascular 
disease in this population (Tomkin, 2010; Tomkin and Owens, 2015; King and Grant, 
2016). Interestingly, in vivo evidence suggest that increased chylomicron production can 
occur in healthy individuals during the postprandial phase in response to glucose and 
insulin levels (Harbis et al., 2001; Xiao et al., 2013; Xiao et al., 2016). This could 
contribute to the metabolic dysregulation observed during this period such as endothelial 
dysfunction and low grade inflammation with important long-term metabolic 
consequences on insulin resistance and type 2 diabetes onset.  
 
Several lines of evidence including epidemiological studies, human intervention studies 
as well as mechanistic studies in animal and in vitro models have highlighted the potential 
of polyphenols to confer cardiprotection (Hertog et al., 1997; McCullough et al., 2012; 
Kishimoto et al., 2013). Due to the potential of polyphenols to attenuate carbohydrate 
digestion and sugar absorption and to the intrinsic link between glucose metabolism and 
luminal cholesterol uptake, it can be hypothesised that polyphenols can reduce 
chylomicron-rich cholesterol particles by downregulating apical NPCL1 expression in the 
enterocytes. This mechanism could have a positive knock on effect on insulin resistance, 
type 2 diabetes and cardiovascular health and may partially explain the modulatory 
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effects of polyphenols on postprandial lipid metabolism observed in some human 
intervention studies (Pal and Naissides, 2004; Annuzzi et al., 2014). Therefore, the 
present study was undertaken to examine for the first time the regulation of NPC1L1 and 
cholesterol uptake by glucose in intestinal Caco2 cells during postprandial conditions and 
to assess the potential of polyphenols to modulate this metabolic pathway by inhibiting 
the glucose transporter protein GLUT2. 
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5.3 Materials and methods. 
 
5.3.1 Materials. 
The ChE and authentic standards of apigenin and apigenin 7-O-glucoside were obtained 
from PhytoLab Co. KG.h as a lyophilised powder. D-glucose, cholesterol, L-α-
phosphatidylcholine, oleic acid, taurocholic acid sodium salt hydrate, cytochalasin B from 
Drechslera dematioidea, Dulbecco's Modified Eagle's Medium (including L-glutamine, 
NaHCO3 and pyridoxine HCl) and phosphate buffer saline (PBS) were all purchased from 
Sigma-Aldrich. Co., Ltd., Dorset, UK. [4-14C]-cholesterol was purchased from Perkin 
Elmer (Boston, USA). TATA-box binding protein (TBP, Hs01086390_m1), NPC1L1 
(Hs00905233_m1), ABCG5 (Hs00223686_m1) and ABCG8 (Hs00223690_m1) FAMTM-
labelled TaqMan primers and RIPA lysis buffer and Dulbecco's Modified Eagle's 
Medium without glucose (including L-glutamine) were from Thermo Fisher Scientific, 
Leicestershire, UK. RNAqueous-4PCR (AM1912) and high capacity RNA-to cDNA 
master mix kits were obtained from Applied Biosystems, Warrington, UK. Caco-2 cell 
line (HTB-37) was obtained from the American Type Culture Collection (LGC 
Promochem, Middlesex, UK). Distilled water was used for all the experiments (Millipore 
UK Ltd., Hertfordshire, UK). All the reagents were of the highest purity and standards 
were ≥98 %. 
 
5.3.2 Methods. 
5.3.2.1 Preparation of ChE for bioactivity studies. 
ChE was prepared as previously described in chapter 2 section 2.3.2.1. 
 
5.3.2.2 Cell culture. 
Caco-2 cells were cultured as described in chapter 4, section 4.3.2.1. 
5.3.2.3 Preparation of mixed-micelles. 
Stock solutions of micelle components including oleic acid, L-α-phosphatidylcholine, 
cholesterol, taurocholic acid and [4-14C]-cholesterol were prepared on the day of the 
experiment in ethanol (100 %) and mixed in pre-defined molar ratios. After drying with a 
stream of N2, serum-free supplemented medium containing varying concentrations of 
glucose (5, 10, 15, 20 and 25 mM) was added to the lipid layer and stirred vigorously at 
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37 °C for 45 min. The final concentrations of the individual micelle components were as 
follows: 0.05 mM cholesterol, 0.3 mM oleic acid, 0.01 mM L-α-phosphatidylcholine, 5 
mM taurocholic acid and 0.12 µCi/mL of [4-14C]-cholesterol. The incorporation of 
cholesterol into the mixed-micelles was confirmed by measuring their size using light 
scattering. For this experiment, a solution containing only cholesterol was prepared to 
assess the formation of the lipid-self-assembly mixed-micelles. Additionally, mixed-
micelles were prepared as described above with and without cholesterol to measure its 
incorporation into the self-assembly bodies. For each measurement, ~1 mL of micellar 
mixture was placed in plastic cuvettes in a Zetasizer NanoSeries Nano ZS (Malvern, 
U.K.) particle characterisation system and particle size distribution was measured using a 
standard protocol. The confirmation of the formation of mixed-micelles and the 
incorporation of cholesterol is shown in figure 5.2. 
 
 Figure 5.2 Formation of mixed-micelle containing cholesterol as assessed by particle size 
and distribution. (A) Insoluble cholesterol in solution, B) mixed-micelle formation without 
cholesterol and C) mixed-micelle containing cholesterol. The formation of self-assembly micelles 
can be observed by the homogenous distribution of size particle when comparing with insoluble 
cholesterol. Micelles containing-cholesterol presented an increase in particle size of more than- 
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 100 %. Three individual experiments were conducted and the average particle size was analysed 
in triplicate. PSD: particle size distribution. 
 
 
For initial experiments, Caco-2 cells (between passages  48–60) were seeded in transwell 
and flat bottom 6-well plates at a density of 6.43 and 5.6 x 104 cells/cm2 per well 
respectively. Cells were grown under a humidified atmosphere containing 5 % CO2 at 37 
°C, Dulbecco's Modified Eagle's Medium (1000 mg/L glucose), supplemented with 15 % 
heat-inactivated fetal calf serum, 2 % L-alanyl-L-glutamine (200 mM) and 1 % penicillin-
streptomycin (100 U/mL). The media in the apical (1.5 mL) and basal (2 mL) 
compartments was replaced every other day for 21 days; the time at which cells are 
completely differentiated and ready for uptake experiments. In cells seeded on transwell 
plates, the integrity of the monolayer was assessed by measuring the TEER values 
obtaining an average value of 500 ohms. On day 21, cells were washed three times with 
PBS solution (37 °C) and incubated in a glucose-free supplemented media containing the 
final concentration of 5 mM glucose added to the apical and basolateral compartments for 
24 h. After, cells were washed twice with PBS and uptake assay was initiated by 
incubating the cells at 37 °C for 60 min with a mixed-micelle solution (1.5 mL) 
containing 5 mM glucose (for transwell plates, serum-free supplemented medium with 5 
mM glucose was added to the basal compartment). At the end of the incubation, the 
unincorporated radiolabelled cholesterol was removed by washing the cells four times 
with 1.5 ml of ice-cold PBS, scraped in 0.1 (transwell plates) and 0.2 (bottom flat plates) 
mL of RIPA lysis buffer (25 mM Tris•HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% 
sodium deoxycholate, 0.1% SDS) followed with dilution (1:3 v/v) with ice-cold PBS and 
centrifugation at 14000 g for 10 min to remove cell debris. The radioactivity was 
estimated from an 8-point linear calibration curve using scintillation counting and 
normalised to the concentration of protein in the sample to represent total cholesterol 
uptake. Protein content was determined by Bradford according to the manufacturer 
procedure. As depicted in figure 5.3, there were no differences in the total [4-14C]-
cholesterol uptake between transwell plates and flat bottom plates, implying that the 
formation of the basolateral side is not required for the synthesis of cholesterol transporter 
proteins. 
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Figure 5.3 Effect of type of plate on [4-14C]-cholesterol uptake in Caco-2 cells. Differentiated 
Caco-2 cells were cultured for 24 h in media containing 5 mM glucose. At the end of the 
preincubation time, cells were exposed to micelle solution spiked with [4-14C]-cholesterol in the 
presence of the same concentrations of glucose for 60 min. No differences in uptake were 
observed regardless of the plate used (p<0.05). Three biological replicates with three technical 
replicates were employed. Results are expressed as mean values ± SEM.  
 
 
Further assays looking at the influence of glucose concentration on [4-14C] cholesterol 
uptake and the effect of glucose inhibitors on this pathway were conducted on 6-well flat 
bottom plates after cells were completely differentiated.  
 
5.3.2.4 Acute inhibition of D-[U-14C]-glucose uptake. 
For D-[U-14C]-glucose uptake, cells were grown and treated with different glucose 
concentrations as described above for [4-14C]-cholesterol uptake assays with an 
incubation period of 3 h in the presence and absence of the GLUT2 inhibitors. Then the 
uptake assay was initiated by adding 1.5 µL of radiolabelled glucose (0.15 µCi/mL) and 
stopped after 1 h with ice-cold PBS. Cells were processed and D-[U-14C]-glucose uptake 
estimated with an 8-point linear calibration curve as indicated for [4-14C]-cholesterol 
experiments. For this experiment, the GLUT2 inhibitors Cytochalasin B, ChE and 
apigenin 7-O-glucoside were used since this protein is the main active transporter of 
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glucose at concentrations ≥10 mM in Caco-2 cells (Grefner et al., 2012; Zheng et al., 
2012). Cytochalasin B was used as a positive control due to its higher capacity to inhibit 
GLUT2 than polyphenols. To assess the potential of polyphenols, ChE and apigenin 7-O-
glucoside were employed.  
 
5.3.2.5 Gene expression analysis of cholesterol flux transporters. 
RNA isolation and quantitative gene expression analysis of cholesterol flux transporter 
proteins were conducted as described in chapter 4 section 4.3.2.3 with the appropriate 
primers. The average number of accepted droplets was 14130 ± 2130 (n= 27).  
 
5.3.3 Statistical analysis. 
Statistical analysis was performed by one-way analysis of variance using the Number 
Cruncher Statistical System version 6.0 software (NCSS, LLC). Significant differences 
were assessed with Tukey-Kramer multiple comparison test and t test when appropriate 
(p<0.05). Data is expressed as the mean ± SEM.  
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5.4 Results and discussion.  
 
5.4.1 Glucose promote [4-14C]-cholesterol uptake in Caco-2 cells. 
Cardiovascular disease represents the main cause of morbidity and mortality in diabetes 
(King and Grant, 2016). The typical dyslipidaemia that is associated with insulin 
resistance  has been proposed to play an important role in the atherogenic process 
mediated by cholesterol-rich lipoproteins (Nordestgaard and Varbo, 2014). Furthermore, 
the now established observation that Apo-B48-containing remnant lipoproteins are 
elevated in insulin resistant and type 2 diabetes (Adeli and Lewis, 2008; Tomkin and 
Owens, 2011; Veilleux et al., 2014; Tomkin and Owens, 2015) has encouraged the study 
of the metabolic events that promote cholesterol rich-lipoprotein overproduction in the 
small intestine. Special attention has been put on the contribution of NPC1L1 to this 
condition, since elevated expression levels have been found under these 
pathophysiological conditions in both animal and human subjects (Lally et al., 2007; 
Levy et al., 2010), suggesting it represents an important control point for the assembly of 
cholesterol-rich ApoB-48 particles and whose expression can be regulated by glucose 
levels. Indeed, mechanistic studies in Caco-2 cells employing experimental settings that 
resemble chronic exposure to elevated glucose levels, have shown that glucose 
upregulates the expression of NPC1L1 increasing the uptake of cholesterol (Ravid et al., 
2008; Malhotra et al., 2013) corroborating the observations found in vivo.  
In order to confirm the previous observations and validate the model for subsequent 
studies, two concentrations of glucose on [4-14C]-cholesterol uptake were examined. 
Following pre-incubation (24 h) of differentiated Caco-2 cell monolayers on solid 
supports with medium containing 5 or 25 mM glucose, [4-14C]-cholesterol uptake was 
determined with short- and long-term incubation. As shown in figure 5.4, [4-14C] 
cholesterol uptake was linear as a function of time up to 1 and 2 h in cells treated with 25 
and 5 mM glucose respectively.  
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Figure 5.4 Effect of glucose concentration and incubation time on [4-14C]-cholesterol uptake 
in Caco-2 cells.  Differentiated Caco-2 cells were cultured for 24 h in media containing either 5 
or 25 mM glucose. At the end of the pre-incubation time, cells were exposed to a micelle solution 
spiked with [4-14C]-cholesterol in the presence of the same concentrations of glucose (either 5 or 
25 mM) for the indicated time (30-180 min). Linear uptake of [4-14C]-cholesterol is indicated with 
dotted lines. The diagram showing the procedure used to treat the cells is presented next to the 
panel. The data represent the mean value of three seeding experiments with at least 3 technical 
replicates. Results are expressed as mean values ± SEM. **p<0.01 compared with cells incubated 
with 5 mM glucose. When not visible, the error bars are smaller than the data point.  
 
 
Caco-2 cells incubated with 25 mM glucose showed an increase of total [4-14C]-
cholesterol uptake with an absorption rate of 0.04 µmol/mg of protein/min which was 
higher than when cells were incubated with 5 mM glucose (0.026 µmol/mg of 
protein/min) after 60 min. In contrast, no differences were observed in [4-14C]-cholesterol 
uptake at 120 and 180 min between cells incubated at 5 and 25 mM glucose indicating 
that equilibrium was reached at those time points. These data confirm previous 
observations on glucose-mediated increase of cholesterol uptake in Caco-2 cells, 
validating the suitability of the model for the subsequent studies (Ravid et al., 2008; 
Malhotra et al., 2013). 
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The majority of the studies conducted in cell models looking at the effect of glucose 
concentration on different biomarkers, including cholesterol uptake, normally have 
employed 25 mM glucose (Ravid et al., 2008; Malhotra et al., 2013) which represents a 
value that might not be achieved under physiological circumstances, even in type 2 
diabetic subjects. Therefore [4-14C]-cholesterol uptake assays were conducted using 
varying concentrations of glucose to reveal if the promoting effect on uptake can be 
maintained at concentrations below 25 mM (figure 5.5). The results indicate that the 
uptake of [4-14C]-cholesterol in Caco-2 cells is stimulated at concentrations above 5 mM 
(control conditions). However, no significant changes (p<0.05) in uptake induction were 
observed at concentrations between 10-25 mM glucose which showed an overall increase 
~28 % as compared to cells incubated in 5 mM glucose. 
  
 
 
 
 
 
 
 
 
Figure 5.5 Effect of glucose concentration on [4-14C]-cholesterol uptake in Caco-2 cells. 
Differentiated Caco-2 cells were cultured for 24 h with different concentrations of glucose. At the 
end of the pre-incubation time, cells were exposed to a micelle solution spiked with [4-14C]-
cholesterol in the presence of the same concentration of glucose before uptake was assessed. The 
diagram showing the procedure used to treat the cells is presented next to the panel. The data 
represent the mean value of three seeding experiments with at least 3 technical replicates. Results 
are expressed as mean values ± SEM. Different letters denote significant differences (p<0.05) 
between treatments. When not visible, the error bars are smaller than the data point. 
 
 
The experiments in figure 5.4 and 5.5 were conducted by incubating the cells in varying 
concentrations of glucose for 24 h before [4-14C]-cholesterol uptake was assessed. 
However, the observed changes in uptake influenced by glucose may occur at shorter 
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incubation times, which would prove the relevance of glucose concentrations on 
cholesterol uptake during the postprandial period using an in vitro model. In order to 
elucidate this, Caco-2 cells were incubated at different times with 10 mM glucose and [4-
14C]-cholesterol uptake was examined. As illustrated in figure 5.6, exposure to 10 mM 
glucose compared with 5 mM resulted in a significant increase in the uptake as soon as 3 
h postincubation time and, in general, the effect was maintained constant over a period of 
24 h with a maximum increase in uptake ~25 % with regard to control incubations (5 
mM). Moreover, there was a slight but significant effect of glucose concentration on the 
initial uptake. 
 
Figure 5.6 Time-dependence effect of glucose concentration on [4-14C]-cholesterol uptake in 
Caco-2 cells. Caco-2 cells were incubated with 10 mM glucose at different times and uptake 
examined and compared with those incubated with 5 mM glucose. The diagram showing the 
procedure used to treat the cells is presented next to the panel. The data represent the mean value 
of three seeding experiments with at least 3 technical replicates. Results are expressed as mean 
values ± SEM. Different letters denote significant differences (p<0.05) between treatments. When 
not visible, the error bars are smaller than the data point.  
 
 
Importantly, these results suggest that increased uptake of cholesterol via NPC1L1 is not 
exclusively of insulin resistance and type 2 diabetes, it could also occur in response to 
acute glucose excursions in healthy individuals. In support of this statement, acute 
infusion of glucose alongside with a lipid emulsion directly into the duodenum or through 
intravenous administration, and under conditions of a pancreatic clamp (to avoid any 
cofounding effect of insulin), stimulated the production and increased plasma 
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concentration of Apo-B48 lipoproteins (~2-2.5-fold) compared to a saline infusion in 
healthy subjects over a period of 10 h (Xiao et al., 2013; Xiao et al., 2016). Furthermore, 
glucose triggered the release of lipids from the enterocytes increasing Apo-B48 levels in 
serum compared to water intake in healthy individuals (Robertson et al., 2003). Although 
the content of cholesterol contained in the chylomicrons was not evaluated in these 
studies, based on these results, it can be predicted a higher concentration in the test 
subjects than controls. Therefore further studies are warranted looking at the impact of 
glucose on the concentration of cholesterol in chylomicrons during the postprandial 
phase.    
 
5.4.2 [4-14C]-cholesterol uptake in Caco-2 cells is attenuated by acute inhibition of 
glucose absorption by ChE and apigenin 7-O glucoside. 
The observation that glucose control the expression of intestinal NPC1L1 and therefore, 
the uptake of luminal cholesterol during the postprandial phase, led us to hypothesise that 
polyphenols can have a positive knock-on effect on cardiovascular health by attenuating 
glucose availability within the enterocyte. This may represent a mechanism through 
which polyphenols in general and ChE in particular confer cardioprotection as observed 
in vivo in mice (Weidner et al., 2013) and humans (Rafraf et al., 2015).  
 
Caco-2 cells were incubated with 10 and 25 mM glucose in the presence of varying 
concentrations of previously characterised inhibitors of glucose absorption ChE and 
apigenin 7-O-glucoside (figure 5.7). In general, pre-incubation of cells with ChE and 
apigenin 7-O-glucoside resulted in an attenuation of [4-14C]-cholesterol uptake by Caco-2 
cells. ChE was effective at attenuating [4-14C]-cholesterol uptake in a dose-dependent 
manner, with the greatest effect shown at concentrations above 0.1 mg/mL and 
maintained up to 1 mg/mL and this effect was irrespective of the glucose concentration 
used to pre-treat the cells (figure 5.7A and B). The overall response induced by ChE was 
comparable to that obtained for the positive control cytochalasin B (~82 %) (figure 5.7C 
and D). 
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Figure 5.7 Effect of acute inhibitors of glucose absorption on [4-14C]-cholesterol uptake.  
Caco-2 cells were cultured for 3 h in media containing either 10 or 25 mM glucose in the presence 
of varying concentration of glucose inhibitors. At the end of the preincubation time, cells were 
exposed to micelle solution spiked with [4-14C]-cholesterol in the presence of the same 
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concentrations of glucose (10 or 25 mM) for the indicated period of time. (A and B) Uptake of  
[4-14C]-cholesterol after preincubation of cells with ChE. (C and D) Uptake of- [4-14C]-cholesterol 
after preincubation of cells with cytochalisin B. (E and F) Uptake of [4-14C]-cholesterol after 
preincubation of cells with apigenin 7-O-glucoside (A7G). (G) After the preincubation period 
with glucose and inhibitors as indicated in the adjacent diagram, D-[U-14C]-glucose was directly 
added to the media and uptake was assessed over a period of 1 h.  In all the experiments, cells 
incubated with 5 mM glucose were used as general control. In panel (A-F), inhibition is expressed 
as % compared to control incubations (5 mM glucose; normalised to 100 %). The data represent 
the mean value of three seeding experiments with at least 3 technical replicates. Results are 
expressed as mean values ± SEM. Different letters indicate significant differences (p<0.05) 
between treatments. When not visible, the error bars are smaller than the data point. 
 
 
Previous characterisation studies on the effect of apigenin 7-O-glucoside to reduce 
glucose absorption revealed an IC50 value around its maximum soluble concentration 
(~200 µM). Therefore in the present experiment Caco-2 cells were pre-incubated only 
with a single concentration of apigenin 7-O-glucoside. The results show that apigenin 7-
O-glucoside was effective at reducing glucose-induced [4-14C]-cholesterol uptake with a 
decrease of ~50 and 30 % when incubated in 10 and 25 mM glucose respectively (figure 
5.7E and F). Although apigenin 7-O-glucoside showed a much more modest effect at 
attenuating [4-14C]-cholesterol uptake by Caco-2 cells, based on the results, a more 
pronounced reduction of cholesterol uptake can be predicted if higher concentrations are 
used. A direct evidence between the attenuation of [4-14C]-cholesterol uptake in Caco-2 
cells and reduction of glucose availability was established by measuring D-[U-14C]-
glucose uptake. As expected, ChE and cytochalasin B showed the strongest inhibitory 
effect on D-[U-14C]-glucose absorption regardless of the concentration of glucose 
employed to incubate the cells (figure 5.7G). ChE was effective at reducing D-[U-14C]-
glucose uptake when cells were incubated in 10 mM glucose showing reductions 
comparable to control incubations (5 mM). However in cells incubated in 25 mM glucose 
the effect is clearly reduced, which was reflected in a lower attenuation of [4-14C]-
cholesterol uptake by Caco-2 cells; this observation was also held for Cytochalasin B. 
Apigenin 7-O-glucoside showed the lowest attenuation effect of D-[U-14C]-glucose 
uptake with an overall reduction of ~50 and 35 % in cells incubated with 10 and 25 mM 
glucose respectively. 
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The levels of cholesterol uptake into the enterocyte are dictated by the balance of the 
expression and function of apically-located transporter proteins responsible for 
cholesterol flux. Therefore the reduction of [4-14C]-cholesterol uptake exhibited by Caco-
2 cells incubated in the presence of ChE and apigenin 7-O-glucoside may be due to an up-
and downregulation in the expression of cholesterol efflux and influx transporters 
ABCG5/G8 and NPC1L1, respectively. To test this hypothesis, the protein expression of 
cholesterol transporters present in intestinal epithelial cells was examined. As shown in 
figure 5.8, Caco-2 cells did not show any expression of the efflux transporters ABCG5 
and ABCG8 which is in line with previous observations reporting no expression of these 
proteins in Caco-2 cells from 10 different laboratories (Hayeshi et al., 2008). The results 
indicate that the attenuation of [4-14C]-cholesterol uptake may be caused solely by the 
lowered expression levels of the influx transporter receptor NPC1L1. Indeed, cells 
exposed to ChE, apigenin 7-O-glucoside and Cytochalasin B presented reduced 
expression levels of this protein than their counterparts exposed to 10 and 25 mM glucose 
(figure 5.9).  
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Figure 5.8 Representative examples of ABCG5/G8 and TBP ddPCR expression analysis following incubation in media with different 
glucose concentrations. (A1-A3) Quantitative expression analysis of ABCG5. (B1-B3) Quantitative expression analysis of ABCG8. (A1-B1), 5 
mM glucose, (A2-B2), 10 mM glucose and (A3-B3), 25 mM glucose. Data viewed as a 1-D plot with each droplet from a sample plotted on the 
graph of fluorescence intensity vs droplet number. Left panels represent the droplets recorded for either ABCG5 or ABCG8. Right panels 
represent the droplets recorded for TBP. Positive and negative droplets are indicated in green and grey respectively for TBP. For ABCG5/8 only 
negative droplets were recorded indicating null expression of these proteins.  Three biological replicates in three seeding experiments were pooled 
and analysed six times.  
- 154 - 
 
 
  
Figure 5.9 Quantitative mRNA expression analysis of 
NPC1L1 in differentiated Caco-2 cells following 
incubation in media containing 5, 10 and 25 mM 
glucose and with and without inhibitors of glucose 
uptake.(A) 5 mM glucose, (B) 10 mM glucose, (C) 25 
mM glucose, (D) 10 mM glucose + 5 µM cytochalasin 
B, (E) 10 mM glucose + 1 mg/mL ChE, (F) 10 mM 
glucose + 200 µM apigenin 7-O-glucoside (A7G), (G) 
25 mM glucose + 5 µM cytochalasin B, (I) 25 mM 
glucose + 1 mg/mL ChE, (J) 25 mM glucose + 200 µM 
A7G. Top panels show data as a 1-D plot with each 
droplet from a sample plotted on the graph of 
fluorescence intensity vs droplet number. Positive and 
negative droplets are indicated in blue and grey 
respectively for NPC1L1. Exact copy numbers of 
NPC1L1 are indicated per ng of cDNA since changes 
were also observed for TBP copy numbers (insert figure) 
when multiplexed with each cell line. Three biological 
replicates in three seeding experiments were combined 
and analysed six times. Results are expressed as mean 
values ± SEM. Different letters indicate significant 
differences (p<0.05) between treatments. 
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In general, the results on NPC1L1 mRNA expression are in line with [4-14C]-cholesterol 
uptake where cells showing higher expression of this transporter protein presented greater 
uptake rates indicating higher protein expression levels of NPC1L1 at the apical 
membrane. 
 
Increase in NPC1L1 mRNA expression levels by glucose were attenuated with ChE and 
apigenin 7-O-glucoside irrespective of the concentration of glucose used, although the 
glucose concentration determined the extended of the reduction. The presence of ChE and 
apigenin 7-O-glucoside reduced NPC1L1 mRNA expression causing reductions of ~3.5- 
and ~3-fold respectively when incubated with 10 mM glucose. However, this effect was 
decreased when cells were exposed to 25 mM glucose showing a reduction of ~50 % in 
their effectiveness to attenuate NPC1L1 expression. Due to its higher potency to attenuate 
glucose transport, cytochalasin B showed the strongest effect on reducing NPC1L1 
mRNA expression causing a ~4-fold decrease compared to cells incubated in 10 and 25 
mM glucose. This result suggest that the use of higher concentrations and a combination 
of polyphenols, which presumably can happen after dietary exposure could maximise the 
response observed for ChE and apigenin 7-O-glucoside. 
 
The atherogenic process has been proposed to be a postprandial event caused by the 
accumulation of remnant cholesterol into sub-endothelial space, leading to inflammation 
and vascular injury (Nordestgaard and Varbo, 2014) increasing the risk of cardiovascular 
disease (Jørgensen et al., 2012; Varbo et al., 2013). Therefore overproduction of 
cholesterol-rich Apo-B48 lipoproteins might be implicated in the low-grade inflammation 
and endothelial dysfunction observed during the postprandial phase mediated by 
hyperglycaemia and the concomitant hyperinsulinemia. In this sense, reducing 
postprandial glycaemic impact by the intake of polyphenols could be link with previous 
observations stating an association between diet rich in polyphenols and cardioprotection 
(Kishimoto et al., 2013). This is further supported by a human intervention study were the 
consumption of a polyphenol-rich diet reduced the postprandial levels of cholesterol-rich 
chylomicrons (Annuzzi et al., 2014).  
 
This work has proved for the first time that individual polyphenols and polyphenol-rich 
extracts capable of inhibiting glucose absorption, as exemplified with ChE and apigenin 
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7-O-glucoside, can reduce the expression of intestinal NPCL1, which is associated with 
lower rates of cholesterol uptake in Caco-2 cells. Although speculative, the findings of 
this work may be to some extent linked with the reduction of cardiovascular disease risk 
(49 %) found by the STOP-NIDDM study in impaired glucose tolerant subjects after 
acarbose treatment (Chiasson et al., 2003). For instance, under pathophysiological 
conditions, acarbose reduced the activity and nuclear localization of the pro-inflammatory 
transcription factor NF-𝜅B (Rudofsky Jr et al., 2004), possibly due to a reduction of 
atherogenesis (Inoue et al., 2006). Like acarbose, polyphenols have been related with 
cardioprotective effects via multiple mechanism.  
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5.5 Conclusion  
 
In summary, this study provides evidence that acute attenuation of glucose absorption has 
a positive effect in reducing cholesterol uptake and polyphenols are able to mediate this 
response. This could have important implication in modulating metabolic abnormalities 
observed during the postprandial phase such as endothelial dysfunction and inflammation 
with long-term health benefits by polyphenol-rich diets. 
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Chapter 6 Polyphenols and type 2 diabetes : perspectives and 
conclusion.  
 
Over the last 3 decades, research in the area of polyphenols and health has expanded 
significantly. Polyphenols have been identified as the most likely class of small molecules 
present in plant-derived products capable of affecting physiological processes that protect 
against cardiometabolic diseases including type 2 diabetes (Arts and Hollman, 2005; 
Bertoia et al., 2016).   
 
Consistent outcomes from large epidemiological and dietary intervention studies greatly 
suggest the likelihood of a robust and potentially causal relationship of the intake of diets 
rich in polyphenols with a reduced risk of developing type 2 diabetes (Knekt et al., 2002; 
Wedick et al., 2012; van Dam et al., 2013; Bertoia et al., 2016). For instance in a 
prospective cohort of 40,011 participants with a mean follow-up of 10 years, the 
consumption of coffee or tea (3 cups/day) were both inversely associated with the onset 
of type 2 diabetes by ~42 % where blood pressure, intake of magnesium, potassium and 
caffeine did not explain this relationship (Van Dieren et al., 2009). Results from the 
PREDIMED study showed a 40 % risk reduction in type 2 diabetes in a population at 
high cardiovascular risk (cohort of 3541 participants) consuming a Mediterranean diet 
(i.e. high intake of olive oil, fruit, nuts, vegetables, and cereals) in comparison with a diet 
low in fats after a follow-up of 4.1 years without specific restrictions in energy intake or 
an increase of physical activity (Salas-Salvadó et al., 2014).  
 
Based on mechanistic evidence from animal and in vitro studies, the connection of 
polyphenols with the reduction of type 2 diabetes risk is likely through potential multiple 
mechanisms; these have been proposed and reviewed elsewhere (Hanhineva et al., 2010; 
Williamson, 2013; Carpene et al., 2015; Kim et al., 2016) and exemplified with 
polyphenols in chamomile and apigenin in this thesis (chapter 1). These include 
attenuation of post-prandial glycaemic responses by inhibiting digestion and/or sugar 
transport, improved fasting blood glucose levels by enhancing insulin secretion and 
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improving insulin sensitivity in peripheral tissues via activation of insulin receptors, 
protection of pancreatic β-cell function, modification of hepatic glucose release and 
modulation of signalling pathways and gene expression.  
 
Certainly, when linking the epidemiological evidence with bioavailability studies, logic 
suggest that mammalian -and bacterial-derived metabolites should be the compounds 
mediating the health effects since they are the most abundant chemical forms present in 
circulation. However, it is important to point out that most of the mechanistic evidence 
existing so far have been generated using supramolecular doses of aglycones and so, there 
is limited evidence supporting the bioactivity of mammalian and bacterial metabolites. 
For instance, resveratrol but not its sulphated (trans-3-O-sulfate) nor glucuronidated 
(trans-O-β-D-glucuronide) forms had an antilipolytic effect on adipocytes at 
physiological doses (0.3-3 µM) (Gheldof et al., 2017). In one study, only 2 phenolic 
metabolites (protocatechuic acid-3-sulfate and isovanillic acid) out of 20 had an effect on 
reducing soluble vascular cell adhesion molecule 1(VCAM-1) expression with a 
minimum active dose of 10 µM in activated human umbilical vein endothelial cells 
(Warner et al., 2016). Furthermore, there was no synergistic or additive effects in this 
response when tested at equimolar doses (Warner et al., 2016). In contrast, a mixture of 
cyanidin-3-glucoside-derived metabolites reflecting dietary concentrations and ratios after 
the intake of 500 mg, reduced VCAM-1 and IL-6 production in in human endothelial 
cells and this effect was sustained even when the dose was reduced 10-fold (Warner et 
al., 2017). Similarly, 4 combinations of phenolic metabolites out of 29 reduced TNFα 
secretion in human THP-1 monocytes (di Gesso et al., 2015). 
 
Based on the information above and making a simple extrapolation without taking into 
account interactions with other molecules present in serum, which may affect their 
activity, it seems that only certain mixtures present in a defined ratios may have some 
beneficial effects. This pose a practical challenge to unravel the active compounds and 
their molecular targets since there is a wide interpersonal variation in the production of 
these metabolites (Manach et al., 2017; Milenkovic et al., 2017) and some changes in 
their profile can be also predicted from meal to meal in free living subjects. With 
numerous possible combinations of metabolites, there are multiple and complex 
metabolic pathways affected making almost an impossible task to establish a clear 
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association between plasma metabolites and the range of claimed metabolic changes in 
tissues such as the pancreas, liver, skeletal muscle and adipose tissue (Hollman, 2014). 
Although it has not been decisively proven, undoubtedly, plasma metabolites contribute 
to some extend to the cardiometabolic protection of polyphenols observed in 
epidemiological studies, however, what if circulating metabolites were not the big part of 
the story?   
 
6.2 Advances in polyphenol research: the GI tract as a prime site of 
action? 
 
Given the importance of high metabolic tissues such as the liver, adipose tissue, pancreas 
and skeletal muscle and their cross-talk in handling energy, it is not surprising that a great 
number of studies have tried to unravel the potential modulatory effects of polyphenols in 
these tissues, while the metabolic capabilities of the GI tract and its influence in energy 
homeostasis have not been fully appreciated. However, an increasing number of studies 
are starting to establish that the GI tract initiate direct and anticipatory metabolic control 
of distant organs including those regulating energy uptake and utilisation. Thus, the GI is 
far from being a simple absorptive and excretory organ as it was previously thought 
(Stringer et al., 2015; Tomkin and Owens, 2015; Fändriks, 2016; Bhat and Kapila, 2017) 
and its metabolic relevance is now recognised by 45 professional societies proposing that 
the GI tract and, particularly, the bariatric surgery should be considered as an standard 
treatment for type 2 diabetes (Brito et al., 2017). This procedure has the potential to 
reverse obesity, type 2 diabetes and the associated cardiovascular risk factors by 
modulating energy sensing and availability in the GI tract (Rubino et al., 2006) together 
with a shift of the gut microbiota ecology (Liou et al., 2013).  
  
Polyphenols are found in plant-based diets at high concentrations, even comparable to 
those of pharmacological doses (Williamson, 2017). According to some bioavailability 
studies in mice and humans, after intake, most of the active chemical forms 
(unmetabolised aglycones) stay in the intestinal mucosa up to 24 h before absorption 
(Patel et al., 2013; Ferrars et al., 2014). Furthermore, their concentration can be 1000-
times higher than the one in circulation with an estimated total concentration of 1 mM 
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reaching the colon (Williamson, 2017). Thus, even though the action of parent 
polyphenols in peripheral tissues is limited by its low bioavailability, their persistence in 
the GI tract after ingestion may indicate that this tissue is a key site for cardiometabolic 
protection by modulating GI functions. This notion is further supported by previous 
findings demonstrating that polyphenols can favour chemical interactions with proteins 
altering the digestion and absorption process of nutrients (Williamson, 2013) and exert 
cellular modulatory effects such as secretion of GI hormones (McCarty, 2005; Panickar, 
2013; Song et al., 2015), tight junction (TJ) proteins (Suzuki and Hara, 2011) and gut 
microbiota ecology (Tzounis et al., 2011; Anhê et al., 2015; Roopchand et al., 2015; 
Most et al., 2017). Some of these metabolic actions are similar to the ones observed after 
the bariatric surgery so, the GI tract may represent the missing link between the 
consumption of polyphenol-rich diets and the maintenance of cardiometabolic. 
 
The gastrointestinal tract is the body’s principal nutrient provider and therefore, it 
represents a cellular link to metabolic disorders caused by excessive and readily nutrient 
supply. As discussed in chapter 1, continuous acute supply of carbohydrates and simple 
sugars triggers a sharp increase in blood glucose and insulin concentration and these 
events have been considered prime factors in the pathogenesis of insulin resistance and 
type 2 diabetes via altered energy partitioning (Brand-Miller et al., 2002), increased 
oxidative stress, low-grade inflammation and endothelial dysfunction (Kawano et al., 
1999; Ceriello et al., 2004). More gentle responses by the consumption of low GI diets 
have shown to prevent these metabolic disturbances and they are inversely associated 
with insulin resistance and type 2 diabetes risks (Bhupathiraju et al., 2014) and to help in 
the management of type 2 diabetes (Brand-Miller et al., 2003).  
 
The content of naturally occurring polyphenols has been linked with low GI response 
since ~30 years ago when Thompson et al. (1984) observed a negative correlation 
between polyphenol content in legumines, and blood glucose response in normal and 
diabetic individuals after intake of 50 g of available carbohydrates. This study and many 
others suggest that polyphenols added as part of a meal or during it, could be used to 
mimic the slow release of glucose into the blood of low GI foods and/or acarbose without 
altering the carbohydrate and sugar composition of diets. However, after ~35 years of the 
first observation, there is not consensus on the potential of polyphenols to affect 
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postprandial glycaemic impact. This is due in part to the wide variations in in vitro 
experimental settings and outcomes, which have produced inconsistent findings, limiting 
the identification and recognition of plant extracts or specific polyphenols to attenuate 
glycaemic response in a consistent manner.  
 
In order to narrow the bridge that connects the identification of polyphenol-rich extracts 
and specific polyphenols with further development of human intervention studies, we 
have improved a method to accurately measure their potency to inhibit human α-amylase 
activity in vitro (described in chapter 3). Using this method along with the use of human 
cell lines (described in chapter 4) we have demonstrated that apigenin and apigenin 7-O-
glucoside present in Chamomile are effective modulators of the carbohydrate digestion 
and sugar absorption process. These metabolic actions may be related with the 
cardiometabolic protection reported for chamomile in animal and human intervention 
studies by mimicking the effect of low glycaemic index diets and the antidiabetic drug 
acarbose. Therefore this research work not only contributes to decipher plausible 
molecular targets of chamomile polyphenols but also provides robust evidence for the 
inclusion of apigenin in acute and long-term animal and human intervention studies. 
Furthermore, although it remains to be demonstrated in vivo, the attenuation of 
postprandial glycaemia by polyphenols might reduce the atherogenesis process (discussed 
in chapter 5) and conferring protection against the risk of developing cardiovascular 
disease.   
 
6.2.1 Perspective 
 
It has been widely acknowledge that part of the metabolic effects of polyphenols at the GI 
tract is due to the reduction of glucose influx into circulation attenuating postprandial 
hyperglycaemia, as demonstrated in this research work. However, adding to, and 
complementing, the effect of polyphenols could be related with the maintenance of an 
adequate intestinal AMP-activated protein kinase (AMPK) activity and related signalling 
pathways, thus preserving the chemosensory functions of the GI tract and preventing 
aberrant metabolism in absorptive cells. This statement is based on two main recent 
findings, i) activation of duodenal-AMPK activity by antidiabetic drug metformin and 
AICAR (an AMPK agonist) lowered hepatic glucose release in rat models of 
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hyperglycaemia (high-fat diet and streptozotocin-induced prediabetes), an effect that was 
suppressed when duodenal AMPK was blocked or by intravenous administration of 
metformin (Duca et al., 2015) and ii) maintenance of AMPK-signalling pathway in 
enterocytes of insulin resistant and type 2 diabetes mice improved insulin sensitive and 
decreased dyslipidaemia (Harmel et al., 2014). 
 
Some dietary polyphenols have been reported to be agonist of AMPK in the liver and 
skeletal muscle (Zang et al., 2006; Collins et al., 2007; Lin et al., 2007; Hwang et al., 
2009; Price et al., 2012), although whether polyphenols can mediate this metabolic action 
in the GI remains largely unexplored. A pioneering study was conducted by Cote et al. 
(Côté et al., 2015) showing that acute infusion of resveratrol into the duodenum 
attenuated hepatic glucose release in insulin resistant rats via a vagal gut-brain neuronal 
axis improving hypothalamic insulin sensitivity, an effect that required the AMPK-SIRT1 
cycle in this tissue (Ruderman et al., 2013). Interestingly, chronic feeding with high fat 
diet decreased the mRNA and protein expression of SIRT1 and this was immediately 
normalised to those of chow-fed rats with resveratrol infusion, enhancing insulin 
sensitivity and lowering hepatic glucose release (Côté et al., 2015). Similarly, an acute 
and chronic administration of chlorogenic acid improved fasting glucose level and 
postprandial glucose tolerance in Leprdb/db mice which was related with AMPK activation 
and attenuation of gluconeogenesis (Ong et al., 2013). Although the later study did not 
established a direct relationship between duodenal AMPK and hepatic gluconeogenesis, 
the fact that chlorogenic acid was tested directly to a liver cell line raise the possibility 
that the metabolic improvements were mediated via the gut-brain-liver axis. These results 
suggest that chronic perturbation of the intestinal physiology disrupts the chemosensory 
capacity of the duodenum, impairing the glucoregulatory function of the GI tract and 
liver. This disruption may also be acute and independent of a pathological state since 
healthy subjects supplemented with a single oral dose of saturated fat increased hepatic 
gluconeogenesis by 70% with a net decline in glycogenosis of 20% concomitant with an 
increase in hepatic lipid storage and insulin resistance (Hernández et al., 2017).  
 
Maintaining AMPK activity by polyphenols in absorptive cells either by reducing glucose 
influx (inhibition of GLUT2 and/or SGLT1) or direct signalling. i.e SIRT1 activation 
(Chung et al., 2010) could reduce the postprandial processing of lipids and maintain a 
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functional insulin signalling pathway (Harmel et al., 2014). For instance, in the study of 
Ong et al. (2013) the chronic intake of clorogenic acid in Leprdb/db mice improved 
systemic insulin sensitivity, lipid profile and lowered dyslipidemia. However, whether the 
metabolic effects triggered by chlorogenic acid intake were mediated by regulating GI 
functions in this study is uncertain.  
 
The glucoregulatory capacity of the duodenum seems to be mediated in part by an 
increase of GLP-1 as observed with the antidiabetic drug metformin and the polyphenol 
resveratrol (Côté et al., 2015; Duca et al., 2015). It has been suggested that GLP-1 has 
different actions depending whether is released by EECs in the small intestine or in the 
colon (Greiner and Bäckhed, 2016). Given the short-half of active GLP-1 (Holst, 2007) 
and that GLP-1 receptors are expressed on nerves in the intestinal submucosa and the 
liver (Richards et al., 2014), it has been proposed that GLP-1 secreted in the small 
intestine signals directly to GLP-1 receptor expressed on vagal afferent nerves that relay 
signals to the brain (Vahl et al., 2007; Richards et al., 2014; Greiner and Bäckhed, 2016) 
(for a comprehensive review of these pathways see (Holst, 2007)) rather than to boost 
insulin secretion from pancreatic β-cells (Smith et al., 2014). This is in line with the 
observation that chlorogenic acids in coffee induce GLP-1 secretion along with a 
reduction of postprandial glucose but without changes in insulin levels (Jokura et al., 
2015). Although it remains to be demonstrated, perhaps chlorogenic acids acts as ligands 
on GLP-1-secreting cells localized in the small intestine since this activity has been 
observed in vitro (Fujii et al., 2015); thus reducing hepatic glucose production with a 
global effect in serum glucose levels. The inhibition of SGLT1 transporter in GLP-1-
secreting cells would reduce the flux of Na+ into the cells blocking membrane 
depolarisation and Ca+2 entry (Parker et al., 2012; Psichas et al., 2015) suppressing the 
release of GLP-1, an effect that has been observed by polyphenol supplementation 
(Castro-Acosta et al., 2016). Therefore polyphenols could induce and supress GLP-1 
secretion depending on their molecular targets and this may explain the discrepancies on 
GLP-1 secretion by polyphenol intervention (Burton-Freeman, 2010).  
           
The evidence presented underscores the possible role of polyphenols to maintain the 
energy sensing capacity in the small intestine, which is complementary to their role to 
attenuate carbohydrate digestion and sugar absorption, both contributing to maintain 
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energy homeostasis and cardiometabolic health. These mechanisms may partially clarify 
the debated explanation behind the antidiabetic effects of some polyphenols such as 
resveratrol (Timmers et al., 2011; Bhatt et al., 2012; Crandall et al., 2012). Further 
studies are warranted to identify other polyphenols capable of maintaining the 
chemosensory capacity of the small intestine which could act in cohort with the inhibition 
of glucose transporters.  
 
Dietary molecules that escape absorption in the small intestine reach the colon where they 
are metabolised by the resident microbiota producing a series of microbial metabolites 
and affecting microbiota ecology with an impact on metabolic process locally, and in the 
periphery (Cani et al., 2013; Greiner and Bäckhed, 2016). For instance, propionate, and 
butyrate are well characterised microbial metabolites derived from fermentable 
carbohydrates that regulate energy metabolism in both animals and humans. Propionate 
has beneficial effects on β-cell function in humans and in vitro analyses with human islets 
suggest that it acts synergistically on glucose-stimulated insulin release which was 
independent of GLP-1 secretion (Pingitore et al., 2017). Butyrate regulates glucose and 
energy metabolism in mice, an effect that has been ascribed to partially be mediated via a 
gut–brain axis (De Vadder et al., 2014), once again highlighting the significance of the GI 
tract on controlling global energy homeostasis. There are plausible many other microbial-
derived metabolites with the potential to regulate energy balance remained to be 
discovered and characterised. For instance, it has been recently reported that N-acyl 
amides activate intestinal GPCRs and improve glucose tolerance in mice (Cohen et al., 
2017). 
 
On the other hand, diets rich in fats and simple sugars alters the gut microbiota affecting 
metabolic pathways implicated in insulin resistance, type 2 diabetes and cardiovascular 
disease such as inflammation and adiposity (Turnbaugh et al., 2006; Samuel et al., 2008). 
Experimental data has confirmed that microbiota is actively involved in the development 
of local and systemic inflammation through a lipopolysaccharide (LPS)-dependent 
mechanism which may acts via an impaired mucosal barrier (Cani et al., 2007; Cani et 
al., 2008; Cani et al., 2009). Indeed, significant endotoxaemia was found in individuals 
with metabolic syndrome (Lassenius et al., 2011) and type 2 diabetes (Pussinen et al., 
2011) and it could represent the root cause of altered adipose tissue and liver metabolism 
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characteristic of these phenotypes (Cani et al., 2008; Cani et al., 2009). While microbial 
metabolites such as butyrate and propionate could regulate energy metabolism by 
preserving intestinal barrier function and downregulated immune local responses and 
inflammation (Postler and Ghosh, 2017), a particular ‘healthy’ bacteria signature may 
also be required. i.e Akkermansia muciniphila (Everard et al., 2013; Derrien et al., 2017; 
Plovier et al., 2017). Moreover, the microbiota seems to have a high degree of plasticity 
in response to diet (Cotillard et al., 2013; Carmody et al., 2015), suggesting that dietary 
manipulation can be used to prevent and/or manage metabolic disorders.         
 
The interaction of polyphenols with intestinal proteins, such as the sugar transporter 
SGLT1 has presumed to be reversible (Schulze et al., 2014), indicating that polyphenols 
can reach the colon and affect GI metabolism, maximising any modulatory effect on 
energy homeostasis.  The connection of polyphenols with microbiota is more intricate 
than initially thought. Polyphenols may exert a ‘prebiotic effect’ promoting the growth of 
intestinal health-associated bacteria.  
 
Several human intervention studies have observed an increase in bifidobacteria and 
lactobacillus population after dietary intervention with different polyphenol sources 
including cocoa, red wine, blueberries, grape seeds, oranges, apples, virgin olive oil, 
pomegranate and green tea (Yamakoshi et al., 2001; Tzounis et al., 2011; Vendrame et 
al., 2011; Jin et al., 2012; Queipo-Ortuño et al., 2012; Boto-Ordóñez et al., 2014; Cuervo 
et al., 2015; Li et al., 2015; Martín-Peláez et al., 2017). Most of these studies focused on 
establishing a relationship between changes in microbiota ecology with the production of 
colonic catabolites that might benefit the host after absorption, thus is uncertain whether 
this changes can be related with improvement in cardiometabolic health in humans, 
although some evidence do exist. For instance, in a randomised, cross-over study, the 
intake of cocoa flavonols for 4 weeks (494 mg cocoa flavanols/day) increased the 
bifidobacterial and lactobacilli populations and decreased clostridia counts which was 
related with reductions in plasma triacylglycerols and C-reactive protein concentrations 
(Tzounis et al., 2011). Akkermansia muciniphila has been indetified as a beneficial 
microbiota signature and has been positively associated with the attenuation of 
pathological conditions such as obesity, type 2 diabetes, inflammatory bowel diseases and 
liver diseases (Cani and De Vos, 2017). Interestingly, intervention with a pomegranate 
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extract for 4 weeks (1000 mg/day) increased the population of bacteria in healthy subjects 
(Li et al., 2015). This observation also has been reported in animal models after 
polyphenol intervention (Anhê et al., 2015; Roopchand et al., 2015; Zhang et al., 2017).  
 
Two independent studies evaluated the metabolic effects of polyphenol-rich extracts, 
cranberry and concord grape on mice fed a high fat/high sugar and high fat diet 
respectively (Anhê et al., 2015; Roopchand et al., 2015). In both studies A. muciniphila 
was a strong biomarker of cranberry and grape extracts supplementation, and 16S rRNA 
gene sequencing of faecal samples revealed a striking ~30 and 50 % increase in the 
relative abundance of this bacteria. At the functional level, polyphenol supplementation 
decreased body and liver weight gain in mice, improved insulin and glucose tolerance, 
lowered hepatic, intestinal, and plasma triglycerides and attenuated intestinal and hepatic 
inflammation alongside with reduced serum LPS. Although the increase in A. muciniphila 
and the improvement of metabolic biomarkers in these studies was merely correlative, a 
body of evidence suggest that A. muciniphila protects against cardiometabolic diseases 
(Everard et al., 2013; Schneeberger et al., 2015; Dao et al., 2016). Chlorogenic acids 
have also been reported to increase A. muciniphila in mice resulting in a lower intestinal 
and systemic inflammation (Zhang et al., 2017), outlined another potential mechanism of 
the protection of coffee against type 2 diabetes.  
 
Gut permeability has been shown to be a key component in the dysregulation of energy 
metabolism. A direct link of A. muciniphila with an improved gut barrier function which 
prevents metabolic endotoxemia and inflammatory tone averting the disruption of 
junctional proteins has been established, possibly via an outer-membrane protein 
(Amuc_1100*) which signals toll-like receptor 2 (Plovier et al., 2017). There is evidence 
underlying the potential of polyphenols to preserve intestinal barrier function (Amasheh 
et al., 2008; Suzuki and Hara, 2011; Suzuki et al., 2011), targeting signal transduction 
pathways involved in tight junction regulation such as PKCδ (Suzuki et al., 2011) and 
cytokine signalling, thus decreasing inflammatory tone and maintaining tight-junction 
protein structure. In Caco-2/15 cell line, cranberry extract offset LPS-mediated 
inflammation via inhibition of nuclear factor κB activation and production of pro-
inflammatory cytokines along with an increased expression of tight junction proteins 
(Denis et al., 2015). In the study of Ahne et al. (2015) cranberry polyphenols completely 
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suppressed NFκB activation in the intestine of mice. This functional overlap between 
polyphenols and A. muciniphila makes not possible to distinguish who is responsible for 
keeping intestinal barrier function intact after the high-fat high-sugar challenge, although 
a synergistic effect cannot be ruled out.    
 
As highlighted before, there might be a number of microbiota-encoded small molecules 
that influence energy metabolism. Although it remains to be tested, it is possible that 
microbial catabolites derived from dietary polyphenols influence energy balance before 
colonic absorption in a manner similar to the short chain fatty acids butyrate and 
propionate. The fact that some these catabolites present a tmax after 6 h suggest that they 
remain in the colon long enough to act as functional and signalling molecules. Moreover, 
the problem of having a great chemical diversity of polyphenols in the diet and those of 
circulating metabolites is drastically reduced in the colon. The microbiota transform the 
most abundant dietary polyphenols in the same set of catabolites while other catabolites 
are a signature of the intake of a particular polyphenol from the diet (Williamson and 
Clifford, 2017). Therefore unravelling whether some microbial polyphenol-derived 
metabolites are involved in energy homeostasis acting locally may provide a clearer 
pathway of how dietary polyphenols positively influence cardiometabolic health.        
 
6.2.2 Concluding comments. 
 
Given the evidence supporting the critical role of the GI tract on glucose and energy 
homeostasis, it is intuitive that polyphenols may have a key role in metabolic control 
acting at this site since they reach concentrations that are several orders of magnitude 
higher than in the serum in the appropriate chemical form.  
 
The mechanistic evidence generated with non-mammalian metabolites whose action is 
questionable in peripheral tissues and the liver (i.e activation of AMPK, downregulation 
of inflammatory pathways, maintenance of insulin signalling pathway), supports the 
potential modulatory role of polyphenols at the GI tract. Therefore, it is reasonable that a 
two-compartment model where cardiometabolic of polyphenols comes from a cooperative 
action of the chemical forms present at the GI tract and the circulating metabolites 
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derived after mammalian and bacterial metabolism. However whether polyphenols acting 
at the GI tract play a more crucial role than circulating metabolites needs to be 
determined.  
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Appendix A. Assay parameters used for measuring the inhibition of human salivary α-amylase by polyphenols. 
Adapted from Nyambe-Silavwe et al. (2015).   
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Appendix B. Assay parameters used for measuring the inhibition of porcine α-amylase by polyphenols. Adapted 
from Nyambe-Silavwe et al. (2015).  
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Appendix C. Assay parameters used for measuring the inhibition of microorganism α-amylase by polyphenols. 
Adapted from Nyambe-Silavwe et al. (2015). 
 
 
